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Childlessness is a life crisis with impaired fertility affecting 1 in 7 couples globally. 
Since the introduction of in vitro fertilisation in 1978, the treatment of subfertility 
has evolved substantially to incorporate an advanced set of clinical diagnostic 
tests and novel stratified care pathways encompassing appropriate and effective 
treatment strategies. To accompany these technological developments, the 
continued elucidation of the contribution of the female and male preconceptual 
phenotype in determining clinical outcomes, and identification and influence of 
potentially modifiable biological pathways is critical.  
 
In this thesis, I outline the development of an original prospective cohort of 400 
women and their male partners undertaking in vitro fertilisation. For each 
participant, I performed extensive pre-treatment phenotyping, collected 
meticulous clinical and laboratory data, and undertook prolonged follow-up 
allowing ongoing pregnancies from both fresh and frozen embryo outcomes to be 
considered as clinical outcomes. In parallel, I collected biological samples 
enabling the creation of a unique comprehensive biobank encompassing pre-
treatment serum, plasma, DNA, and vaginal swab samples for each participant.  
 
Utilising a high-throughput NMR metabolomics platform, covering a wide range of 
metabolic pathways including lipoprotein lipids, fatty acids, amino acids, ketone 
bodies, and glycaemic traits which are highly relevant to cardiometabolic risk and 
overall health, I assessed the association of 155 metabolites with the ovarian 
reserve, semen parameters, the correlation between couples and the clinical 
outcome of treatment as defined by an ongoing pregnancy. I conduct a novel 
insight into the association of ovarian biomarkers with metabolic profiles 
conjointly with other recent studies. My results suggest that dyslipidaemia has a 
limited role in the relationship between ovarian reserve and cardiovascular 
diseases. Some fatty acids and amino acids may have a role in mediating an effect. 
My study provides preliminary data on a range of metabolic pathways and their 
association with semen parameters. I identified several metabolites associated 




and ketone bodies were associated with increased odds of low total motile sperm 
counts. I have also explored within couples correlations of multiple metabolomic 
traits and found weak to modest positive correlations for the vast majority of 
traits that are known to be influenced by assortative mating or shared couple 
behaviours. This correlation suggests assortative mating and might have some 
potential weak to modest impact on couples having similar metabolic traits. After 
assessing the association of metabolite concentrations with ongoing pregnancy, I 
was the first to report a higher likelihood of ongoing pregnancy after IVF among 
both women and men with higher pre-conceptual histidine concentrations. For all 
these findings, confirmation with a larger number of participants to evaluate the 
potential clinical implications more fully is essential. My aspiration is that this 
unique cohort and accompanying biobank will be an important resource 
contributing to and enabling future collaborative and contemporary research 
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Chapter 1 Introduction 
Fertility is a key element of reproductive health and infertility is recognized as a 
global public health issue by the World Health Organisation (WHO) (Boivin et al., 
2007, Macaluso et al., 2010). Infertility is defined by the International Committee 
for Monitoring Assisted Reproductive Technology (ICMART) and WHO as the ‘failure 
to achieve a pregnancy after 12 months or more of regular unprotected sexual 
intercourse’(Zegers-Hochschild et al., 2009). The experience of infertility can 
cause those affected personal distress (Schneider and Forthofer, 2005), significant 
treatment costs (Bell, 2010) and in some contexts, ostracism and discrimination 
(Cui, 2010). The significant medical, social and demographic consequences of 
infertility have led to its widespread awareness.  
 
Infertility may be considered a characteristic of the couple, with female or male 
factors implicated, or in some cases, both. Some risk factors such as age and 
lifestyle factors have been the topic of considerable epidemiological research. 
However, other risk factors including maternal and paternal metabolism have 
received little investigation, with the majority of research focusing on novel 
therapies rather than considering assessing and identifying potential baseline 
determinants of treatment outcomes. This lack of attention has continued despite 
increasing recognition of pre-treatment maternal and paternal phenotypes as 
critical factors in determining clinical outcomes. Even in the context of single or 
heavily sponsored multicentre clinical trials, Biobanks are rarely established, 
limiting the potential for discovery-based science even when the trial findings are 
null.  
 
This thesis describes the establishment of a cohort of couples undertaking IVF in 
a single centre, with an accompanying comprehensive Biobank.  Thereby enabling 
the analytical investigation of the role of the circulating maternal and paternal 
metabolite profile on both the pre-treatment phenotype but also clinical 
outcomes, while also establishing a future resource for researchers for discovery 
or replication focused studies.  Each results chapter has its own pertinent 
introduction and discussion, consequently this overall introduction is used to set 




theoretical potential for the baseline phenotype to be a critical determinant of 
both immediate and long-term outcomes. 
 
1.1 Infertility – a global problem 
Infertility or the inability to conceive remains a problem of global proportions. In 
the third decade of the new millennium, six demographic realities regarding 
infertility treatment remain salient, and are summarised in Table 1.1, with the 
first and last particularly relevant to this thesis. The first demographic reality is 
that millions of people around the globe continue to suffer from infertility.  The 
totality of the worldwide population of infertile couples is extremely difficult to 
ascertain because of (i) the heterogeneity in the criteria used to define infertility 
(e.g. 1 versus 2 versus 5 years of trying); (ii) the critical differences between 
estimates of infertility based on large-scale population surveys versus 
epidemiological studies of infertility and (iii) whether infertility is defined as being 
located in ‘women’, ‘couples’, ‘people’ or ‘individuals’, units of analysis that are 
often used interchangeably or without precision (Gurunath et al., 2011, 
Mascarenhas et al., 2012b).  
 
Demographic surveys have provided varying estimates (Boivin et al., 2007, 
Mascarenhas et al., 2012a), with the most recent providing a global examination 
of infertility trends based on analysis of 277 reproductive and health surveys from 
190 countries and territories during the period of 1990 to 2010 (Mascarenhas et 
al., 2012a). In this study rather than use the WHO’s clinical or epidemiological 
definitions (i.e. absence of conception after 1 or 2 years of trying, respectively), 
primary infertility was defined as the ‘inability to have any live birth’ and 
secondary infertility as the ‘inability to have an additional live birth’. The primary 
outcome assessed was a live birth over a 5-year exposure period, based on the 
couple being in a stable union, neither used contraception and that there was a 
clear desire for a child. Using this demographically based definition of infertility, 
the study estimated that 48.5 million couples were affected by infertility in 2010 
– considerably lower than previous reports (Boivin et al., 2007, Mascarenhas et al., 
2012a). However, by reducing the time-frame from 5 to 2 years would be 
associated with an increase in the total number of infertile couples of 2.5-fold to 
121 million (Mascarenhas et al., 2012a). Within the UK it is estimated that 1 in 7 




and men who experienced infertility seeking medical or professional help (Datta 
et al., 2016, Mills et al., 2011).  
 
Demographic Reality 
1. Millions of people around the globe suffer from infertility  
2. Women in many low-resource settings continue to suffer from high rates of 
secondary infertility  
3. Africa continues to suffer from inordinately high rates of infertility  
4. High rates of infertility coexist with high rates of fertility in Africa—a 
demographic paradox known as ‘barrenness amid plenty’  
5. Lack of infertility prevention and treatment services is often justified as a 
form of population control, particularly in high-fertility settings such as sub-
Saharan Africa 
6. Those parts of the world with the highest rates of infertility are least likely 
to offer reliable diagnosis and treatment, including IVF services 
Table 1.1 Global infertility: six demographic realities. 
 
Despite the differing estimates of global infertility prevalence, and the lack of 
information on the total number of infertile men, who contribute substantially to 
the cases of childlessness, infertility rates are only slowly increasing over the 
preceding decades as compared to other non-communicable diseases 
(Mascarenhas et al., 2012b). A Global Burden of Disease survey reported that 
between 1990 and 2017, the age-standardised prevalence of infertility increased 
annually by 0·37% in women and by 0·29% in men (Sun et al., 2019). This relatively 
small increase reflects that global fertility rates have dropped significantly – i.e. 
fewer people are trying to have children as population growth has slowed 
(Mascarenhas et al., 2012a). Accompanying this decline in intended family size is 
the competing / opposing risk factor of an increase in the anticipated age at which 
couples wish to have a family, with a marked trend for delaying the timing of first 
birth in both developed and more recently developing countries (Rosero-Bixby et 
al., 2009). The inevitable consequence of this postponement of parenthood is the 
potential for impaired fertility and the risk that prolonged deferral of parenthood 
will rule it out even as a possibility with respect to natural conception or the use 




infertility will continue to rise albeit slowly, with the concomitant need for 
increased interventions across society.  
 
The other pertinent demographic reality relates to access to infertility services. 
The limited access to  in vitro fertilisation (IVF) and related ART can be considered 
as a global reproductive health disparity (Jain, 2006). Those parts of the world 
with the highest rates of infertility are least likely to have reliable diagnosis and 
treatment, including IVF services (Adamson et al., 2018). This is particularly true 
in sub-Saharan Africa (Ombelet and Onofre, 2019), where tubal infertility 
dominates and despite IVF being originally developed to overcome blocked 
fallopian tubes, these nations are the least likely to be served by IVF clinics (Giwa-
Osagie, 2002). Even within developed countries access to IVF is not equitable for 
couples with primary infertility, with fertility treatment provision not routinely 
mandated by all insurance providers or state funders (Bitler and Schmidt, 2012).  
Furthermore, secondary infertility is largely not addressed by state providers, 
except in a few countries such as Belgium, where a lifetime approach to 
reproductive health is taken and reimbursement of six IVF cycles per patient in a 
lifetime is available to ensure minimal financial burden to the patient (Ombelet 
et al., 2005). Interventions which could reduce the prevalence of infertility and / 
or reduce the need for more advanced therapies would be welcome additions to 
the public health armamentarium in its battle to reduce the global burden of 
infertility 
 
1.2 Male infertility 
The cause of infertility lies solely with the man in 20–30% of cases and a male 
cause is contributory in a further 20% (Thonneau et al., 1991). A large meta-
analysis by Carlsen and colleagues in 1992, initially highlighted concerns regarding 
declining sperm counts with the suggestion that sperm counts had declined by 50% 
during a 60-year period (Carlsen et al., 1992). Subsequently, numerous studies 
have shown similar declines globally (Mishra et al., 2018, Swan et al., 2000), and 
although some studies have disputed this claim (Ravanos et al., 2018), there is 
now a large body of evidence that supports a reduction in sperm counts of 50–60% 
between 1973 and 2011, and an overall increase in the burden of infertility that 





The multitude of causes and risk factors contributing to the overall increase on 
the incidence of male infertility (Krausz, 2011, Unuane et al., 2011), can be 
principally considered as congenital, acquired, and idiopathic.  The primary 
genetic causes of male infertility are congenital bilateral absence of the vas 
deferens secondary to cystic fibrosis gene mutations, Kallmann syndrome, 
chromosomal abnormalities leading to deterioration of testicular function, and Y 
chromosome microdeletions resulting in isolated spermatogenic defects. Among 
acquired factors, varicocele is the most common and correctable cause of 
infertility in men, with a prevalence of 40% (Damsgaard et al., 2016). In addition 
to this various childhood conditions (e.g., cryptorchidism, postpubertal mumps 
orchitis, and testicular torsion or trauma) can result in testicular atrophy or 
decreased semen quality (Lewis et al., 2009). Infections of the male urogenital 
tract (prostatitis, urethritis, epididymitis, and orchitis) may also be implicated 
(Salonia et al., 2020), as the prevalence of male urogenital tract infection was 
reported to be as high as 35% in a study of more than 4000 subfertile men (Henkel 
et al., 2007). While a cross-sectional study of 1689 men revealed that 20% of men 
with primary infertility had asymptomatic semen infections (Boeri et al., 2020). It 
is estimated that ~17% of men with infertility have erectile dysfunction, or 
premature ejaculation, or both (McCabe et al., 2016). Sexual disorders, including 
hypoactive sexual desire and an absence of sexual satisfaction (pleasure, positive 
feeling, and orgasm) are less common but may coexist with other classical causes 
(Lotti and Maggi, 2018). The psychological effects of sexual dysfunction and / or 
other pathological causes of male infertility can be overwhelming and when 
combined may have a substantial detrimental impact on overall fecundity.  
 
In the absence of a demonstrable pathological cause, about 30–50% of male 
infertility cases are idiopathic. In these seminal oxidative stress may contribute, 
and abnormal levels as evidenced by increased sperm DNA damage, have been 
associated with altered semen characteristics (Agarwal et al., 2019b). 
Environmental or occupational exposure to toxic chemicals and various lifestyle 
factors (e.g., smoking (Sharma et al., 2016a), alcohol consumption (Ricci et al., 
2017b), recreational drug use (Gundersen et al., 2015), obesity (Eisenberg et al., 
2014a) and psychological stress (Durairajanayagam, 2018)) are also all potential 
risk factors for male infertility. The association between obesity and male 




continues to rise (Craig et al., 2017). Obesity-induced endocrine alterations that 
result in peripheral conversion of testosterone to oestrogen have been linked with 
reduced sperm concentrations (Alshahrani et al., 2016). Among the subsets of 
obesity, metabolically unhealthy obesity (i.e., with metabolic abnormalities such 
as diabetes, hypertension, dyslipidaemia, insulin resistance) is known to be a risk 
factor for erectile dysfunction, and the combination of erectile dysfunction and 
metabolically healthy obesity (i.e., without evidence of metabolic and 
cardiovascular disease) in men represents an early marker for future adverse 
metabolic consequences (Rastrelli et al., 2019). 
 
1.2.1 Assessment of the male 
Routine evaluation is recommended for couples who do not conceive naturally 
after at least 12 months of regular, unprotected sexual intercourse, or after 6 
months for couples in which the female partner is older than 35 years. Inevitably 
evaluation and treatment may be considered prior to these broad time limits 
based on medical history or physical examination. For the male, initial evaluation 
is a reproductive history and at least one semen analysis (Salonia et al., 2020). At 
present laboratory evaluation is still required as home-based testing systems are 
primarily limited to assessment of sperm concentrations (Yu et al., 2018). The 
WHO Laboratory Manual for the Examination and Processing of Human Semen and 
Sperm–Cervical Mucus Interaction has been published since 1980, with the most 
recent manual released in 2010 (WHO, 2010).  
 
The recommended cut-off values for semen parameters have evolved dramatically 
over the years (Table 1.2). The lower reference limits in the latest iteration shown 
in Table 1.2 are derived from the statistical analysis of the semen parameters of 
1953 fertile men from around the world (Cooper et al., 2010). However, these 
reference limits have been criticised for not considering the female factor, high 
biological variation among individuals, and the absence of data from 
representative ethnic groups (Patel et al., 2018). Consequently, standard semen 
analysis has limited accuracy for determining male fertility potential or predicting 
reproductive success. In fact, interpreting semen analysis using WHO 2010 
reference values resulted in samples being considered normal that would have 






















































≥60% ≥50% ≥50% ≥50%  ≥32% 
Sperm 
vitality (%) 




≥80·5%† ≥50% ≥30%‡ ≥15%§  ≥4% 
Table 1.2 The evolution of normal values for semen parameters from 1980 to 
2010 across the first five editions of the WHO Laboratory Manual for the 
Examination and Processing of Human Semen and Sperm–Cervical Mucus 
Interaction 
Data extracted from WHO manuals. ND=not defined. †Mean of fertile population. 
‡Arbitrary value. §Value not defined but strict criteria and in-vitro fertilisation 
data suggest a 14% cutoff value. 
 
Interpretation of a semen sample report is primarily referent to the individual 
categories presented in Table 1.2, with an overall judgement made on whether it 
is normal or not. Consistent with this overall view, analysis of the diagnostic 
potential of the cut-off values for each single value, suggested that single sperm 
parameters were of little prognostic value in differentiating men who were fertile 
from subfertile men, and that a combination of these parameters should be used 
to predict a man’s fertility status (Ombelet et al., 1997). Notably sperm 




laboratories are compliant with the WHO recommendations (Riddell et al., 2005), 
exhibited the best area under the receiver operator characteristic curve (Ombelet 
et al., 1997). Semi and fully automated computer assisted sperm analysis systems 
have limited capacity to analyse sperm morphology, however their wider adoption 
would potentially ensure stricter adherence to quality control procedures and 
more accurate quantification of sperm numbers and motility (Mortimer et al., 
2015). Unfortunately, at the time of sample collection for this thesis neither 
morphology nor computer assisted sperm analysis systems were in use at Glasgow 
Royal Infirmary.  
 
Routine physical examination and hormonal investigation (follicle stimulating 
hormone and testosterone) are still considered by some to be part of the standard 
investigation for every male patient with infertility (Ring et al., 2016). Although 
international societies recommend limiting their use to particular groups of 
patients, including men with a sperm concentration below 5 x 106/mL or impaired 
sexual function, or if an endocrinopathy is suspected (EAU Medicine, 2015). 
However, endocrine testing is not routinely performed in many centres based 
solely on a reduced sperm count, with the validity of these guidelines for 
predicting hypogonadism challenged due to their low accuracy (Ventimiglia et al., 
2016).   
 
Testing for genetic abnormalities, is mainly targeted based on evidence of 
defective spermatogenesis, resulting in severe oligozoospermia or azoospermia 
and largely takes the form of karyotype, Y-microdeletions and CF status. 
(Lipshultz and Lamb, 2007) Although a wide range of genes have been linked to 
different male infertility phenotypes targeted panels have yet to be fully 
developed (Oud et al., 2019), rather the focus is on identifying karyotypic 
abnormalities which are the most common with a prevalence of 12–15% in 
azoospermia, 5% in severe oligozoospermia, as compared to less than 1% in men 
with normal semen analysis (Ravel et al., 2006).  
 
Additional tests to evaluate specific functional aspects of spermatozoa have also 
been developed to augment baseline semen analysis. The necessity for these came 
to light after the emergence of in vitro fertilisation and intracytoplasmic sperm 




interaction is the main reason for fertilisation failure. However, in the current era 
of ICSI, hemizona or acrosome function assays are no longer used in clinical 
practice, because the penetrating capability of sperm is bypassed by direct 
intracytoplasmic injection of the sperm. Therefore, greater emphasis has been 
placed on the assessment of sperm chromatin quality using sperm DNA 
fragmentation testing. Despite a substantial body of work implicating DNA damage 
in altered sperm function, the absence of strict standardisation and clear 
threshold values for diagnostic tests (Agarwal et al., 2019a), have deterred its 
wider application or recommendation by professional bodies (EAU Medicine, 
2015). Additional alternative tests such as determination of seminal oxidative 
stress remain experimental and are not recommended pending validation of their 
utility in randomised controlled trials (Salonia et al., 2020).  
 
1.2.2 Management of male infertility 
The clinical management of male infertility is largely dependent on the cause and 
whether there is sperm albeit of a reduced concentration or quality in the 
ejaculate or if there is azoospermia, which can then be classified as pretesticular, 
testicular, or post-testicular (Agarwal et al., 2020). The overarching themes of 
the different clinical pathway are to improve sperm number and quality and obtain 
sufficient sperm to enable natural or assisted reproduction. For many men ICSI is 
the final step in their clinical journey.  
 
In men with idiopathic infertility, treatment consists of assisted reproductive 
technology and / or empirical medical therapy, which includes lifestyle 
improvement and hormonal or non-hormonal therapy. Lifestyle modifications 
(e.g., weight loss, physical activity, and cessation of smoking) are important non-
invasive measures (Salonia et al., 2020), and have been linked to improvements 
in sperm parameters (Ibañez-Perez et al., 2019, Guthauser et al., 2013, Prentki 
Santos et al., 2011).  
 
Separate treatment pathways for the different causes of azoospermia exist but all 
with the primary purpose of ensuring adequate sperm for conception whether this 
be natural or assisted (Agarwal et al., 2020). Patients with obstructive 
azoospermia have several options, including epididymal or testicular sperm 




injection or surgical reconstruction. For men with impaired spermatogenesis as 
the cause of their non-obstructive azoospermia, although sperm production in 
non-obstructive azoospermia is often inadequate to reach the ejaculate, the 
finding of heterogeneous patchy spermatogenesis on testicular biopsy, and 
demonstrable sperm within the testes in 60% of men with non-obstructive 
azoospermia, provide the rationale for sperm retrieval in the management of non-
obstructive azoospermia (Schlegel, 1999). For those men where sperm retrieval or 
induction of spermatogenesis is unsuccessful the option of donor sperm 
insemination or adoption are the only viable options.  
 
1.2.3 Future therapies and challenges for male fertility 
The use of ICSI has substantially improved the ability of men with severe male 
factor infertility, to have their own biological children. Despite the success of this 
technique, the importance of the paternal contribution and the need to optimise 
preconceptual sperm function cannot be understated, as ICSI from men with 
severe oligoasthenoteratozoospermia and non-obstructive azoospermia have 
substantially poorer clinical outcomes when compared to sperm derived from 
normozoospermic men (Lee et al., 2009).  
 
Advancements in omics technologies have facilitated improved diagnosis and 
management of male infertility at genetic, molecular, and cellular levels. Next-
generation sequencing technologies, such as disease-targeted sequencing, whole 
exome and genome sequencing, and epigenetic analysis of sperm, will enable 
further elucidation of the genetic architecture of male infertility (Thirumavalavan 
et al., 2019). Discoveries on the role of small RNAs and microRNAs in epigenetic 
regulations, and their involvement in spermatogenesis and epididymal sperm 
maturation, will continue to expand current understanding of these processes 
(Hilz et al., 2016). Metabolic fingerprinting of seminal plasma is another promising 
area of research, especially in cases of idiopathic male infertility (Jafarzadeh et 
al., 2015). Analysis of the circulating metabolome referent to sperm function is a 
similarly another exciting area. However, at present studies using a scalable 
reproducible platform providing quantitative measures are limited. In the current 
thesis I detail how I have used one such approach, nuclear magnetic resonance 
(NMR) spectroscopy, to begin to assess whether the circulating metabolite profile 




1.3 Female infertility 
Primary female subfertility refers to women who have never achieved a clinical 
pregnancy, whereas secondary female subfertility refers to women who have 
previously achieved a clinical pregnancy who cannot establish a subsequent 
clinical pregnancy (Zegers-Hochschild et al., 2017). These definitions are clinical 
definitions that are designed for the early detection and treatment of subfertility, 
as previously noted alternative definitions of infertility may be used for 
demographic or epidemiological purposes (Mascarenhas et al., 2012a). 
 
In women several critical steps are involved in achieving a natural conception. In 
brief follicular development leading to oocyte release from the ovary requires a 
normal menstrual cycle, which is coordinated by a complex interplay of pituitary-
derived and follicle-derived hormones. After an oocyte is released, it enters the 
fallopian tube where it can be fertilized by spermatozoa (sperm) that have 
travelled through the female genital tract. The fertilized oocyte develops as it 
moves through the fallopian tube into the uterine cavity, where the developing 
embryo implants in the endometrium. In women, subfertility can involve any of 
these processes, whereas in men as discussed above, subfertility centres around 
absent or inadequate sperm production. 
 
Common causes of female subfertility include ovulatory dysfunction (such as 
ovarian insufficiency or polycystic ovary syndrome (PCOS)), damaged or blocked 
fallopian tubes, endometriosis and uterine fibroids. Ovarian insufficiency is a loss 
of function of the ovaries that reduces the chance of pregnancy in all women from 
~35 years of age but occurs prematurely in some women. Blocked or damaged 
fallopian tubes can cause subfertility or an increased risk of tubal pregnancy (Shaw 
et al., 2010). Endometriosis can create an unfavourable pelvic environment 
(Horne and Saunders, 2019), whereas uterine fibroids can impede tubal transport, 
cause tubal obstruction or affect embryo implantation, any of which can lead to 
subfertility in women (Hur et al., 2019). In up to 30% of couples, no identifiable 
cause of subfertility can be found after completion of a standard investigation 
protocol, which would include tests of ovulation, tubal patency and semen 
analysis, all of which would be normal (Ray et al., 2012). These cases are 
commonly referred to as unexplained subfertility. In this thesis, I retain this term 




mean that subfertility has no underlying cause, rather, it means that the cause 
has not been identified through a conventional diagnostic work-up, however, age 
which has a critical factor in determining fecundity is not recognised as a 
diagnostic label for a cause of infertility (ESHRE Group, 2017).  
 
1.3.1 Key risk factors for female subfertility 
1.3.1.1 Age 
The pre-eminent and best-established factors that affects fertility is female age 
(Eijkemans et al., 2014)(Figure 1.1). This risk factor is increasingly relevant as 
women worldwide delay childbearing and choose to have their first child at an 
older age. The impact of age is such that for women, the likelihood of pregnancy 
is stable from puberty to approximately 30 years of age, after which it declines in 
an accelerating rate until menopause, when the chance of pregnancy approaches 
zero (Broekmans et al., 2009). Concomitant with this reduction in natural fertility 
is an increase in the risk of miscarriage (Andersen et al., 2000) reflecting a decline 
in oocyte quality and increase in embryos with aneuploidies. 
 
 
Figure 1.1 Reduction in female natural fertility with increasing age. 
The reduction of the ovarian follicle or oocyte pool with increasing age likely 
dictates the onset of declining fertility, the transition from regular to irregular 
menstrual cycles and the onset of menopause. Ageing is associated with a 
logarithmic decline in the number of ovarian follicles and a simultaneous decrease 
in oocyte quality, the latter of which is reflected here by an increased percentage 
of embryos with chromosomal abnormalities / aneuploidies. Reproduced from 





As such chronological age is a strong predictor of the chance of pregnancy, in part 
through its association with the number of follicles present in the ovaries and that 
it reflects oocyte quality. At birth, girls have ~2 million oocytes in their ovaries, 
of which more than half are lost before puberty (Baker, 1963). Following the onset 
of ovulation, a cohort of 40–500 follicles develops each month, of which usually 
only one (the so-called dominant follicle) releases an oocyte (Hodgen, 1983). The 
other follicles degenerate and are ultimately lost through the process of follicular 
atresia. This overall pattern of decline in the number and quality of remaining 
oocytes with increasing age (Figure 1.1), leads to the age-related decline in 
female fertility.  
 
The detrimental effect of increased age on oocyte quality and chance of 
pregnancy is further illustrated by pregnancy outcomes in women who receive 
donor oocytes, with oocytes from young donors having a substantially higher rate 
of subsequent pregnancy than oocytes from older donors, irrespective of the age 
of the recipient (Sunderam et al., 2018). Except for the use of donor oocytes, no 
other established interventions to prevent the age-related decline in fertility are 
available. The precise mechanism by which age affects oocyte quality is unknown. 
One hypothesis is an accumulation of DNA damage in oocytes over time through 
environmental stressors, for example, by certain food or drug residues or by 
reactive oxygen species (Harraan, 1955, Armstrong, 1986). Alternatively, a first-
in-first-out principle (also known as a production line principle) has been 
proposed, whereby high-quality oocytes are primarily ovulated early in life, 
causing lower quality oocytes to be ovulated at later ages. This hypothesis is based 
on the decrease in the frequency of chiasmata (the physical crossover of 
homologous chromosomes) in mouse oocytes with increasing maternal age (Polani 
and Crolla, 1991, Henderson and Edwards, 1968). The reduction in chiasmata 
frequency could also explain the increased number of aneuploidies in oocytes, 
embryos and other products of conception in miscarriages in older women (Hassold 
and Hunt, 2001, van Echten-Arends et al., 2011, Nakagawa and FitzHarris, 2017).  
 
1.3.1.2 Lifestyle factors 
In observational studies, lifestyle factors such as smoking, excessive alcohol 
consumption and caffeine use have been consistently associated with reduced 




significantly associated with current subfertility, including being overweight, 
unprotected sexual intercourse with multiple partners, stress and use of 
marijuana have also been identified as possible contributors (Bunting and Boivin, 
2010). At present whether occupations involving exposure to reproductive toxins 
such as nitrosamines and formaldehyde affect fertility continue to be evaluated 
in prospective studies (Pak et al., 2013). These lifestyle factors are recognised in 
the NHS Scotland eligibility criteria for IVF and form the foundation for access to 
NHS funded IVF, with further details provided in Chapter 2 with discussion of the 
cohort eligibility. 
 
1.3.2 Specific causes of female subfertility, initial evaluation and 
treatment 
A comprehensive fertility assessment is designed to identify the underlying cause 
of subfertility and establish a prognosis. In the context of the recruited cohort for 
this thesis, all couples were already proceeding to IVF so only a brief summary of 
female causes, and diagnostic workup is provided here.  In women the causes may 
be related to ovulatory dysfunction, tubal abnormalities ranging in severity from 
scarring and mild adhesions (fibrous bands between organs) to complete blockage 
or absence of the fallopian tubes, endometriosis, defects in the development of 
the Mullerian duct (which forms the cervix, uterus, fallopian tubes and part of the 
vagina), or other uterine abnormalities can be caused by fibroids, polyps or 
adenomyosis (in which endometrial tissue grows within the muscle walls of the 
uterus). A detailed medical history encompassing menstrual patterns, previous 
pregnancies, medical and surgical factors, lifestyle and family history is designed 
to point to these different causes and guide investigations.  
 
Given the extensive range of causes, baseline investigations for subfertility 
primarily consist of tests to confirm ovulation and tests to identify structural 
abnormalities. A history of regular menstrual cycles is suggestive of satisfactory 
ovulation in most women, although a test to confirm ovulation such as a mid-
luteal-phase progesterone or urinary LH estimation via self-testing is normally 
recommended, with the latter having a strong concordance with both ultrasound 
and serum hormone detected ovulation (Behre et al., 2000). Tubal patency tests 
are advised for suspected tubal diseases, with commonly performed tests 




(HyCoSy) and diagnostic laparoscopy with chromotubation. Hormonal tests (for 
example, serum prolactin, follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) levels) are advised for suspected ovulatory dysfunction. For 
suspected uterine abnormalities, two- or three-dimensional ultrasonography is the 
first-line investigation.  
 
Ovarian reserve tests can be used to identify women with diminished ovarian 
reserve and may identify women at high risk of compromised ovarian function 
owing to increased age (>35 years of age), a family history of early menopause, 
previous gonadotoxic therapy, ovarian surgery or idiopathic declines (La Marca et 
al., 2010). The currently available tests of the ovarian reserve essentially provide 
an estimate of ovarian responsiveness to exogenous stimulation i.e., the 
“functional ovarian reserve” and can be useful for planning the dose of ovarian 
stimulation in women who intend to use ART. Common tests of ovarian reserve 
include circulating levels of follicle stimulating hormone (FSH) and Anti-Müllerian 
Hormone (AMH), and the Antral Follicle Count (AFC).  
 
Increased levels of serum FSH during the early follicular phase of the menstrual 
cycle are associated with reduced ovarian reserve. AMH is secreted by the 
granulosa cells of pre-antral and small antral follicles (<8 mm), and AMH 
concentrations decline with advancing age, mirroring the decline in primordial 
follicles (Hansen et al., 2011) Pretreatment baseline AMH concentrations are 
strongly positively correlated with oocyte yields in IVF cycles (Iliodromiti et al., 
2015). The AFC is defined as the number of ovarian antral follicles (measuring 2–
10 mm in diameter) in the early follicular phase and can be measured using 
transvaginal ultrasonography. An AFC of ≥20 per ovary when measured using a 
transvaginal transducer with a frequency of 8.0 MHz, is used to define polycystic 
ovarian morphology (Teede et al., 2018), whereas an AFC of ≤10 is suggestive of 
diminished ovarian reserve (Kline et al., 2005), and a very low AFC (3–6 follicles) 
strongly suggestive of a poor response during IVF (Hendriks et al., 2005). Although 
both AMH and AFC are good predictors of ovarian response to gonadotropin 
stimulation during IVF, they are generally poor at predicting pregnancy as they 





The initial management of women with subfertility requires explanation of any 
identified cause of subfertility, the provision of a realistic prognosis (with and 
without treatment), advice on management options (including non-intervention) 
and provision of information and support. For the women who have participated 
in this thesis, expectant management, induction of ovulation and / or intrauterine 
insemination, surgical interventions had all been unsuccesful, and so their 
rationale or biological basis is not discussed further, as all participants had moved 
on to receiving IVF.  
 
1.4 In vitro fertilisation 
IVF is a fertility treatment whereby mature oocytes are collected from the ovaries 
and fertilized by sperm outside the body and the resulting embryo(s) judged to 
have the best chance of pregnancy are introduced directly into the uterus.  IVF is 
the mainstay of treatment for women with tubal disease and men with poor sperm 
quality but it is also frequently used for unexplained subfertility, or where other 
less invasive treatments have been unsuccesful. The success rates of IVF are 
broadly similar irrespective of the cause of subfertility, with the notable exception 
that unexplained infertility has been associated with marginally higher success 
rates (Nelson and Lawlor, 2011). It is however worth noting that reporting and 
comparing data on the outcomes of IVF is difficult, owing to a lack of a universally 
agreed way of reporting plus the inherent difficulties in accounting for differences 
between women (for example, age and length of subfertility) and treatment (for 
example, whether pre-implantation testing for aneuploidy (PGT-A) was 
undertaken and how many embryos were transferred). To further highlight this 
although data from >144,000 embryo transfer cycles in European centres in 2013 
(including women with all causes of subfertility) showed a clinical pregnancy rate 
of 34.5% per embryo transfer, single embryos were transferred in only 31% of 
women, whereas two embryos were transferred in 56% of women, with the 
remaining 13% receving three or more (Consortium et al., 2017). In contrast in 
Australia and New Zealand, 87.7% of cycles transferred one embryo, and the 







Figure 1.2 Summary of the five key steps in IVF. 
 
The treatment pathway for IVF is complex, comprising many steps and decision 
points; each step has alternative clinical approaches, some of which are supported 
by robust evidence, whereas others require more research. In broad principal the 
five steps are shown in Figure 1.2. These include the administration of 
gonadotropins to stimulate the growth of ovarian follicles, and gonadotropin-
releasing hormone (GnRH) agonists to suppress the natural menstrual cycle and 
down regulate the pituitary gland (step 1). GnRH antagonists are an alternative to 
GnRH agonists, as they are not associated with hypo-oestrogenic adverse effects, 
flare-up or a long down regulation period and can be used at any time during the 
follicular phase; both regimens have similar live birth rates (Farquhar et al., 
2017). During the ovulation stimulation phase, regular monitoring using 
ultrasonography (with or without blood tests) is undertaken to assess the growth 
of the ovarian follicles and to avoid ovarian hyperstimulation (Kwan et al., 2014). 
When the follicles have reached an appropriate size, final maturation of the 
oocytes is induced (ovulation triggering). Human chorionic gonadotropin (hCG) is 
commonly used as a trigger but can negatively affect endometrial receptivity 
(Evans, 2020, Volvosky et al., 2018, Evans & Salamonsen, 2013) and embryo quality 
and increase rates of ovarian hyperstimulation syndrome (OHSS). An alternative is 
the agonist trigger, which is given if there is an increased risk of OHSS. Oocytes 
are collected, usually with a transvaginal ultrasonography probe for guidance, 
under conscious sedation (step 2). Oocytes and sperm are combined in a Petri dish 
for IVF, or alternatively, ICSI can be used when sperm concentration and motility 
are low (step 3). The fertilized oocyte, now called a preimplantation embryo, is 
cultured for 2–6 days in vitro (step 4). From the pool of available embryos, usually 
one embryo (although more can be transferred) is selected for transfer (step 5). 




vitrification and can be subsequently thawed and transferred one-by-one if 
pregnancy was not established after the initial fresh embryo transfer or if all 
embryos were electively cryopreserved or if the couple desires an additional child. 
Drugs such as progesterone or rarely hCG are administered for luteal support to 
improve the likelihood of implantation and pregnancy and are usually stopped at 
12 weeks of gestation (van der Linden et al., 2011). All of these individual 
variables were recorded in the preparation of this thesis and associated database, 
however, in chapter 6 I have focused on the principal outcome of ongoing 
pregnancy as defined by a fetal heart at 20 weeks gestation from the first embryo 
transfer whether it be a fresh or frozen embryo transfer cycle.  
 
1.5 Impact of cardiometabolic health on reproductive outcomes in 
men and women 
In men several studies have shown that men with lower quality semen — as indexed 
by concentration, count, motility — have an increased risk of mortality, chronic 
disease, and health service use in the future (Jensen et al., 2009, Latif et al., 
2017, Eisenberg et al., 2014b), suggesting that semen quality may be an early 
biomarker of long-term health (Del Giudice et al., 2020). Of the observed 
associations with future-health and morbidity, the strongest associations are with 
the full range of cardiometabolic disease including hypertension, hyperlipidaemia, 
peripheral vascular complications, ischaemic heart disease and diabetes mellitus 
(Latif et al., 2017, Eisenberg et al., 2016), with little or no association observed 
with future mental health disorders like depression (Latif et al., 2017, Eisenberg 
et al., 2016).  
 
The mechanistic link between male factor infertility and future adverse health 
remains uncertain, although several alternative potentially non-mutually 
exclusive explanations have been proposed. Firstly as approximately 10% of the 
male genome is involved in reproduction, it is likely that other nonprocreative 
processes may also be affected by aberrations in fertility (Matzuk and Lamb, 
2008). Secondly, investigators have hypothesized that fetal exposures may lead to 
both adverse reproductive and somatic health in adulthood, with testicular 
dysgenesis and testicular cancer being the archetypal example of this (Barker, 
1995). A third theory proposes a hormonal explanation. Men with infertility have 




Because hypogonadism is a risk factor for cardiovascular disease and mortality, 
such an explanation may link infertility to cardiovascular disease (Kay-Tee and 
Chir, 2007). Fourthly, although infertility may be a marker of diminished fitness, 
which may accelerate the development of impaired health in the future, it may 
also occur as a consequence of current ill health, whether it be clinical or 
subclinical (Salonia et al., 2009). As such, unrecognized preclinical chronic 
diseases may diminish male fertility and lead to impaired health later in life. 
Lastly unmeasured confounding may also contribute as the men who have 
participated in these studies (irrespective of whether through data linkage or 
prospective cohorts) have largely been identified through infertility clinics and 
potentially important covariates have typically not been collected. While there 
seems to be a consensus that selected risk factors for mortality — cigarette 
smoking (Sharma et al., 2016b), higher alcohol intake (Ricci et al., 2017a), and 
obesity or overweight (Sermondade et al., 2013) — are correlated with poorer 
semen quality, there is a paucity of evidence for many other characteristics, 
particularly biomarkers such as blood pressure, blood glucose and blood 
cholesterol, which have only been assessed in a few studies (Batty et al., 2019, 
Ma et al., 2020). Assessment of the association of metabolite profiles including 
lipoprotein lipids, fatty acids, amino acids, ketone bodies, and glycemic traits 
which are already known to be associated with cardiometabolic disease and long-
term mortality (Deelen et al., 2019), would be of interest as it may identify a 
common mediation pathway and contribute further to the etiologic understanding 
of male factor infertility (Würtz et al., 2017). 
 
In women, adverse pregnancy outcomes have long been recognised as a potential 
sentinel event for identifying those at increased risk of future cardiovascular 
disease (Bellamy et al., 2007). Women with history of hypertensive disorders of 
pregnancy (HDP) have approximately a 2-fold increased risk of cardiovascular 
disease compared with women with normotensive pregnancies (Brown et al., 
2013, Wu et al., 2017). Reproductive risk factors are not however limited to the 
obstetric period. Common causes of secondary infertility, including polycystic 
ovary syndrome, premature ovarian insufficiency, endometriosis, and pelvic 
inflammatory disease, have all been linked to an increased risk of cardiovascular 
disease (Anderson et al., 2014, Mu et al., 2016, Liou et al., 2013). Also, early age 




associated with an increased risk of cardiovascular disease (Lidegaard et al., 
2012).  
 
Adverse pregnancy outcomes and cardiovascular disease share certain common 
(traditional) risk factors, including hypertension, hyperglycaemia, and obesity. It 
has been suggested that in women experiencing pre-eclampsia and the range of 
hypertensive disorders of pregnancy, the attributable excess risk of cardiovascular 
disease related to these conventional risk factors may be substantial (Haug et al., 
2019).  One cohort study suggested that blood pressure and body mass index alone 
were associated with up to 77% of the excess risk, while glucose and lipids were 
associated with smaller proportions (Haug et al., 2019).  Others have previously 
found that only up to 15% of the risk of coronary heart disease in young women 
(aged <65) could not be accounted for by traditional risk factors (Khot et al., 
2003). That women with hypertensive disorders of pregnancy already had more 
adiposity, higher blood pressure and glucose levels, and more adverse lipid levels 
before their first pregnancy (Magnussen et al., 2007), and that their cardiovascular 
risk factor levels remained higher than women without HDP through age 50 years 
and beyond (Haug et al., 2018), suggests a theoretical risk trajectory which is 
quite different from women without reproductive complications. It also suggests 
that the adverse risk profile precedes any index event or pregnancy and 
potentially continues to be abnormal thereafter. This divergent adult 
cardiovascular risk factor trajectory may reflect a combination of genetic, in-
utero conditions, and different lifestyle patterns in childhood and adolescence 
that culminate in breaching a diagnostic threshold and manifesting clinical disease 
in adult life (Sattar and Greer, 2002). 
 
Despite the wealth of data assessing the key events across a womens life course 
and there association with cardiovascular disease (Okoth et al., 2020), there has 
been limited assessment of the need for fertility treatment i.e. subfertility with 
long term cardiometabolic disease (Park et al., 2015). There is some suggestion 
that a history of subfertlity identifies a subpopulation at increased risk. Women 
who experienced some degree of infertility but eventually still conceive, there is 
evidence of a small increase in cardiovascular disease risk even after accounting 
for traditional cardiovascular risk factors (Parikh et al., 2012). There is also some 




miscarriage with cardiovascular disease (Ranthe et al., 2013, Pell et al., 2004). 
However, receiving fertility treatment (ovulation induction, in vitro fertilisation, 
and intrauterine insemination with drug treatment) has not been associated with 
increasing the risk of developing a composite cardiovascular disease outcome or 
stroke as compared to infertile women not receving fertility treatment (Dayan et 
al., 2017). Collectively this suggests that it is the baseline pretreatment 
phenotype which is critical, and that the associated cardiometabolic profile may 
determine both the immediate IVF clinical outcome and risk of pregnancy 
complications but also the longer term risk of cardiovascular disease.  
 
1.6 Summary  
In conclusion, the preceding literature review has provided evidence regarding the 
magnitude of the problem of infertility, summarised the basic causes, 
investigations and treatment pathways of the infertile couple and tried to 
highlight the need for novel quality research regarding the baseline phenotype 
and its potential impact on male, female and couple outcomes.  In addition to the 
continued efforts to improve established assisted conception techniques and 
radical new approaches including the use of stem cells to create oocytes or sperm, 
the creation of synthetic embryos, gene editing, prolonged embryo culture, 
artificial gametes, and the development of an artificial uterus, three overarching 
priorities for future research have recently been highlighted (Farquhar et al., 
2019). These include addressing the preventable causes of subfertility, providing 
support and alternatives for individuals with subfertility and encouraging new 
initiatives to increase the global accessibility, affordability, and acceptability of 
assisted reproductive techniques. The establishment of a cohort of couples 
requiring IVF with a detailed and comprehensive biobank will contribute to two of 
these overall priorities. Similarly, clarification of the role of the metabolic profile 
in determining male and female fertility and clinical outcomes informs these 
priority areas, as identification of a baseline metabolic phenotype which is 
associated with important clinical outcomes may aid development of novel 





1.7 Overall aim and specific objectives 
This thesis details my recruitment and development of a cohort of 400 women and 
their male partners undertaking IVF, with a detailed and comprehensive database 
detailing pretreatment, clinical and laboratory information and the establishment 
of an extensive accompanying Biobank of biological samples including maternal 
and paternal plasma, serum and DNA and isolated RNA from vaginal swabs suitable 
for future microbiome analysis. On completion of recruitment, I performed 
detailed metabolic profiling of both female and male participants using a high-
throughput NMR metabolomics platform, covering a wide range of metabolic 
pathways including lipoprotein lipids, fatty acids, amino acids, ketone bodies, and 
glycemic traits, which are highly relevant to cardiometabolic risk and overall 
health. This has enabled me to address four specific objectives:  
 
1.  Determine the association of the functional ovarian reserve with the 
circulating metabolite profile. 
2. To determine whether 155 circulating metabolic measures relevant to 
lifestyle and metabolic health are associated with sperm parameters (as 
measured by concentration, motility and total motile sperm count (TMSC)). 
3. To assess the correlation within couples undergoing fertility treatment of 
physical, social and behaviour characteristics, and 155 circulating metabolic 
measures. 
4.  To establish whether in men and women undergoing IVF if preconceptual 
circulating metabolites are associated with ongoing pregnancy rates. While live-
birth per cycle would be the preferred clinical outcome, this was not feasible due 
to time restraints and the prolonged follow-up that would be required for those 
women with multiple frozen embryos. However, it is increasingly recognised that 
ongoing pregnancy per cycle, is an appropriate surrogate particularly if ongoing 
pregnancy is defined at later gestations (e.g. 20 weeks as used in this thesis) due 






Chapter 2 Material and Methods 
2.1 Introduction 
This chapter addresses the methods employed in recruiting volunteers for the 
research, the data collected from the participants and the measurements used to 
conduct the study. Through this thesis, multiple methodologies have been used 
and adapted to address the research questions. In broad terms, participants were 
prospectively recruited, baseline characteristics and medical history recorded, 
biological samples (blood samples and vaginal swab) collected and then 
comprehensive ovarian stimulation, embryology and clinical outcomes were 
gathered for each participant as they progressed through their treatment 
pathway. A unique comprehensive database was developed to record this 
information for all participants. Appropriate statistical analyses were developed 
for each individual research question. 
 
This study was conducted with the ethical approval of Scotland A Research Ethical 
Committee (REC reference 16/WM/308) and Clinical Research & Development in 
NHS Greater Glasgow and Clyde (R&D reference GN16OG323). A research passport 
was granted from the Occupational Health Unit at the University of Glasgow to 
the principal investigator (KA). A copy of the ethical approval documentation is 
provided in Appendix I. Patient recruitment commenced in September 2016, with 
the last particiant recruited in June 2018, with data collection censored in January 
2020. This allowed 18 months from recruitment of the last participant for 
completion of treatment prior to closure of the study.  
 
2.2 Design, Setting and Participants 
This was a prospective longitudinal cohort study of 731 participants, comprising 
of 400 women and 331 male partners, receiving assisted conception at Glasgow 
Royal Infirmary between September 2016 and January 2020. The study was wholly 







Participants were recruited from the assisted conception Unit at Glasgow Royal 
Infirmary, an NHS Scotland Assisted Conception Service providing quaternary level 
care to a regional population of 2,810,900 (Wikipedia, 2018). The service is 
licensed by the Human Fertilisation Embryology Authority (HFEA) for a range of 
assisted conception treatments including ovulation induction with oral agents and 
gonadotrophins, Intra-uterine Insemination (IUI), in vitro fertilisation (IVF), intra-
cytoplasmic sperm injection (ICSI), frozen embryo transfer (FET), pre-
implantation genetic testing for structural rearrangements (PGT-SR), pre-
implantation genetic testing for monogenic disorders (PGT-M), pre-implantation 
genetic testing for aneuploidy (PGT-A) and storage of gametes and embryos. These 
services are provided under a combination of NHS and private funded treatments 
with approximately 1100 IVF/ICSI cycles and 500 FETs undertaken per annum.   
 
NHS Scotland eligibility criteria for the provision of assisted conception services 
and in particular IVF/ICSI are as follows; infertility with an appropriate cause, of 
any duration, or unexplained infertility of two years for heterosexual couples or 
unexplained infertility following six cycles of donor insemination. Additional 
eligibility criteria include; neither partner to have undergone voluntary 
sterilisation or undertaken reversal of sterilisation. Couples must have been 
cohabiting in a stable relationship for a minimum of two years. Couples where 
only one partner has legal parenthood of a child (or a biological child) can access 
NHS funded treatment as long as all other access criteria are met in full. Same sex 
couples will not be eligible if they already have a child in the home and both have 
consented to legal parenthood of that child. There is a responsibility on patients 
to fulfil the following access criteria in the interests of the welfare of the child 
and the effectiveness of treatment. The female partner must have a BMI above 
18.5 and below 30. Both partners must be non-smoking for at least three months 
before treatment and couples must continue to be non-smoking during treatment. 
Both partners must abstain from illegal and abusive substances. Both partners 
must be Methadone free for at least one year prior to treatment. Neither partner 
should drink alcohol prior to or during the period of treatment.  
 
For NHS funding purposes one full cycle of IVF includes ovulation induction, egg 




suitable embryos and the subsequent replacement of these, provided the couple 
still fulfil the access criteria. If suitable embryos are frozen these should be 
transferred before the next stimulated treatment cycle. No individual (male or 
female) can access more than the number of NHS funded IVF treatment cycles 
supported by NHS Scotland under any circumstances, even if they are in a new 
relationship. 
 
The number of cycles initiated by the date of the female’s 40th birthday is up to 
three cycles of IVF/ICSI, where there is a reasonable expectation of a live birth. 
Clinical judgement is required to be applied to determine this, using an 
assessment of ovarian reserve before the first cycle. If there has been no or a poor 
response to ovarian stimulation (<3 eggs retrieved) in the first cycle no further 
IVF/ICSI treatment will be funded. Fresh treatment cycles must be initiated by 
the date of the female partner’s 40th birthday and all subsequent frozen embryo 
transfers must be completed before the woman’s 41st birthday.  
 
For women aged 40 to 42 years old one cycle of treatment may be funded for 
couples if the female has never previously had IVF treatment, if there is no 
evidence of poor ovarian reserve and if in the treating clinician’s view it is in the 
patients’ interest. Eligible patients must be screened before the female partners 
42nd birthday. 
 
For frozen embryo transfers, should circumstances change and couples no longer 
meet the NHS eligibility criteria self-funding for any future transfers will be 
required. 
 
For patients who have previously funded treatment NHS funding may be given to 
those patients who have previously paid for IVF treatment, if in the treating 
clinician’s view, the individual clinical circumstances warrant further treatment. 
 
Patients not meeting these criteria are eligible to self-fund treatment provided 






I prospectively recruited 731 participants undergoing IVF/ICSI treatment. The final 
cohort comprised of 400 females and 331 male partners. The discordance in the 
number of female and male participants reflected that some female participants 
were receiving treatment as either single women or as a same-sex couple using 
donor sperm, the male partner did not accompany the female partner to the 
clinic, the male partner attended on a different day that conflicted with other 
patient's recruitment / pre-existing commitments, or in rare occasions, the male 
partner refused to participate. Detailed inclusion and exclusion criteria are 
provided below, but in brief all participants were greater than 18 years in age, 
were using autologous oocytes and were not participating in oocyte or embryo 
donation. Some couples were female same-sex couples and were using a sperm 
donor. Of the 399 female participants with complete metabolite data, 271 (67.9%) 
participants had primary infertility and 127 (31.8%) secondary infertility. The 
cause of infertility similarly varied, with 211 (52.9%) participants having 
unexplained infertility, 84 (21.1%) with female factor and 87 (21.8%) with male 
factor. Although this range of diversity may have contributed to potential 
heterogeneity between the participants and the associated metabolic profiles, 
adjusted and unadjusted analyses to assess any potential effects of infertility 
status. 
2.2.3 Eligibility 
All women and their partners from all races attending the assisted conception 
service unit at Glasgow Royal Infirmary for IVF/ICSI treatment were eligible for 
participation irrespective of whether they were NHS or privately funded. There 
was no upper age limit. The number of female participants recruited above the 
age of 40 was 34 (8.5%), reflecting the local clinical population. Patients receiving 
NHS funded treatment met the NHS Scotland criteria for funding as listed above.  
 
2.2.3.1 Inclusion criteria 
Undergoing IVF/ICSI treatment at Glasgow Royal Infirmary. 
 
2.2.3.2 Exclusion criteria 
Participants were excluded if ether partner was less than 18 years old or the 




study includes a large number of participants, reflecting a potentially 
heterogenous clinic population. However, this inclusive approach ensured timely 
recruitment, a diverse population ensuring generalisability of my results and I 
undertook appropriate sensitivity, multivariate and univariate analyses to ensure 
the robustness of my findings. 
 
2.3 Study documentation 
All the documents used in the study were developed by the principal investigator 
(KA). Each participant received three documents. The Participant Information 
Sheet (PIS) (Appendix II) was the first document to be handed to the prospective 
participant, as it contained comprehensive details of the study, its purpose, aim 
and anticipated outcome. In addition, it contained the contact details of the chief 
investigator and the principal investigator. The second document was the 
informed consent (Appendix III) which acted as the contract between the principal 
investigator and the participant. By signing the informed consent, the 
participatant acknowledged that the study has been explained, they were aware 
of what was involved and that they consented to participate in in the study. The 
third document represented the baseline questionnaire (Appendix IV). This 
document asked the participant to provide the principal investigator with personal 
information including baseline lifestyle, medical, fertility and family history 
details. Case Report Form (CRF) (Appendix V) is the document where I the 
principal investigator (KA) recorded additional medical information for each 
participant by gaining access to the participant's medical record. All documents 
were created in two versions; male and female. All documents were approved by 
the Ethics panel and Research and Development prior to commencement of the 
study. 
 
2.4 Recruitment process 
The study and participant recruitment were designed to align with routine clinical 
care pathways to minimise disruption to patients and maximise recruitment. The 
majority of the patients treated within the ACS Unit were in receipt of NHS funding 
and thus were subject to NHS waiting list for assisted conception prior to 
commencing treatment. When patients are at the top of the waiting list for NHS 
treatment, they are routinely provided with three separate consecutive clinic 




between the first and the second visit. Whereas the third visit will be after 4-7 
weeks depending on the patient's menstrual cycle. The principal purpose of these 
visits is to provide baseline health screening, completion of HFEA consents and 
blood sampling for blood borne-viruses respectively. This routine care pathway 
provided a logical sequence of clinics to engage with participants to provide 
information regarding the study, obtain informed consent and collect additional 
blood samples when undergoing routine phlebotomy. The participants were not 
required to attend any additional appointments other than their routine 
appointments within the ACS Unit. An overview of the routine care pathway, 




Figure 2.1 Flowchart illustrating the recruitment process 
Routine care visits are contained within rectangles and the action by the principal 
investigator KA at each visit are shown in the circles.  
 
At the first visit, all couples attending the ACS Unit to commence their IVF/ICSI 
treatment were provided with a Patient Information Sheet. The principal 
investigator (KA) discussed the study in detail with the potential participants and 
answered any questions they might have. The principal investigator assured the 
participants that they had the right to decline participation or withdraw from the 
study at any time, without any adverse on their clinical care. 
 
At their second visit, prospective participants were asked if they wished to 




participation in the study. This enabled me to collect routine clinical data related 
to their treatment from their medical notes and perform study specific 
procedures. After obtaining the consent, both partners were asked to complete 
the baseline questionnaire, which took approximately 10 minutes to complete. 
After completing the baseline questionnaire, participant height, weight and blood 
pressure were measured as detailed below.  
 
At the third and final visit, on approximately day 21 of the menstrual cycle prior 
to initiating ovarian stimulation, blood was routinely taken from both partners for 
assessment of blood borne-viruses (Hepatitis B, Hepatitis C and Human 
Immunodeficiency Virus (HIV)). At this visit, I took an additional aliquot of blood 
(24mL) for isolation of serum, plasma and DNA. In addition, a high vaginal swab 
was obtained for DNA extraction and future bacterial taxonomic assessment. 
 
After this final visit there was no further direct interaction between myself and 
the participant, with all subsequent data collected from routine clinical records. 
The recruitment process took 21 months to be completed. 
 
2.5 Development of the study-specific database 
A comprehensive study-specific database was created by myself in Excel 
(Microsoft, Redmond, USA) to facilitate detailed data collection for each 
participant. This database was designed to enable recording of all lifestyle, family 
and personal medical history characteristics, baseline infertility assessment, 
ovarian stimulation details, embryological outcomes including time-lapse 
parameters for transferred embryos and clincial and pregnancy outcomes for both 
the fresh and frozen embryo transfers. In additon the database incorporated the 
Nuclear Magnetic Resonance (NMR) testing results. For each participant the final 
database contained more than 500 individual variables, with subsequent transfer 
to Stata v15.1 (College Station, Texas, USA) for statistical analyses.  
 
2.5.1 Participant's baseline, personal and family medical history 
and lifestyle characteristics. 
Each participant completed a questionnaire to provide general lifestyle data 




in the relevant methods of each results chapter. In brief these characteristics 
included their self-reported ethnicity, their marital status, their occupation, 
educational attainment, smoking status, alcohol consumption, the frequency and 
intensity of exercise per week. With respect to their own medical history 
participants were asked if they were currently receiving any medical care or 
taking any medication and specifically whether they have taken steroids within 
the last 2 years. They were also asked if they had suffered a prolonged illness or 
been hospitalized in the past, or had any major surgery. Participants were 
specifically questioned regarding a personal history of cardiometabolic conditions 
including heart attacks, strokes, high blood pressure, elevated cholesterol, 
diabetes, congenital heart disease, cardiac operations and obesity. Female 
participants were also asked regarding vaginal symptoms including vaginal 
discharge and itch, dyspareunia and whether they had ever sought medical advice 
for the symptoms and if so the diagnosis and treatment provided. Both male and 
female participants were asked regarding whether their sexual partner had 
symptoms of irritation burning or discharge and if so the details of this including 
diagnosis and treatment provided. With respect to family history they were asked 
whether first-degree relatives had experienced cardiometabolic conditions 
including heart attacks under the age of 50, strokes under the age of 50, 
hypertension, elevated cholesterol, diabetes, congenital heart disease, cardiac 
operations or obesity.  
 
2.5.2 Additional details regarding the participant's medical history 
As part of the consent the participant had signed, permission to access the 
participant's medical record in the NHS database was provided. Additional 
information regarding any operations, or past medical history of note was 
recorded.   
 
2.6 Anthropometry and blood pressure  
All participants male and female had baseline anthropometric and blood pressure 





2.6.1 Height  
A stadiometer (Invicta Plastics Ltd, Leicester, UK) was used to measure the height 
of the participant with no shoes on, their feet joint at their heels and resting flat. 
The participant's buttocks and upper part of their body were positioned against a 
fixed surface and touching the stadiometer. The participants were instructed to 
straighten their back and take a deep breath in and the height was measured at 
the end of the exhalation by the PI lowering a moveable headboard on the top of 
the patient's head by applying a gentle pressure downward to allow hair 
compression. The measurement was taken to the nearest millimetre. 
 
2.6.2 Weight and body mass index 
The body weight of the participants was measured using calibrated scales 
(Marsden Ltd, Rotherham, UK), approved for medical and research purposes. 
Patients were weighted wearing lightweight clothing, barefoot, having both feet 
flat and arms in a lateral resting position. Measurements were taken to the nearest 
0.1 kilogram.  
 
Body Mass Index was calculated as weight / height2 and recorded to one decimal 
place. 
 
2.6.3 Blood pressure 
Resting seated blood pressure was measured using an Omron automated monitor 
(Omron Healthcare Ltd, Milton Keynes, UK). Patients were asked to sit with their 
arm resting on a table, relax, not to cross their legs during the procedure and to 
stop talking. Two blood pressure recordings were taken two minutes apart and the 
average of the two blood pressure measurements recorded.  
 
2.7 Creation of the Biobank 
2.7.1 Blood sample collection   
A non-fasting blood sample (total 24mls) was collected at the third visit by myself 
using venipuncture from an antecubital vein with the use of a vacutainer blood 
collection set (BD Vacutainer; Push Button Blood Collection Set, BD, New Jersey). 
Blood samples were collected in collection tubes (BD Vacutainer; Blood Collection 




purple top) and two 4ml serum blood (yellow top). The collected sample tubes 
were inverted several times after collection and left on ice, or in the fridge at 4oC 
if multiple participants were having venepuncture consecutively before being 
moved by the PI to the laboratory for sample preparation.  
 
2.7.2 Sample preparation and storage 
On transfer to the laboratory the blood samples were centrifuged at 2,000 G-force 
and 4-6 °C for 10 minutes. After centrifugation, the sample layers could be 
distinguished. For the EDTA tubes; a layer of clear fluid (the plasma), a layer of 
red fluid containing most of the red blood cells, and a thin layer in between, the 
buffy coat which contains most of the white blood cells and platelets (Figure 2.2 
below). The plasma was aliquoted into multiple separate tubes each containg at 
least 350µl and the the separated buffy coat stored separately with each tube 
labelled with the participant unique ID. Serum samples were similarly aliquoted 
into labelled tubes. All aliquots were split between two -80 °C freezers and stored 
at -80 °C in the main laboratory at Level 3, New Lister Building (Glasgow Royal 
Infirmary) (each participant has 4 plasma aliquots and 2 serum aliquots). 
 
Figure 2.2 Illustration of the different layers of blood after centrifugation.  
 
EDTA samples were centrifuged at 2,000 g for 10 minutes and the plasma and buffy 
coat layers stored separately.  
 
2.8 Vaginal swab samples 
The development of non-culture-dependent DNA sequencing has aided our general 
understanding of the composition of the microbial communities which inhabit the 




that the balance of microbial species may greatly affect the health of the host, 
with disturbances in the composition of the bacterial communities, contributing 
to various disease states including infertility. As part of the development of a 
comprehensive Biobank we collected a vaginal swab sample from each participant, 
with isolation of the DNA and storage for future interrogation.  
 
2.8.1 Collection procedure 
The vaginal swab was collected using a Regular Nylon Flocked Swab which was 
individually wrapped to prevent contamination (Thermo Scientific, UK). The swab 
was taken by the participant herself in the third visit as it was a relatively 
straightforward procedure with guidance provided by the PI during the process. 
The PI encouraged the participant to wash her hands before and after the process. 
The patient was instructed to pull the cap with the attached swab off  the tube 
and not to touch the soft tip or lay the swab down. Then, to hold the swab by the 
cap with one hand so the swab tip is pointing toward the participant and with the 
other hand, gently spread the skin outside the vagina to insert the tip of the swab 
into the vaginal opening pointing the tip toward her lower back with her muscles 
relaxed. The patient was advised to gently slide the swab no more than two inches 
into the vagina. If the swab does not slide easily, then the participant was 
instructed to gently rotate the swab as she pushed and to make sure the swab 
touched the walls of the vagina so that moisture was absorbed by the swab. 
Finally, the participant was asked to rotate the swab for 10 to 15 seconds before 
withdrawing the swab without touching the skin and place it in the tube and secure 
the cap. Figure 2.3 shows the process of the vaginal swab sample collection. The 
swabs were appropriately labelled after collection by the participant and stored 
in cold environment (i.e the clinic refrigerator), before being transferred later 
that day to the laboratory. 500μl of DNA free treated water was placed into a 2ml 
microtube and the end of the swab placed into it and agitated for 2 minutes before 
the swab was cut appropriately to facilitate secure closure and then stored in the 
assigned -80oC freezer in the laboratory of Level 3 in the New Lister Building, 





Figure 2.3 Illustration of the steps for vaginal swab self-collection.  
Panel 1: Twist the cap to break the swab seal. Panel 2: gently spread the outer 
skin of the vagina and slowly insert the swab through the vagina. Panel 3: keep 
inserting the swab for no more than 2 inches approximately. Panel 4: Rotate the 
swab to collect the sample from the inner wall of the vagina. Panel 5: slowly 
retrieve the swab and immediately put it again into the cap and reseal it by 
twisting the swab with caution. 
 
 
2.8.2 DNA extraction protocol  
As there is the potential for DNA degadation with time, it was essential to perform 
DNA extraction within 6 weeks of sample collection. To ensure uniformity of 
storage conditions I selected three weeks after the sample was collected as an 
appropriate time to perform DNA extraction. 
 
Several methods were initially compared for DNA extraction using pilot samples 
obtained from healthy volunteers. The optimal method based on DNA purity and 
quantity was the DNeasy PowerSoil kit (Qiagen, Germany), which was performed 
according to the manufacturers instructions. In brief I added 0.25g of the swab 
sample to the PowerBead Tubes which contained a proprietary buffer and then 
gently vortexed to mix. After that, 60μl of solution C1 was added and the tube 
vortexed briefly (Solution C1 contains SDS and additional disruption agents 
required for cell lysis). Next, the PI heated the mixture to 70°C for 5 minutes then 
vortexed it for 3-4 seconds. The PI used the fast preparation methodology with 24 
devices treated concurrently for 60 seconds with setting 6, then rested for 2-3 




minutes at room temperature. A supernatant appeared within the tube and this 
was subsequently transferred to a clean 2ml collection tube. I added 250μl of 
solution C2 and vortexed for 5 seconds then incubated at 4°C for 5 minutes. After 
that, the tubes were centrifuged at room temperature for 1 minute at 10,000g. 
Avoiding the pellet, I transferred up to, but not more than, 600μl of supernatant 
to a clean 2ml collection tube. Then, a 200μl of solution C3 was added and 
vortexed briefly before it was incubated at 4°C for 5 minutes. Solution C3 is 
patented Inhibitor Removal Technology (IRT) and is a second reagent to 
precipitate additional non-DNA organic and inorganic material including humic 
acid, cell debris and proteins.  The tubes were centrifuged at 10,000g at room 
temperature for 1 minute. Avoiding the pellet, I transferred up to, but no more 
than, 750μl of supernatant into a clean 2ml collection tube. Then, 1200μl of 
solution C4 (a high-concentration salt solution) was added to the supernatant and 
vortexed for 5 seconds. Approximately 675μl was loaded onto a Spin column and 
centrifuged at 10,000g for 1 minute at room temperature, with the flow through 
discarded. This was repeated with an additional 675μl of supernatant added to 
the Spin column and centrifuged at 10,000g for 1 minute at room temperature. 
Next, the remaining supernatant loaded onto the Spin column and centrifuged at 
10,000 g for 1 minute at room temperature. I then added 500μl of solution C5 (an 
ethanol based wash solution) and centrifuged the sampel at room temperature for 
30 seconds at 10,000g and discarded the flow through, then centrifuged again at 
room temperature for 1 minute at 10,000g. After that, the Spin column was placed 
carefully in a clean 2ml collection tube while ensuring there was no splashing of 
any Solution C5 onto the Spin column. Then, 100μl of solution C6 (sterile elution 
buffer) was added to the centre of the white filter membrane and centrifuged at 
room temperature for 30 seconds at 10,000g. The final step was discarding the 
Spin Filter and by then, the DNA in the tube was ready for any downstream 
application.  
 
I used a Nanodrop Spectrophotometer (Thermo Scientific, Waltham, 
Massachusetts, USA) to quantify and assess the purity of DNA extracted from each 
sample. This device performs full-spectrum UV-Vis absorbance analyses (220-
750nm) and is designated for measuring the absorbance of DNA, RNA, microarray 
labelling dyes, and proteins. The advantages of the Nanodrop Spectrophotometer 




dilution needed for most samples and no cuvettes or capillaries. Figure 2.4 below 
shows two examples of DNA extraction from two different vaginal swab samples. 
Samples that has a 260/280 value greater than 1.6, a 260/230 ratio >2.0 and a 
concentration greater than 50 ng/uL were deemed acceptable.  
 
 
Figure 2.4 Nanodrop Spectrophotometer screenshots assessing purity and 
quantity of DNA derived from vaginal swabs. 
Panel (a): The concentration is 32.8 ng/uL, the 260/280 value is 1.64, and the 
260/230 value is 1.28. The 260/280 value, which indicated the contamination 
relative to other protein, was at low end of the acceptable range. In addition, the 
260/230 value of 1.28 indicates potential contamination. The concentration is also 
low. Overall this sample was not acceptable.  
Panel (b): The concentration is 61.8 ng/uL, the 260/280 value 1.78, and the 




2.9 Clinical procedures 
2.9.1. Clinical investigation  
All patients underwent full clinical assessment to diagnose the cause of infertility 
prior to being placed on the waiting list for treatment. All blood tests (FSH, 
Oestradiol, LH, Prolactin, Thyroid hormones, Androgens, Progesterone, viral 
screen) and semen evaluation were performed by Clinical Pathology Accredited/ 
ISO15189 laboratories within 12 months of treatment starting. Tubal patency 
testing if undertaken was either by hysterosalpingogram, hysterosonography or 
laparoscopic hydrotubation as deemed appropriate by the referring clinician.  
 
2.9.2 Anti-Müllerian Hormone Measurement  
Anti-Müllerian Hormone serum concentrations were determined when the patient 




determine which ovarian stimulation protocol they would receive. AMH was 
measured on a random day of the menstrual cycle using the Beckman Coulter AMH 
automated method on a clinically validated immunoassay platform (Access 2, 
Beckman Coulter, USA). The assay was calibrated and quality controlled using the 
manufacturer's reagents and is known to have a measuring range of 0.08 – 24ng/ml 
(0.57 – 171 pmol/l). The limit of quantitation (LoQ) was 0.02 ng/ml (0.014pmo/l), 
with the 20% CV LoQ 0.08ng/ml (0.57pmol/l). The coefficient of variation between 
runs for two levels of control ran at <4.4%.  
 
2.9.3. Antral Follicle Count Measurement 
Antral Follicle Count was determined on day 2–4 of the menstrual cycle, prior to 
the patient commencing ovarian stimulation. Transvaginal ultrasound was 
performed by reproductive endocrinologists or nurses experienced in the 
measurement of AFC. AFC was defined as the sum of follicles 2–10 mm in diameter 
in both ovaries (Broekmans et al., 2010) 
 
2.9.4 Down-regulation, stimulation and follicle tracking 
Stimulation protocols were based on plasma AMH for treatment naïve patients 
(Nelson et al., 2009), and for those with previous treatment this was guided by 
previous ovarian response to gonadotrophin stimulation. The aim for all patients 
was to optimize the ovarian response and facilitate a fresh embryo transfer while 
maintaining a low risk of OHSS and minimal treatment burden. 
 
Pituitary Regulation was achieved in one of two ways: 
(a) Down regulation with agonist leuprorelin acetate 3.75mg (Prostap, Takeda UK 
Ltd, UK) was commenced on approximately day 21 of the cycle and topped up if 
required with buserelin (Suprecur®, supplied by Pharmasure) given at a dose of 
0.5mg once a day, and continued throughout FSH administration; 
 
(b) GnRH Antagonist; Cetrorelix acetate (Cetrotide® Merck Serono) was given as 
an additional injection during the time patients were being given stimulation 






For those patients receiving down-regulation this was confirmed after 14 days by 
determination of serum oestradiol <50pg/ml or 180pmol/L and a transvaginal 
ultrasound of the uterus and ovaries (endometrial thickness, ovarian volume, 
number and size of follicles). If the endometrium was not less than 4mm or a cyst 
≥10mm was observed (functional or not), the scan was repeated in one week. If 
the endometrium continued to be greater than 3mm or a cystic structure was seen 
on the ovaries (polyps ≥1cm are removed), then the stimulation cycle was delayed 
pending further investigation. 
 
FSH stimulation (Menopur® Ferring or Gonal F® Serono) was started at a dose that 
was determined by the serum AMH and response in previous cycles (starting dose 
of 150IU, with increments of 75IU to a possible maximum of 450IU of FSH). 
 
All patients were scanned by ultrasound on Day 6 or 8 of FSH administration at 
which time endometrial thickness was determined and the sizes of all ovarian 
follicles above 10mm were recorded. In addition, the number of follicles less than 
10mm were recorded. Daily FSH administration was continued at the same dose, 
if follicular development was seen, and patients scanned at regular intervals. The 
daily dose of FSH was adjusted according to the total follicle number and size of 
the follicular cohort. Patients were only accepted for egg collection when there 
were three follicles ≥17mm in diameter on ultrasound, or there was no potential 
for further follicular development in anticipated poor responders. Thirty-six hours 
prior to oocyte retrieval, 6,500IU of human Chorionic Gonadotrophin (hCG; 
Ovitrelle® Merck) was administered. Patients stopped Buserelin injections or 
Cetrotide after the hCG was administered and started taking micronized 
progesterone (Cyclogest® Abbott) 400mg twice daily the evening of the oocyte 
retrieval. For those patients at risk of excessive response, the cycle was either 
cancelled if it was an agonist-controlled cycle or for those on antagonist protocols 
an agonist trigger was administered (0.5mg Buserelin) and the cycle segmented, 
with cryopreservation of all embryos.  
 
2.9.5 Oocyte retrieval and sperm preparation 
Oocyte retrieval was performed 36 hours after hCG injection under conscious 
sedation with a double channel 15-gauge needle. All follicles greater than 10mm 




(G-MOPS, Vitrolife). Eggs were collected into tubes containing gassed G-MOPS and 
incubated at 6% CO2/ 5%O2/Bal N2 at 37oC for up to 4 hours prior to insemination 
or injection. 
 
Puresperm (Nidchem) gradients were used to prepare sperm samples. Samples 
were centrifuged at 200g for 15 minutes. The pellet was washed and spun for a 
further 5 minutes at 200g. Samples were re-suspended in culture medium and 
placed into the incubator. Sperm parameters were assessed according to WHO 
manual criteria (WHO 2010) before and after sample work-up. Patients were 
scheduled for IVF or ICSI accordingly. 
 
2.9.6 Insemination, injection and fertilisation 
Where IVF was indicated, eggs were retrieved from tubes 3-4 hours after collection 
and transferred into 4-well culture dishes (up to 6 eggs per-dish). Oocytes were 
then graded under a stereomicroscope (x15 to x40 magnification) and assigned a 
score of 1 to 3 according to the extent of cumulus oocyte expansion, according to 
previous published criteria (Mikkelsen et al., 2001). Oocytes were co-incubated 
with 1.0-1.5 x 105 sperm per ml of culture media. 
 
Where ICSI was indicated, oocytes were placed into 50ul droplet of cumulase 
(Origio) for 40 seconds, before being transferred to 50ul droplets of HEPES (QA). 
After 5 minutes, the cumulus and corona cells were removed by mechanical 
manipulation. Approximately 4 hours after retrieval, MII oocytes were loaded in 
individual 4ul droplets of HEPES surrounding a central droplet containing PVP 
(Origio) and 1ul of sperm. Injections were performed on an Integra Ti 
micromanipulator (Research Instruments) fitted with Hoffman Modulation 
Contrast System. Humagen micromanipulation tools were used to immobilise the 
oocyte with the polar body at the ‘6 o’clock’ position and injection at ‘3 o’clock’ 
position. Once injected, oocytes were cultured in QA cleavage medium in 4-well 
culture plates at 6% CO2/ 5% O2/ Bal N2 at 37oC. 
 
2.9.7 Embryo culture  
Approximately 17 ± 1 hours after insemination or injection, oocytes were assessed 
for fertilisation and normally fertilised embryos were moved to G-TL media 




2.10 Time-lapse imaging 
Time lapse technology has been introduced into human IVF in recent years, and 
has shown great potential in improving treatment outcomes, most likely due to 
the optimised embryo culture conditions via closed incubation and/or improved 
embryo selection based on morphokinetic information collected via continuous 
observations. The traditional approach for morphological assessment of human 
embryos is carried out at a low frequency (mostly 24 hour intervals or even longer) 
and the timing of these may not be consistent but rather reflect the workflow of 
the laboratory. The emergence of time-lapse imaging in the human IVF has further 
offered as opportunity to perform consistent temporal scoring, and more detailed 
developmental processes throughout the first days of development. All embryos 
cultured at Glasgow Royal infirmary are cultured within a time-lapse imaging 
system, EmbryoScope Time-Lapse System  (TLS) (FertiliTech (Vetrolife), 
Denmark). Figure 2.5 illustrates the components of the EmbryoScope TLS.  
 
The key component is the EmbryoScope Incubator which is an integrated benchtop 
incubator with the capacity of 6 patients holding 12 embryos in each culture dish. 
The EmbryoScope Incubator ensures a stable incubation environment while 
automatically taking high-quality images of the embryo development at pre-set 
intervals (10 minutes). These images are transferred to the EmbryoScope server, 
which is the second component of the time-lapse system. The EmbryoScope server 
will receive the images from the incubator and transformed the data into user-
friendly formate to be accessed by the user via the EmbryoViewer software and 
hardware, which is the third and last component of the EmbryoScope TLS. The 
EmbryoViewer is the tool for embryo analysis and evaluation. The hardware 
consists of a thin client computer and computer workstation (high-resolution 
monitor with keyboard and mouse). Figure 2.6 shows some an example of the 
observed embryo development and how to distinguish between the embryos in 






Figure 2.5 The Embryoscope system. 
This is a complete Time-Lapse System, including EmbryoScope Incubator, 
EmbryoScope Server and EmbryoViewer Software & Hardware. This system has 




Figure 2.6 Screenshots of an embryo contained within the EmbryoScope. 
The panels show the different embryo development stages along with the time 
the image was taken and the current development stage. A: The 2PN, which refers 
to two ProNucleus, is the first indication that an egg has become an embryo. As 
day1 passes, the pronuclei breakdown and cell division begin. B: The embryo has 
already started to divide. Blastomeres often divided evenly, thus 2 cells. C: The 
second day almost passes and the embryo still dividing evenly. D: A morula stage 
contains 10-30 cells. It's the final stage prior to the formation of a fluid-filled 
cavity, which called blastocoel cavity. E: The embryo continues to grow and 
develop into a compact ball of cells, about 16 morulas. F: The embryo is 
progressing fast and continues dividing forming early Blastocyst. G: Blastocyst 
stage is where the embryo has developed to have two different cell components 
and a fluid cavity. H: Expand Blastocyst is an advanced development stage of 
Blastocyst where the blastocoel cavity enlarges and the zona pellucida (the 




2.10.1 Embryo culture within the Embryoscope  
2.10.1.1 Device setup 
The EmbryoScope is turned on at least three hours prior to use to allow 
temperature and gaseous equilibrium. The device is checked to be grounded 
through the power connector, gas connections are not leaking, and the gas 
reservoir is full. The residual pressure of gas cylinders are checked daily, with CO2 
or nitrogen cylinders replaced if the pressure is below 40 bar. The back pressure 
in the connecting tubes should not exceed 1 bar or drop below 0.6 bar.  
 
2.10.1.2 EmbryoSlides preparation and culture 
On confirmation of fertilisation the embryos are transferred from each participant 
are transferred into an EmbryoSlide, which have been allowed to calibrate for 20 
hours with media in a general incubator with similar temperature and gas 
conditions. Each EmbryoSlide contains a large oil reservoir with 12 25µl wells 
enabling the incubation of 12 individual embryos. Within each well, there is a 
central depression where the embryo resides, with a diameter of approximately 
250 µm. 
 
Figure 2.7 The well and micro-well in the EmbryoSlide where the embryos 
were placed and then transferred into the incubator for observation 
 
Each individual well are numbered at their bottom, allowing tracking of each 
embryo within the well. As the embryo naturally migrates to he micro-well, the 
inverted microscope that is built into the Embryoscope can immediately start to 
acquire images as soon as the Embryoslide is loaded within the system.  
 
 
2.10.2 Embryo grading  
Embryos were principally graded according to the Association of Clinical 




information taken into account where there was a cohort of embryos available for 
selection. For cleavage stage embryos the scheme takes into account the cell 
number, evenness of cells and degree of fragmentation (Table 2.1). The ACS unit 
primarily focuses on cleavage stage assessment on day 3 (68 ± 1 h) (Figure 2.9), 








 Presented as nc (n= number of cell) 
Blastomere 
size 
4 Regular, even division 
 3 <20% difference (cell diameter) 
 2 20-50% difference 
 1 >50% difference 
Fragmentation 4 <10% fragmentation by volume 
 3 10-20% 
 2 20-50% 
 1 >50% 
Table 2.1 BFS and ACE cleavage stage embryo grading system. 
 
 
On the morning of day 5 (116 ± 1 h), embryos were subsequently graded according 
to their degree of expansion status and integrity of the inner cell mass and 
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Table 2.2 Blastocyst grading scheme. 
 
As all embryos were cultured in the Embryoscope, further information regarding 
their development was determined by scrolling through the time-lapse images and 
ensuring no abnormal cell divisions occurred.  The annotation of key events 
combined with the D5 KiD score were used to decide which of two similar graded 
embryos were to be replaced.  
 
2.10.3 Time-lapse parameters for transferred embryos.  
For all embryos which were transferred, I recorded the timing of the 




with international guidelines. The derived morphokinetic variables indicated in 





Figure 2.8 Embryo growth and development over time which illustrates all the 











Time Definition of expected event 
t0 Time of IVF or mid-time of micro/injection (ICSI/IMSI) 
tPB2 The second polar body is completely detached from the 
oolemma 
tPN Fertilisation status if confirmed 
tPNa Appearance of individual pronuclei ; tPN1a, tPN2a, tPN3a.... 
tPNf Time of pronuclei disappearance ; tPN1f, tPN2f.... 
tZ Time of PN scoring 
t2 to t9 two to nine discrete cells 
tSC First evidence of compaction 
tMF/p End of compaction process (last frame before cavity 
formation) 
'f' corresponds to fully compacted 
'p' corresponds to partial compaction 
tSB iniriation of blastulation 
tByz Full blastocyst (last fram before zona starts to thin) 
'y' corresponds to morphology of inner cell mass 
'z' corresponds to morphology of trophectoderm cell 
tEyz Initiation of expansion; first frame of zona thinning 
tHNyz Herniation; end of expansion phase and initiation of hatching 
process 
tHDyz Fully hatched blastocyst 
Table 2.3 Summary of morphokinetic variables and proposed definitions.  
Each timing defines the first time lapse frame in which the expected phenomenon 







Calculated duration of 
events Dynamic event 
VP tPNf-tPNa PN dursation 
ECC1 t2-tPB2 Duration of first cell cycle 
ECC2 
t4-t2        cc2a=t3-t2 
                cc2b=t4-t2 Duration of second embryo cell cycle    
ECC3  
t8-t2        cc3a=t5-t4 
                cc3b=t6-t4 
                cc3c=t7-t4 
                cc3d=t8-t4 
Duration of third embryo cell cycle 
S2 t4-t3 Synchronisation of cell divisions  






Duration of compaction 
dB tB-tSB Duration blastulation 
dexp tHN-tE Duration of blastocyst expansion 
dcol tBCend(n)-tBC(n) 
Duration of blastocyst collapse: 
'n' is number of episodes of collapse 
and re-expansion  
dre-exp 
tre-exp end(n)-tre-
expi(n) Duration of re-expansion 
dHN tHN-tHD Duration of herniation 
Table 2.4 Summary of calculated variables of dynamic monitoring of human 
preimplantation embryo development. 
 
2.11 Embryo selection transfer and cryopreservation 
In accordance with the multiple birth minimisation strategy one or two of the top 
scoring embryos were selected for transfer. The number of embryos transferred 
reflected the female age, overall embryo quality score and past treatment history. 
All excess good quality embryos (3Bb or above) were vitrified on day 5 or 6. 
 
2.12 Determination of pregnancy outcome / perinatal data  
Positive pregnancy was determined by a positive urinary pregnancy test 10 days 
after embryo transfer. A clinical pregnancy was defined as presence of a fetal 
heartbeat at 6 to 8 weeks gestation. An ongoing pregnancy was defined as a fetal 
heartbeat at 20 weeks gestation. Pregnancy outcome, offspring sex, birthweight, 





2.13 Detailed metabolic analysis using NMR metabolomics platform 
Profiling of 155 lipid and metabolite measures was performed by a high-
throughput targeted NMR platform [Nightingale Health© (Helsinki, Finland)] at the 
University of Bristol. The platform applies a single experimental setup, which 
allows for the simultaneous quantification of routine lipids, 14 lipoprotein 
subclasses and individual lipids transported by these particles, multiple fatty 
acids, glucose, the glycolysis precursors lactate and pyruvate, ketone bodies, and 
amino acids in absolute concentration units (mostly mmol/l).  The NMR-based 
metabolite quantification is achieved through measurements of three molecular 
windows from each sample. Two of the spectra (LIPO and LMWM windows) are 
acquired from native serum and one spectrum from serum lipid extracts (LIPID 
window). The NMR spectra were measured using Bruker AVANCE III spectrometer 
operating at 600 MHz. Measurements of native serum samples and serum lipid 
extracts are conducted at 37OC and 22OC, respectively. Details of this platform 
have been published previously (Wurtz et al., 2017; Soininen et al., 2009) and it 
has been widely applied in genetic and observational epidemiological studies 
(Akbaraly et al., 2018; Wurtz et al., 2014,2015; Deelen et al., 2019; Wang et al., 
2016,2018; Fischer et al., 2014; White et al., 2017; Mills et al., 2019).  
 
I transferred the samples to Bristol, under dry ice and the samples were then 
analysed in accordance with standard operating procedures in two runs. A 
summary of the process is provided in Figure 2.10 and accompanying figure legend, 







Figure 2.10 NMR spectroscopy complete system with an extended illustration 
of the process. 
The automated high-throughput serum NMR metabolomics platform—process from 
the population to the individual comprehensive quantitative molecular data. Any 
routine serum (or ethylenediaminetetraacetic acid plasma) samples can be 
profiled. For integrity and biological stability, long-term (>1 month) storage must 
be at −80°C and the samples must stay frozen during the transport. The samples 




serum mimic and a mixture of 2 low-molecular–weight metabolites. The former is 
used to monitor the consistency of quantifications, whereas the latter is a 
technical reference to monitor the performance of the automated liquid handler 
and the spectrometer. Barcoding is preferred for sample identification. Before the 
NMR measurements, 260 μL of serum and 260 μL of a sodium phosphate buffer (75 
mmol/L Na2HPO4 in 80%/20% H2O/D2O, pH 7.4; including also 0.08% sodium 3-
(trimethylsilyl)propionate-2,2,3,3-d4 and 0.04% sodium azide) is carefully mixed 
and moved to the NMR tubes. All the liquid handling steps for native serum samples 
are done with a PerkinElmer JANUS Automated Workstation equipped with an 8-
tip dispense arm with Varispan. The automated liquid handler can prepare 96 
samples in ≈30 minutes. The current NMR metabolomics laboratory setup at the 
University of Bristol combines a Bruker AVANCE III 500 MHz and Bruker AVANCE III 
HD 600 MHz spectrometers, both with the SampleJet robotic sample changer. The 
SampleJet can hold 480 samples (5 positions for NMR tubes in the standard 96-
well plate array) in a cooled (+6°C) temperature. The cooled sample changer is a 
prerequisite when working with biological samples to prevent degradation. The 
500 MHz spectrometer is equipped with a selective inverse room temperature 
probe head, whereas the 600 MHz system has a cryogenically cooled triple 
resonance probe head (CryoProbe Prodigy TCI). For the native serum samples the 
Lipoprotein (LIPO) and Low-Molecular-Weight Metabolites (LMWM) data can be 
automatically collected either with the 500 MHz or the 600 MHz spectrometer. 
Standardized parameters are used for data acquisitions. The entire time required 
for the sample handling and measurements is ≈8 and 5 minutes at 500 and 600 
MHz, respectively. After these measurements, the same samples go through a 
standardized lipid extraction procedure based on multiple extraction steps 
containing saturated sodium chloride solution, methanol, dichloromethane, and 
deuterochloroform. The extraction procedure is done manually with an Integra 
Biosciences VIAFLO 96 channel electronic pipette. These lipid extracts are then 
moved into the NMR tubes and the extracted lipid data are collected in full 
automation with the 600 MHz instrument using a standard parameter set. The time 
required for the sample handling and the LIPID measurement is ≈5 minutes. The 
depicted setup of a 500 MHz and a 600 MHz platform allows ≈80 000 samples to be 
analysed annually. The initial data processing, including the Fourier 
transformations to NMR spectra and automated phasing are done using the 




transferred to a centralized server, which performs various further automated 
spectral processing steps, including overall signal check for missing/extra peaks, 
background control, baseline removal and spectral area-specific signal 
alignments. The spectral information of the actual sample also undergoes various 
comparisons with the spectra of the 2 quality control samples; the data for which 
is also followed and compared in a consecutive manner. For those spectral areas 
that pass all the quality control steps, regression modelling are performed to 
produce the quantified molecular data. Also, the individual metabolic measures 
undergo various statistical quality control steps and are also checked against an 
extensive database of quantitative molecular data. The metabolic measures that 
pass all quality control steps are stored in the database and are ready for various 
epidemiological data analysis. FA indicates fatty acid; MUFA, monounsaturated 







class Lipid, lipoprotein or metabolite name Units* 
   
Extremely 
large VLDL 
Concentration of chylomicrons and 
extremely large VLDL particles mol/l 
Total lipids in chylomicrons and extremely 
large VLDL  mmol/l 
Phospholipids in chylomicrons and 
extremely large VLDL  mmol/l 
Total cholesterol in chylomicrons and 
extremely large VLDL  mmol/l 
Free cholesterol in chylomicrons and 
extremely large VLDL  mmol/l 
Triglycerides in chylomicrons and extremely 
large VLDL  mmol/l 
Very large 
VLDL 
Concentration of very large VLDL particles mol/l 
Total lipids in very large VLDL  mmol/l 
Phospholipids in very large VLDL  mmol/l 
Total cholesterol in very large VLDL  mmol/l 
Cholesterol esters in very large VLDL  mmol/l 
Free cholesterol in very large VLDL  mmol/l 
Triglycerides in very large VLDL  mmol/l 
Large VLDL Concentration of large VLDL particles mol/l 
Total lipids in large VLDL  mmol/l 
Phospholipids in large VLDL  mmol/l 
Total cholesterol in large VLDL  mmol/l l 
Cholesterol esters in large VLDL  mmol/l 
Free cholesterol in large VLDL  mmol/l 
Triglycerides in large VLDL  mmol/l 
Medium VLDL Concentration of large VLDL particles mol/l 
Total lipids in small VLDL  mmol/l 
Phospholipids in small VLDL  mmol/l 
Total cholesterol in small VLDL  mmol/l 
Cholesterol esters in small VLDL  mmol/l  
Free cholesterol in small VLDL  mmol/l 
Triglycerides in small VLDL  mmol/l 
Small VLDL Concentration of very small VLDL particles mol/l 
Total lipids in very small VLDL  mmol/l 
Phospholipids in very small VLDL  mmol/l 
Total cholesterol in very small VLDL  mmol/l 
Cholesterol esters in very small VLDL  mmol/l 
Free cholesterol in very small VLDL  mmol/l 
Triglycerides in very small VLDL  mmol/l 
IDI Concentration of IDL particles mol/l 
Total lipids in IDL mmol/l 
Phospholipids in IDL mmol/l 
Total cholesterol in IDL mmol/l 
Cholesterol esters in IDL mmol/l 
Free cholesterol in IDL mmol/l 




Large LDL Concentration of large LDL particles mol/l 
Total lipids in large LDL mmol/l 
Phospholipids in large LDL mmol/l 
Total cholesterol in large LDL mmol/l 
Cholesterol esters in large LDL mmol/l 
Free cholesterol in large LDL mmol/l 
Triglycerides in large LDL mmol/l 
Medium LDL Concentration of medium LDL particles mol/l 
Total lipids in medium LDL mmol/l 
Phospholipids in medium LDL mmol/l 
Total cholesterol in medium LDL mmol/l 
Cholesterol esters in medium LDL mmol/l 
Free cholesterol in medium LDL mmol/l 
Triglycerides in medium LDL mmol/l 
Small LDL Concentration of small LDL particles mol/l 
Total lipids in small LDL mmol/l 
Phospholipids in small LDL mmol/l 
Total cholesterol in small LDL mmol/l 
Cholesterol esters in small LDL mmol/l 
Free cholesterol in small LDL mmol/l 
Triglycerides in small LDL mmol/l 
Very large HDL Concentration of very large HDL particles mol/l 
Total lipids in very large HDL mmol/l 
Phospholipids in very large HDL mmol/l 
Total cholesterol in very large HDL mmol/l 
Cholesterol esters in very large HDL mmol/l 
Free cholesterol in very large HDL mmol/l 
Triglycerides in very large HDL mmol/l 
Large HDL Concentration of large HDL particles mol/l 
Total lipids in large HDL mmol/l 
Phospholipids in large HDL mmol/l 
Total cholesterol in large HDL mmol/l 
Cholesterol esters in large HDL mmol/l 
Free cholesterol in large HDL mmol/l 
Triglycerides in large HDL mmol/l 
Medium HDL Concentration of medium HDL particles mol/l 
Total lipids in medium HDL mmol/l 
Phospholipids in medium HDL mmol/l 
Total cholesterol in medium HDL mmol/l 
Cholesterol esters in medium HDL mmol/l 
Free cholesterol in medium HDL mmol/l 
Triglycerides in medium HDL mmol/l 
Small HDL Concentration of small HDL particles mol/l 
Total lipids in small HDL mmol/l 
Phospholipids in small HDL mmol/l 
Total cholesterol in small HDL mmol/l 
Cholesterol esters in small HDL mmol/l 
Free cholesterol in small HDL mmol/l 
Triglycerides in small HDL mmol/l 
Lipoprotein 
particle size 
Mean diameter for VLDL particles nm  
Mean diameter for LDL particles nm  






Total cholesterol  mmol/l 
Total cholesterol in VLDL mmol/l 
Remnant cholesterol (non-HDL and non-LDL 
cholesterol) mmol/l 
Total cholesterol in LDL mmol/l 
Total cholesterol in HDL mmol/l 
Total cholesterol in HDL2 mmol/l 
Total cholesterol in HDL3 mmol/l 
Esterified cholesterol mmol/l 






Total triglycerides mmol/l 
Triglycerides in VLDL mmol/l 
Triglycerides in LDL mmol/l 
Triglycerides in HDL mmol/l 
Total phosphoglycerides mmol/l 
Ratio of triglycerides to phosphoglycerides  
Phosphatydilcholine and other cholines mmol/l 
Sphingomyelins mmol/l 





Apolipoprotein A-1 g/l 




Total fatty acids mmol/l 
Estimated degree of saturation  
22:6, docosahexaenoic acid mmol/l 
18:2 linoleic acid mmol/l 
Omega-3 fatty acids mmol/l 
Omega-6 fatty acids mmol/l 
Polyunsaturated fatty acids mmol/l 
Monounsaturated fatty acids; 16:1, 18:1 mmol/l 
Saturated fatty acids mmol/l 
Fatty acid 
ratios 
Ratio of 22:6, docosahexaenoic acid to total 
fatty acids % 
Ratio of 18:2 linoleic acid to total fatty 
acids % 
Ratio of omega-3 fatty acids to total fatty 
acids % 
Ratio of omega-6 fatty  acids to total fatty 
acids % 
Ratio of polyunsaturated fatty acids to total 
fatty acids % 
Ratio of monounsaturated fatty acids to 
total fatty acids % 



















branched Isoleucine mmol/l 
branched Leucine mmol/l 
branched Valine mmol/l 
aromatic Phenylalanine mmol/l 












Glycoprotein acetyls, mainly a1-acid 
glycoprotein 
mmol/l 
Table 2.5 metabolic measures 
*These are the units used for each of the metabolic measures, unless we state 
that we are presenting results in standard deviation (SD) units. 
VLDL: very low density lipoprotein; LDL: low density lipoprotein; IDL: 
intermediate density lipoprotein; HDL: high density lipoprotein 
 
 
2.14 BioBank and database creation 
I created two excel sheet to organise the participant's appointments and the data 
collected from them. The first datasheet included the basic identification 
information of the participant, including their name, CHI number, when they 
signed the informed consent, their unique alphanumeric ID for the study and any 
other remarks or notes. The second datasheet acted as the core database for the 
study as it included all data collected from the participants including (but not 
limited to); the participant's CHI number, unique alphanumeric ID, personal 
details (name, address and contact number, daily job, education level and date 
of birth), anthropometric data (height, weight and BMI), lifestyle (amount of 
alcohol consumption per week, number of cigarettes smoked per week and 
frequency of weekly exercise), medical history (routenly taken medication, major 
operation and any allergies), family medical history (diabetes, cardiometabolic 
health, blood pressure and obesity), obstetric history (number of previous natural 
pregnancies, number of natural lifebirth, number of previos ART pregnancies, 
number of IVF lifebirth), infertility history (duration of infertility and cause and 
type of the infertility), hormone level (AMH), ultrasound baseline scan, ultrasound 
last tracking scan, semen parameters before preparation, semen parameters after 




drug, drug protocol, date of stimulation, drug dose, date of triggering, number 
and date of oocytes collected, number and date of oocytes inseminated, number 
of oocytes fertilised, total number and date of embryos transferred, number of 
embryos freezed and treatment cycle remarks), embryo transferred details 
(includes all the phases of development starting from day 1 until embryo transfer 
or vitrification), embryo kinetic data and treatment cycle outcome (including the 
pregnancy outcome and any complications and remarks). 
 
2.15 Statistical analysis 
2.15.1 Sample size and power calculation  
The ACS performs approximately 1,000 IVF/ICSI cycles for ages 18-44 every year. 
Considering the historical success rates and age of the treated population the 
success rate for ongoing pregnancy per cycle was estimated to be 30%. I recruited 
400 couples over the duration of recruitment (19 months), to ensure I had 80% 
power to detect a 0.23 standard deviation difference in baseline measures 
between women who achieved ongoing pregnancy to those who do not at an alpha 
of 5%.  This equates to roughly 2 mmHg of systolic blood pressure and 0.15 mmol/l 
of cholesterol (based on general population statistics for adult women). The 
sample size and power calculation were based on the Avon Longitudinal Study of 
Parents and Children (ALSPC) (Macdonald-Wallis et al., 2015) where a small (~ 2 
mmHg) nadir of systolic blood pressure was the reported difference between 
pregnant women at 17-18 weeks of gestation and non-pregnant women. 
 
2.15.2 Statistical analysis  
All statistical analyses were performed using Stata (version 15.1, StatCorp, Texas, 
USA) and/or the statistical software package R (version 3.4.2), with additional 
related specialist packages as required. Full details of the analyses are provided 






Chapter 3 Association of the functional ovarian reserve 
with serum metabolomic profiling by nuclear magnetic 




Female reproductive aging is the result of a gradual decrease in both the quantity 
and quality of oocytes (Velde & Pearson, 2002). Genetic, environmental and 
lifestyle factors are all known to contribute to the timing and depletion of the 
ovarian reserve. Markers of diminished ovarian reserve, such as low AMH and low 
AFC have been shown to associate with earlier menopause (Broekmans et al., 
2004; Dolleman et al., 2013). Several observational studies have investigated the 
association between these markers of diminished ovarian reserve and 
cardiovascular risk factors, with several (Bleil et al., 2013, 2017; Kat et al., 2016; 
Tehrani et al., 2014; Dam et al., 2019) but not all studies (Yarde et al., 2016; 
Anderson et al., 2013; Ramezani et al., 2016), suggesting that a diminished 
ovarian reserve may be associated with an unfavourable circulating 
cardiometabolic risk profile and cardiovascular events.  However, these studies 
have been limited to a restricted number of established cardiovascular risk 
factors, including evaluation of total and LDL cholesterol (Tehrani et al., 2014), 
Homeostatic Model Assessment as a surrogate for Insulin Resistance (HOMA-IR) 
(Park et al., 2010) or have considered these established risk factors together as a 
composite outcome of cardiometabolic risk (Bleil et al., 2013; Kat et al., 2016).  
 
Detailed metabolic profiling or metabolomics, has been applied successfully to 
identify novel biomarkers for the development of cardiovascular disease (Akbaraly 
et al., 2018; Wurtz et al., 2015) and all-cause-mortality (Deelen et al., 2019), 
with improved prediction as compared to models containing conventional risk 
factors (Deelen et al., 2019). That serum NMR metabolomics enables reproducible 
quantification of circulating lipids and abundant metabolites (Wurtz et al., 2017) 
has facilitated its use in the assessment of the changes in metabolites with 
adiposity (Wurtz et al., 2014), glycemia (Wurtz et al., 2012), pregnancy (Wang et 




The aim of the current study was to assess the association of ovarian reserve (as 
measured by AMH and AFC) with 155 circulating metabolic measures. These 
measures were profiled by a high-throughput NMR metabolomics platform, 
covering a wide range of metabolic pathways including lipoprotein lipids, fatty 
acids, amino acids, ketone bodies, and glycemic traits, which are highly relevant 
to cardiometabolic risk and overall health. 
 
3.2 Methods 
3.2.1 Study Design and Participants 
Cross-sectional study of women aged 18 to 45 who presented at Glasgow Royal 
Infirmary, UK for assessment prior to assisted conception between 1 April 2017 
and 31 March 2019. Exclusion criteria were a documented positive pregnancy test 
at time of presentation, body mass index (BMI) ≥35kg/m2, and/or requiring oocyte 
or embryo donation. A total of 400 women were recruited and of these 398 (99%) 
had complete data on AMH, AFC and at least one NMR metabolite and were 
included in the analyses presented in this chapter (see chapter 2 section 2.2 for 
further details). 
 
The study was conducted according to ICH Guideline for good clinical practice, 
the Declaration of Helsinki and the Convention of the Council of Europe. All 
women provided written informed consent. The study protocol was approved prior 
to study initiation by the relevant institutional review boards (see Materials & 
Methods Chapter for further details).  
 
3.2.2 Study procedures 
Demographic, lifestyle, fertility and medical history was obtained by self-reported 
questionnaire and clinical data by linkage to electronic medical records (further 
details can be found in chapter 2 section 2.5).  
 
AFC was determined by two- or three-dimensional transvaginal ultrasound (AFC 
was defined as the total number of antral follicles with a size of 2–10 mm in both 
ovaries) on menstrual cycle day 2-4. Follicle counts greater than 20 follicles per 
ovary were classed as ≥20, consistent with the diagnostic threshold for PCOS, and 




inter-sonographer variability, sonographers were provided with training and were 
asked to follow published practical recommendations for accurate transvaginal 
ultrasound (Broekmans et al., 2010); each sonographer used standard equipment 
(Acuson Sequoia, Siemens Germany) (further details can be found in chapter 2 
section 2.9.3).  
 
Non-fasted blood samples were collected during the same visit that transvaginal 
ultrasound was performed. AMH was measured using the Beckman Coulter AMH 
automated method on a clinically validated immunoassay platform (Access 2, 
Beckman Coulter, USA). The assay was calibrated and quality controlled using the 
manufacturer's reagents and is known to have a measuring range of 0.08 – 24ng/ml 
(0.57 – 171 pmol/l). The Limit of Quantitation (LoQ) was 0.02 ng/ml (0.014pmo/l), 
with the 20% CV LoQ 0.08ng/ml (0.57pmol/l). The coefficient of variation between 
runs for two levels of control ran at <4.4% (further details can be found in chapter 
2 section 2.9.2).   
 
Additional blood samples were taken for NMR analyses and immediately spun and 
frozen at −80 °C and all NMR assays completed for this study were undertaken 
within 1 year of storage and with no previous freeze/thaw cycles (further details 
can be founr in chapter 2 section 2.7).  
 
3.2.3 NMR protocol  
Profiling of 155 lipid and metabolite measures was performed by a high-
throughput targeted NMR platform [Nightingale Health© (Helsinki, Finland)] at the 
University of Bristol. The platform applies a single experimental setup, which 
allows for the simultaneous quantification of routine lipids, 14 lipoprotein 
subclasses and individual lipids transported by these particles, multiple fatty 
acids, glucose, the glycolysis precursors lactate and pyruvate, ketone bodies, and 
amino acids in absolute concentration units (mostly mmol/l).  The NMR-based 
metabolite quantification is achieved through measurements of three molecular 
windows from each sample. Two of the spectra (LIPO and LMWM windows) are 
acquired from native serum and one spectrum from serum lipid extracts (LIPID 
window). The NMR spectra were measured using Bruker AVANCE III spectrometer 
operating at 600 MHz. Measurements of native serum samples and serum lipid 




have been published previously (Wurtz et al., 2017; Soininen et al., 2009) and it 
has been widely applied in genetic and observational epidemiological studies 
(Akbaraly et al., 2018; Wurtz et al., 2014,2015; Deelen et al., 2019; Wang et al., 
2016,2018; Fischer et al., 2014; White et al., 2017; Mills et al., 2019). Further 
details of the platform are provided in Chapter 2 (Materials & Methods Chapter) 
 
3.2.4 Metabolite quantification and quality control 
The NMR spectra were analysed for absolute metabolite quantification (molar 
concentration) in an automated fashion. For each metabolite a ridge regression 
model was applied for quantification in order to overcome the problems of heavily 
overlapping spectral data. In the case of the lipoprotein lipid data, quantification 
models were calibrated using high performance liquid chromatography methods, 
and individually cross-validated against NMR-independent lipid data. Low-
molecular-weight metabolites, as well as lipid extract measures, were quantified 
as mmol/l based on regression modelling calibrated against a set of manually 
fitted metabolite measures. The calibration data are quantified based on iterative 
line-shape fitting analysis using PERCH NMR software (PERCH Solutions Ltd., 
Kuopio, Finland). Absolute quantification cannot be directly established for the 
lipid extract measures due to experimental variation in the lipid extraction 
protocol. Therefore, serum extract metabolites are scaled via the total 
cholesterol as quantified from the native serum LIPO spectrum.  
 
3.2.5 Assessment of potential confounders 
In relation to our analyses and control for confounders, we used currently 
recommended practice of defining confounders a priori (before undertaking 
analyses) using Directed Acyclic Graphs (DAG) (Pearce & Lawlor, 2016; Williamson 
et al., 2014). This approach defines confounders as any characteristic that is 
known to cause variation in the exposure (here ovarian biomarkers AMH and AFC) 
and outcome (NMR metabolites) or is plausibly a cause of exposure and outcome. 
Using a priori knowledge and relevant literature, our selected confounders were 
age, BMI, educational attainment, ethnicity, family history of cardiovascular 
disease (defined as first degree relative affected) physical activity, alcohol intake, 
smoking status, duration and cause of infertility whether infertility was primary 
or secondary (with secondary defined as a woman unable to establish a clinical 




(Zegers-Hochschild et al., 2017). These are known to or plausibly influence both 
ovarian reserve and the NMR metabolites (Mathews et al., 2009). Figure 3.1 shows 
the DAG for this, our main, confounder-adjusted analyses. Following reviewer 
comments, we also considered the extent to which PCOS might be part of a 
confounding path and whether we should also adjust for it. There is evidence 
ovarian reserve and PCOS may share underlying common causes, including genetic 
variation and intrauterine exposures. If these, specific genetic variants and expo-
sures are also related to cardiometabolic health, then PCOS may be on a 
confounding path between ovarian reserve and cardiometabolic health. Three 
possibilities are considered in Figure 3.1b–d. Whether or not to adjust for PCOS is 
in part related to the fact that we do not have genetic or intrauterine data on the 
women included in this study, and so, these would be potential unmeasured 
confounders. In Figure 3.1b, we assume that there is no causal relationship 
between PCOS and cardiometabolic health. Whilst observational studies have 
shown associa-tions of PCOS with type 2 diabetes, and some also show associations 
with CHD, a recent Mendelian randomisation study has suggested no causal effect 
of PCOS on type 2 diabetes, coronary heart disease or stroke (Pearce & Lawlor, 
2017), making this scenario plausible. In this scenario, PCOS is not on a 
confounding path, and adjusting for it should not alter the results. Figure 3.1c and 
Figure 3.1d suggest PCOS does causally influence cardiometabolic health. In Figure 
3.1c, PCOS is on a confounding path, and we would want to adjust for it. In Figure 
3.1d, it is on a mediating path, and we would not want to adjust for it. Given we 
cannot be certain which of these scenarios is correct in additional analyses we, 
repeat all of our main analyses with those with known PCOS removed. We chose 








Figure 3.1 Directed acyclic graphs (DAGs) of the association of ovarian 





Our main analyses, in which we a priori considered factors that were known to, or 
highly plausibly influenced ovarian reserve and cardiometabolic health, as 
confounders to be controlled for. Figures 3.1b–d shows further consider whether 
we should or should not control for PCOS. In all of these, we assume that there 
are underlying unmeasured factors that generate an association between ovarian 
reserve and PCOS (U1). For example, it has been suggested that common genetic 
and/or intrauterine factors affect both of these. In Figure 3.1b we assume that 
PCOS is not causally related to cardiometabolic health (no arrow from PCOS to 
cardiometabolic health). Whereas in Figure 3.1c, PCOS does causally influence 
cardiometabolic health and that it is on a confounding path between ovarian 
reserve and cardiometabolic health via U1. Figure 3.1d assumes that PCOS causally 
influences cardiometabolic health but that it is a mediator between ovarian 
reserve and cardiometabolic health. Deciding whether we need to adjust for PCOS 
therefore depends on evidence for a causal link between PCOS and 
cardiometabolic health and if there is a link evidence as to whether PCOS is likely 
to be a confounder or a mediator. In relation to point 1, whilst there have been 
several observational studies showing an association of PCOS with cardiometabolic 
health, recent  Mendelian randomisation studies suggest that PCOS does not 
causally influence type 2 diabetes, coronary heart disease or stroke (making Figure 
3.1b a plausible scenario) (Zhu, 2020). If the scenario depicted in Figure 3.1b is 
correct, then controlling for PCOS is not necessary, but if done, it should have no 
impact on the results. It is not uncommon in observational epidemiology to have 
a risk factor for an outcome and be unsure which is more plausible that it is a 
confounder or a mediator. If PCOS is on the confounding path between 
unmeasured factors (U1) as shown in Figure 3.1c, we would definitely want to 
adjust for it as this would be the only way to block this confounding (given U1 
variables are unmeasured). However, if PCOS is a mediator (Figure 3.1d), then we 
would not want to adjust for it. Primarily, this is because we want to know the 
‘total’ potential effect of ovarian reserve on cardiometabolic health and not 
remove any of that going via mediation. It is also possible that adjusting for a 
mediator can introduce what is known as collider bias (Pearce & Lawlor, 2017). If 
there are unmeasured confounders of the mediator (PCOS) and cardiometabolic 
health (shown by U2), then adjusting for PCOS could generate spurious associations 





Weight and height [used to calculate the body mass index (BMI)] were measured 
in light clothing and unshod. Weight was measured to the nearest 0.1 kg using 
Tanita scales; height was measured to the nearest 0.1 cm using a Harpenden 
stadiometer. Smoking status was categorised as ever versus never (to be 
considered for state funded assisted conception women had to have not smoked 
for at least 3 months and this was confirmed by a negative cotinine breath test). 
All other confounders, including an existing diagnosis of PCOS, were obtained by 
a questionnaire or from medical notes when the women were originally recruited. 
Full details of the assessment of these confounders is provided in the result sub-
section. 
 
3.2.6 Statistical analysis  
All analyses were conducted using R version 3.4.2 (R Foundation for Statistical 
Computing, Vienna, Austria). Characteristics were summarized as n, total range, 
mean, standard deviation, median, and Inter-Quantile Range (IQR) of 25th and 
75th quantiles as appropriate. Multivariable linear regression was used to examine 
the associations of functional ovarian reserve markers (treated as exposures) with 
serum metabolic profiles (treated as outcomes). Robust standard errors were 
estimated for all associations, as some metabolite concentrations had skewed 
distributions. The metabolic measures were scaled to Standard Deviation (SD) 
units (by subtracting the mean and dividing by the standard deviation of all women 
included in the analyses). This scaling allows easy comparison of multiple 
metabolic measures with different units or with large differences in their 
concentration distributions. AMH and AFC were also scaled to SD units in the same 
way as the metabolites. This was done for ease of comparison of results between 
the two biomarkers.  Associations were adjusted for all a priori selected 
confounders (age, ethnicity, education, family history of cardiovascular disease, 
BMI, physical activity, alcohol, smoking, duration of infertility and whether the 
woman had primary or secondary infertility).  
 
3.2.7 Additional analyses 
In addition to presenting my main results as the difference in mean metabolite in 
SD units per SD of AMH or AFC, I have also tabulated the full results (confounder 
adjusted) in the metabolite, AMH and AFC original units and presented these in an 




woman was taking lipid-lowering medication, and removal of her from the 
analyses did not alter any of the findings from the main results. We repeated our 
main analyses only on those women with a known partner cause of infertility (N = 
87 (22% of the cohort). We knew a priori that this sample size would lack statistical 
power for reliable results but wanted to compare the point estimates in this group 
to the results of the whole cohort to provide some indication as to whether our 
results might be driven by the cause of infertility in the women or potentially 
generalisable to women of reproductive age without infertility. We compared the 
magnitudes of the results in women who were going to undergo assisted 
conception because of partner infertility with those of the whole cohort using a 
scatterplot. As 99% of the women recruited had full data on ovarian reserve and 
at least one metabolite, with < 1% of these having missing covariable data (see 
Table 3.1), we did not need to undertake any additional analyses to explore 
potential biases due to missing data. To explore the departure from linearity 
where there was evidence of an association, AMH and AFC were split into quarters 
of their distribution and regression models were run with these quarters as a 
continuous score and as a 4 level categorical variable (with 3 indicators). A 
likelihood ratio test was used to compare these two models. Statistical support 
that the second (3 indicators) model was a better fit of the data would suggest a 
possible non-linear association. 
 
3.2.8 Accounting for multiple testing 
Due to the correlated nature of the metabolic biomarkers, over 95% of the 
variation in the 155 metabolic biomarkers was explained by 14 principal 
components. Therefore, multiple testing correction, accounting for 14 
independent tests using the Bonferroni method, resulted in P < 0.0036 (0.05/14) 
being denoted as statistically significant.  
 
3.3 Results 
Three hundred and ninety-eight women (99% of the 400 recruited) with available 
AMH and AFC levels and data on at least one metabolite were included in the 
study. Characteristics of the participants are shown in Table 3.1. Mean (SD) age 
of the women was 35.5 (4.4) years and the majority (92%) were white European, 
with over 50% having a university degree, 26% being ever smokers, 68% exercising 




disease and median alcohol consumption being 4 units per week. Mean (SD) BMI 
was 25 (3) Kg/m2 and 95% were due to start their first treatment cycle, with 49% 
having an unknown cause of infertility and 24% a cause related to their partner.  
Median AMH was 16.1 pmol/l (IQR 8.8, 28.0 pmol/l) and median AFC of 12 (IQR 7, 
16). AMH and AFC were positively correlated (Spearman’s correlation coefficient 
= 0.55, p<0.001).  
 









Highest Education N(%) 







BMI: Mean, SD, Range 24.7 (3.2) 18.2-32.5 
Ever smoked: N(%) 104 (26%) 
Alcohol (units per week) : Median, 
IQR, Range 
4 (1,8) 0-27 















Family history of cardiometabolic 
disease: N(%) 
208 (52%) 
Gravidity: Median, IQR, Range 0 (0,1) 0-12 
Parity: Median, IQR, Range 0 (0,0) 0-4 
Duration infertility (years): Median, 
IQR, Range  
3 (2,4) 1-13 
Primary infertility: N(%) 271 (68%) 














First IVF cycle (missing data N=3) 376 (95%) 
AMH: Median, IQR, Range 16.1 (8.9,28.0) 1-170.8 
Total AFC: Median, IQR, Range 12 (7,16) 0-40 






The unadjusted associations of AMH and AFC with selected confounders are shown 
in Tables 3.2 and 3.3, respectively. Age was negatively associated with AMH 
(difference in mean −0.09 SD per 1-year older age, 95% CI −0.11, −0.07) and AFC 
(−0.06 SD per 1-year older age, 95% CI −0.08, −0.04). An ovulatory cause of 
infertility compared with an unexplained cause was associated with a higher AMH 
(difference in mean 0.93 SD, 95% CI 0.48, 1.37) and AFC (0.65, 95% CI 0.20, 1.11). 
Secondary infertility was strongly negatively associated with AFC (−0.34SD (95% CI 
−0.55, −0.13), with a weaker negative association with AMH (−0.11 (95%CI −0.32, 
0.11)). Family history of cardiometabolic diseases was negatively associated, and 
non-White European ethnicity positively associated with AMH and AFC. There was 
no strong statistical evidence of an association between BMI or other potential 
confounders and either measure of ovarian reserve. 
 
 
Difference in mean 
AMH per unit or 
category of 
confounder  
(SD) (95% CI) 
P-
value 
Age (years) -0.09 (-0.11, -0.07) <0.001 







0.21 (-0.01, 0.42) 





Physical activity (per category increase) -0.01 (-0.12, 0.10) 0.85 
Ever smoked 0.10 (-0.12, 0.33) 0.32 
Alcohol (units per week) -0.005 (-0.03, 0.01) 0.60 
Family History of cardiometabolic diseases 
(yes vs no) -0.17 (-0.37, 0.02) 0.09 
Ethnicity (Non-white vs White European)  0.33 (-0.02, 0.69) 0.06 
Secondary vs primary infertility -0.11 (-0.32, 0.11) 0.33 
Duration of infertility (years)  0.01 (-0.04, 0.06) 0.59 
Endometriosis vs unexplained cause -0.01 (-0.41,0.39) 0.96 
Tubal vs unexplained cause 0.24 (-0.10,0.57) 0.16 
Ovulatory vs unexplained cause 0.93 (0.48, 1.37) <0.001 
Male factors vs unexplained cause 0.03 (-0.21, 0.28) 0.78 








Difference in mean 
AFC per unit or 
category of 
confounder  
(SD) (95% CI) 
P-value 
Age (years) -0.06 (-0.08, -0.04) <0.001 







-0.07 (-0.29, 0.15) 





Physical activity (per category 
increase) 
0.004 (-0.11, 0.12) 0.94 
Ever smoked -0.14 (-0.36, 0.08) 0.22 
Alcohol (units per week) -0.02 (-0.04, 0.002) 0.07 
Family History of cardiometabolic 
diseases (yes vs no) -0.26 (-0.45, -0.06) 0.01 
Ethnicity (Non-white vs White 
European) 
0.31 (-0.04, 0.67) 0.09 
Secondary vs primary infertility -0.34 (-0.55, -0.13) 0.001 
Duration of infertility (years)  -0.005 (-0.06, 0.04) 0.83 
Endometriosis vs unexplained cause 0.01 (-0.39, 0.41) 0.96 
Tubal vs unexplained cause 0.14 (-0.20, 0.48) 0.41 
Ovulatory vs unexplained cause 0.65 (0.20, 1.11) 0.005 
Male factors vs unexplained cause 0.12 (-0.13, 0.38) 0.34 
Table 3.3 Associations of possible confounders with Total AFC (SD) N=398 
 
The adjusted (for all potential confounders) associations between AMH and AFC 
and the respective metabolomics measures is SD units per SD of AMH/AFC are 
presented in Figures 3.2, 3.3 and 3.4. With the unadjusted associations presented 
in Figures 3.5, 3.6 and 3.7.   
 
In confounder adjusted analyses AMH levels were positively correlated with 
measures of components of medium HDL and small HDL and with concentrations 
of omega-6 fatty acids and polyunsaturated fatty acids (PUFA). AMH was also 
positively associated with the amino acids isoleucine, leucine and tyrosine, and it 
was negatively associated with acetate concentrations. Although there were 
positive associations with lipoprotein subclasses, other cholesterol subtypes, 
glycerides and apolipoproteins, several of which had point estimates of ~0.1SD or 
larger differences, these had wide confidence intervals that included the null and 






Figure 3.2 Associations of lipoprotein classes with AMH and AFC in women 
awaiting IVF. 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 






Figure 3.3 Associations of lipoprotein classes and fatty acids with AMH and AFC 
in women awaiting IVF.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 






Figure 3.4 Associations of metabolic traits with AMH and AFC in women 
awaiting IVF.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 






Figure 3.5 Associations of lipoprotein classes with AMH and AFC (unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 







Figure 3.6 Associations of lipoprotein classes and fatty acids with AMH and AFC 
(unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 







Figure 3.7 Associations of metabolic traits with AMH and AFC (unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 





Overall, the associations for AFC with the metabolic measures were in the same 
direction as those observed for AMH, however they were weaker in magnitude, 
and for many of them close to unity (Figures 3.2, 3.3 and 3.4). The notable 
exceptions were the positive associations with the amino acids alanine, glutamine 
and glycine.  
 
There was no strong evidence of departure from linearity for any of the observed 
associations (all likelihood ratio p-values comparing a model with four categories 
as 3 indicator variables to the simpler model as a 4 level score ≥ 0.05). When 
analyses were repeated only in those undergoing assisted conception due to 
partner infertility (n=87), most of the 155 associations of AMH were stronger than 
those in the main analyses including all women (Figure 3.8a). This included 
strengthening of the previously noted associations of AMH with the metabolomic 
markers. Positive associations were also observed for the various lipid 
concentrations within the medium and small very-low-density lipoproteins, 
intermediate-density lipoprotein and low-density lipoproteins, cholesterol, the 
mono-unsaturated fatty acids, and alanine, with a negative association with 
glucose emerging; the negative association with acetate attenuated (Figures 3.9, 
3.10 and 3.11). In this subgroup some associations of AFC also strengthened (Figure 
3.8b), with positive associations with various lipid concentrations across the size 
range of the very-low-density lipoproteins, triglycerides, apolipoprotein-B, mono-
unsaturated fatty acids, and the amino acids alanine and glutamine (Figures 3.12, 
3.13 and 3.14). When analyses were compared between the whole cohort and 
after exclusion of women with PCOS (n = 24), the associations were similar for 








Figure 3.8 Scatterplot of associations between AMH and AFC and metabolites 
in full sample (N = 398) and sub-sample restricted to females with a reported 
male partner cause of infertility (N = 87).   
Figure 3.8a Top panel shows associations with AMH, Figure 3.8b lower panel shows 






Figure 3.9 Associations of lipoprotein classes with AMH in women with male 
factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.10 Associations of lipoprotein classes and fatty acids with AMH in 
women with male factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.11 Associations of metabolic traits with AMH in women with male 
factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.12 Associations of lipoprotein classes with AFC in women with male 
factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.13 Associations of lipoprotein classes and fatty acids with AFC in 
women with male factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.14 Associations of metabolic traits with AFC in women with male 
factor infertility or no male partner.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for AMH (red) and AFC (black).  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 3.15 Comparison of associations for AMH and AFC for whole cohort and 






In this cross-sectional study of women attending a fertility clinic for evaluation I 
identified several novel associations between the biomarkers of ovarian reserve, 
as measured by AMH and AFC, and circulating metabolites. Specifically, AMH 
showed positive associations with the amino acids isoleucine, leucine and tyrosine, 
Medium HDL and Small HDL, omega-6 fatty acids and polyunsaturated fatty acids, 
and a negative association with acetate. AFC had directionally consistent 
associations to those seen for AMH but the magnitudes of association (measured 
on the same scale as SD difference in metabolite for a 1SD increase in AMH or AFC) 
were weaker overall. Statistical evidence for positive associations with alanine, 
glutamine and glycine were observed. In my main analyses, including all women, 
I did not find strong statistical support for either biomarker being associated with 
an extensive lipid profile. When I restricted analyses to the subgroup (22%) of 
women with male partner infertility, observed associations strengthened and we 
observed positive associations of AMH and AFC with a range of lipids, suggesting 
that the women infertility phenotypes may mask associations with lipid profiles.   
 
Previous studies have suggested an association of lower ovarian reserve with 
vascular health (Kat et al., 2017; Appt et al., 2012; Looby et al., 2016). Whether 
alteration in serum lipids contribute to this association is unclear. One small study 
(n=50) reported a positive correlation between AMH and total cholesterol and LDL-
C, and inverse correlation with HDL-C (Skalba et al., 2011), while a larger study 
(N=252) of women with PCOS, found a weak positive correlation with HDL-C, which 
was attenuated when adjusted for BMI (Feldman et al., 2017). In contrast, larger 
studies of Chinese women did not observe  an association between AMH and  any 
of total cholesterol, LDL-C, HDL-C or triglycerides in either women with PCOS 
(N=304), infertile women (N=1,896) (Cui et al., 2014), or in a general cohort of 
women (N=6,763) (Cui et al., 2016). This is consistent with our own findings, with 
limited statistical evidence of an association between AMH and lipoprotein 
subclasses, lipoprotein particle size, cholesterol, LDL or HDL subtypes or 
triglycerides, phosphoglycerides, or apolipoproteins when the whole population 
was considered. Collectively, the evidence to date (including from our study) 
would support recent observational studies suggesting that the association of AMH 
with atherosclerosis may be independent of lipid levels (Kat et al., 2017; Appt et 




that AMH has a direct effect on cardiovascular tissue (McLennan & Pankhurst, 
2015), making it more prone to injury and atherosclerosis (Kat et al., 2017). 
Though specific evidence for this is lacking. We did not demonstrate associations 
between AFC and lipids, which have to our knowledge not been previously 
explored, further supporting suggestions that alternative mechanisms to 
dyslipidaemia may underlie the relationships between ovarian reserve and 
cardiovascular disease. Though as acknowledged below the greater variability in 
AFC compared with AMH may have attenuated some of these results towards the 
null. 
 
I report a positive association between AMH and higher circulating levels of PUFA 
and omega-6 fatty acids. However, a systematic review and meta-analysis found 
no evidence of either observational associations between dietary intake or 
measured circulating concentrations omega-6 on cardiovascular diseases or any 
effect of dietary supplementation with omega-6 in randomised controlled trials 
(Chowdhury et al., 2014), suggesting that even if the association of AMH with 
omega-6 is causal this is unlikely to be a mechanism for preventing cardiovascular 
diseases. 
 
Branch chain amino acids (BCAA), such as isoleucine, leucine, and valine, have 
been found to positively associated with a number of cardiometabolic risk factors, 
including adiposity, fasting glucose, insulin resistance, blood pressure, 
dyslipidemia, and indicators of coronary artery disease, in cross-sectional studies 
(Tobias et al., 2018). There are also positive associations of BCAA and aromatic 
amino acids with incident cardiovascular events in several studies large 
prospective studies (Wurtz et al., 2014; Shah et al., 2010; Magnusson et al., 2013; 
Ruiz-Canela et al., 2016). However, whether these are causally related is at 
present unknown. My observed AMH-BCAA association are of interest, but 
replication of these findings and confirmation of biological plausibility of causality 
would be required to assess whether the association of AMH with CVD may be 
mediated to some extent by BCAA.  
 
The same NMR platform has previously been used to identify 14 metabolites 
associated with all-cause mortality in a meta-analysis of 12 cohorts and 44,168 




identifying seven metabolites (XXL-VLDL-L, PUFA,  lactate, histidine, leucine, 
phenylalanine and albumin) inversely associated with cardiovascular mortality and 
three (glucose, lactate and glycoprotein acetyls) positively associated with 
cardiovascular mortality (Deelen et al., 2019) . Overall, the observed direction of 
associations wass consistent with markers of low ovarian reserve relating to these 
metabolites that have previously been shown to robustly associated with 
cardiovascular disease mortality. Associations of AMH with PUFA and leucine met 
our adjusted statistical threshold. These findings, if replicated in larger cohorts, 
would support the overall concept that a diminished ovarian reserve may be 
associated with an unfavourable circulating cardiometabolic risk profile (Kat et 
al., 2016). 
 
This study has several strengths. To my knowledge, I am not aware of any study 
with a similar or larger sample size with detailed phenotypic and metabolite 
measurements. All women attended during the early follicular phase for 
measurement of AMH and AFC. I included all women across the range of ovarian 
reserve including some women with extremely low and high AMH and AFC. I wrote, 
and have used, a prespecified analysis plan which incorporated adjustment for a 
wide range of a priori specified potential confounders. Sub-group analyses in those 
women who were awaiting assisted conception because of male partner infertility 
were also assessed, as these women may reflect a general population of women 
of reproductive age.  
 
I do however acknowledge several limitations. The analyses are cross sectional 
and therefore could be explained by variation in metabolism (e.g. of amino acids) 
influencing ovarian reserve rather than the other way around, as we have 
assumed. Furthermore, I cannot assume that the small number of associations 
identified are causal. Residual confounding may have resulted from crude 
questionnaire measurements of physical activity, alcohol intake and family history 
of cardiovascular disease and the lack of any data on dietary intake. However, I 
adjusted for the measures we had of alcohol, physical activity and family history 
of cardiovascular disease, as well as education and BMI, which influence diet and 
physical activity, or are influenced by it, and thus may have captured key 
confounding paths. Of note our adjustment for confounders is more extensive than 




factors. Whilst, this is one of the larger studies to explore these associations our 
results were imprecisely estimated, with wide confidence intervals and we are 
not aware of any independent study that has measures of ovarian reserve and 
multiple metabolites (or even the amino acids and fatty acids that we observed 
associations with) in which to attempt to replicate our findings. 
 
Women were awaiting IVF and related to that were confirmed (through cotinine 
breath test) non-smokers and were of a relatively restricted BMI range. The 
women were also largely white European and educated to degree level. This 
homogeneous relatively healthy population may have resulted in some selection 
bias and may mean that our results do not generalise to a general population of 
women of reproductive age or other infertile populations. AFC was measured by 
several operators, and the known intra- and inter-observer variability of AFC 
(Iliodromiti et al., 2014) and application of a threshold for counting per ovary, 
with the highest value for AFC of 40 (range 0-40), as compared to AMH of 171 
(range 1-171 pmol/l), may explain why I did not see the same strength of 
associations of AFC with the various metabolites compared to what I observed with 
AMH. AMH was measured in a single laboratory on an automated analyser with a 
wide analytical range and low coefficient of variation.  
 
Analyses were undertaken on non-fasting samples. This was necessary to align with 
clinical processes for a population who are undergoing assisted conception, where 
caloric restraint may be detrimental.  In collaborations of several studies using 
this same NMR analysis platform results have not differed notably between studies 
in which the analyses were undertaken in participants who had been advised to 
fast and those who had not, including in analyses exploring the associations of 
these metabolites with cardiovascular diseases (Wurtz et al., 2015).  
 
The NMR platform used in these analyses covers considerably more of the lipidome 
than conventional clinical chemistry measures (total cholesterol, LDL-C, HDL-C 
and triglycerides) that have previously been explored in relation to ovarian 
reserve, and in addition includes fatty acids, amino acids, glycolysis metabolites, 
ketone bodies and an inflammatory marker. I acknowledge it misses a high 
proportion of the currently quantifiable metabolites in human serum/plasma, 




and xenobiotics, that may be influenced by ovarian reserve. High through put 
analyses of a wider range of metabolites measured by mass spectrometry is 
possible in epidemiological studies but considerably more expensive than the NMR 
platform used here, resulting in their use being frequently restricted to 
subsamples of cohorts (Sovio et al., 2020). 
 
3.5 Conclusion 
This study provides novel insight into the association of the ovarian biomarkers, 
AMH and AFC, with metabolic profiles. Taken together with other recent studies 
my results suggest that dyslipidaemia may have a limited role to play in the 
relationship between ovarian reserve and cardiovascular diseases. The novel 
associations we find with some fatty acids and amino acids may have a role in 
mediating any effect of ovarian reserve on cardiometabolic diseases, but these 
require replication in large prospective studies, and we cannot assume that the 













Chapter 4 Association of the serum metabolomic profile by 
nuclear magnetic resonance spectroscopy with sperm 
parameters: A cross sectional study of 325 men.  
 
4.1 Introduction 
Despite increasing concern regarding the significant decline in sperm counts over 
the last few decades (Levine, et al., 2017), therapeutic options for male infertility 
are limited (Barratt, et al., 2017). The significant body of data to support the 
concept that oxidative stress (Aitken, et al., 2014) and also potentially metabolic 
dysfunction (Sermondade, et al., 2013) are associated with sperm dysfunction, 
have driven recent intervention trials to primarily focus on preconceptual 
optimisation of health (Barratt, et al., 2017, Schisterman, et al., 2020, Smits, et 
al., 2019).  
 
Robust identification of additional modifiable and non-modifiable risk factors for 
poor semen quality have however had limited success. For example smoking (Li, 
et al., 2011, Povey, et al., 2012), adiposity (Bieniek, et al., 2016, Macdonald, et 
al., 2013, Pacey, et al., 2014, Povey, et al., 2012, Sermondade, et al., 2013) and 
alcohol excess (Marinelli, et al., 2004, Muthusami and Chinnaswamy, 2005, Povey, 
et al., 2012) have all shown non-consistent associations with the risk of poor 
semen parameters. Consequently, advice is primarily based on a “good health 
advice” model, rather than robust evidence for a detrimental effect on semen 
parameters (Pfeifer, et al., 2017).  An alternative approach to identify risk factors 
for an abnormal semen analysis would be to examine circulating metabolites, 
which may provide insights into downstream factors as well as more upstream 
exposures (Soininen, et al., 2009). Detailed metabolic profiling has previously 
been used to explore the metabolic pathways that may underpin phenotypes, 
including adiposity (Wurtz, et al., 2014), and has been widely used in 
epidemiological studies to identify novel risk factors for a variety of reproductive 
and pregnancy characteristics (Mills, et al., 2019, Taylor, et al., 2019, Wang, et 
al., 2016, Wang, et al., 2016, Wang, et al., 2016, Wurtz, et al., 2015, Wurtz, et 
al., 2017). The application of NMR spectroscopy to male infertility has however 
been limited to the assessment of selected metabolites within the sperm 




seminal fluid (Neto et al., 2020; Morgia et al., 2020; Mehrparvar et al., 202; 
Mumcu et al., 2020). Alternative metabolomic approaches (liquid chromatography 
coupled to mass spectrometry (LC-MS) or high resolution mass spectrometry (LC-
HRMS) or gas chromatography-mass spectrometry (GC-MS)) have been undertaken 
on plasma, serum, seminal plasma and urine, but studies have been of varying size 
(n=30 to 260), primarily used a case-control design with no adjustment for 
confounders, have variable thresholds for defining cases and have utilised 
conventional discovery based metabolomic approaches that have not provided 
absolute quantities (Qiao et al., 2017; Ma et al., 2019; Zhang et al., 2014; Courant 
et al., 2013). 
 
The aim of the current study was to undertake an exploratory analysis of the 
association of 155 circulating metabolic measures with sperm parameters. These 
measures were profiled by a high throughput cost efficient NMR platform, covering 
a range of metabolic pathways, predominantly a lipidome, including lipoprotein 




4.2.1 Study Design and Participants 
Cross-sectional study of men aged 18 to 55 who presented to Glasgow Royal 
Infirmary, UK between 1 April 2017 and 31 March 2019 for assessment prior to 
assisted conception. A total of 331 men were recruited and of these 325 (98%) had 
complete data on semen parameters and at least some NMR metabolites and were 
included in the analyses presented in this chapter. 
 
The study was conducted according to ICH Guideline for good clinical practice, 
the Declaration of Helsinki and the Convention of the Council of Europe. All men 
provided written informed consent. The study protocol was approved prior to 
study initiation by the relevant institutional review boards (see Materials & 





4.2.2 Study procedures 
Demographic, lifestyle, fertility and medical history was obtained by self-reported 
questionnaire and clinical data by linkage to electronic medical records. Blood 
samples were taken for NMR analyses and immediately spun and frozen at −80 °C. 
All NMR assays completed for this study were undertaken within 1 year of storage 
and with no previous freeze/thaw cycles.  
 
4.2.3 Semen analysis 
The semen sample was provided in the morning of the same day as the blood 
sample for NMR analyses. Semen analysis was completed utilizing the World Health 
Organisation guidelines (WHO, 2010). The men were advised to produce a semen 
sample after 2–3 days of sexual abstinence. The semen sample was collected in 
the hospital or at home in the morning (instructions to produce sample within one 
hour of semen analyses appointment which were at 30 minute intervals from 0800 
to 1000) of the same day as the blood sample for NMR analyses were taken (with 
blood samples taken between 1330 and 1600). Giving a range of 3.5 hours to 8 
hours between ejaculation and the blood sample for NMR analysis. Semen volume 
was measured using a graded tube. The concentration was measured in an 
Improved Neubauer chamber in two replicates and at least 200 spermatozoa 
counted in each replicate, at a magnification of 200×. Where the difference 
between the counts was greater than acceptable based on the 95% confidence 
intervals, the first two values were discarded, and two fresh dilutions of semen 
prepared and assessed. Motility was scored manually, as percentages of (A) fast 
forward progressive, (B) slow forward progressive, (C) non-progressive and (D) 
immotile spermatozoa in 200 spermatozoa in at least five power fields per 
replicate, according to recommendations (WHO, 2010). The Glasgow Royal 
Infirmary clinic from which study participants were recruited, collaborates in a 
nationwide quality control system organized by the UK National External Quality 
Assessment Scheme (NEQAS). Where sperm motility categories did not total to 
100% (N=11), motility was rescaled by dividing by the total percentage and 
multiplying by 100. For those men where the initial and repeat sample exhibited 
azoospermia a surgical sperm retrieval was performed, and the sample evaluated 





4.2.4 Total Motile Sperm Count 
The men were grouped according to the Total Motile Sperm Count (TMSC), 
calculated by multiplying the sample volume by the density and the percentage 
of A and B motility divided by 100%. Three groups were created: men with TMSC 
> 15 million (M); men with a TMSC of 5 to 15M; and men with TMSC of <5M 
(including those with azoospermia) (Borges Jr, et al., 2016, Hajder, et al., 2016, 
Tiegs, et al., 2019) (further details can be founr in chapter 2 section 2.5) 
 
 
4.2.5 NMR protocol  
Profiling of 155 lipid and metabolite measures was performed by a high-
throughput targeted NMR platform (Nightingale Health© (Helsinki, Finland)) at the 
University of Bristol. The platform applies a single experimental setup, which 
allows for the simultaneous quantification of routine lipids, 14 lipoprotein 
subclasses and individual lipids transported by these particles, multiple fatty 
acids, glucose, various glycolysis precursors, ketone bodies, and amino acids in 
absolute concentration units.  The NMR-based metabolite quantification is 
achieved through measurements of three molecular windows from each serum 
sample. Two of the spectra (LIPO and LMWM windows) are acquired from native 
serum and one spectrum from serum lipid extracts (LIPID window). The NMR 
spectra were measured using Bruker AVANCE III spectrometer operating at 600 
MHz. Measurements of native serum samples and serum lipid extracts are 
conducted at 37OC and 22OC, respectively. Details of this platform have been 
published previously (Soininen, et al., 2009, Wurtz, et al., 2017) and it has been 
widely applied in genetic and observational epidemiological studies (Fischer, et 
al., 2014, Mills, et al., 2019, Wang, et al., 2018, Wang, et al., 2016, White, et al., 
2017, Wurtz, et al., 2015). Further details of the platform are provided in the 
Materials & Methods Chapter (Chapter 2). 
 
4.2.6 Metabolite quantification and quality control 
The NMR spectra were analysed for absolute metabolite quantification (molar 
concentration) in an automated fashion. For each metabolite, a ridge regression 
model was applied for quantification in order to overcome the problems of heavily 




models were calibrated using high performance liquid chromatography methods, 
and individually cross-validated against NMR-independent lipid data. Low-
molecular-weight metabolites, as well as lipid extract measures, were quantified 
as mmol/l based on regression modelling calibrated against a set of manually 
fitted metabolite measures. The calibration data are quantified based on iterative 
line-shape fitting analysis using PERCH NMR software (PERCH Solutions Ltd., 
Kuopio, Finland). Absolute quantification cannot be directly established for the 
lipid extract measures due to experimental variation in the lipid extraction 
protocol. Therefore, serum extract metabolites are scaled via the total 
cholesterol as quantified from the native serum LIPO spectrum.  
 
4.2.7 Assessment of potential confounders 
Age, BMI, educational attainment, ethnicity, family history of cardiovascular 
disease (defined as first degree relative affected), physical activity, alcohol 
intake, smoking status, and duration of infertility were considered as potential 
confounders because they plausibly influence both semen parameters and the NMR 
metabolites (Eisenberg, et al., 2015). All confounders were obtained by a 
questionnaire or from medical notes when the men were originally recruited.  
 
4.2.8 Statistical analysis  
All analyses were conducted using Stata (Version 15.1) and R version 3.4.2 (R 
Foundation for Statistical Computing, Vienna, Austria). An analysis plan was 
written in June 2019. Characteristics were summarized as number and 
percentage, total range, mean, standard deviation, median, and 25th and 75th 
quantiles (IQR) as appropriate. Multivariable linear regression was used to 
examine the associations of serum metabolic profiles (treated as exposures) with 
% progressive motility and sperm concentration (treated as outcomes). Robust 
standard errors were estimated for associations with continuous sperm outcomes. 
The metabolic measures were scaled to standard deviation (SD) units (by 
subtracting the mean and dividing by the standard deviation of all men included 
in the analyses). This scaling allows easy comparison of multiple metabolic 
measures with different units or with large differences in their concentration 
distributions. Sperm concentration (natural log transformed) and progressive 
motility were also scaled to SD units in the same way as the metabolites. 




metabolic profiles (treated as exposures) with TMSC. Two analyses were 
undertaken: (i) exploring the odds of having a low TMSC (<15M) compared to a 
normal TMSC (i.e. >15M) and (ii) exploring the odds of having a very low TMSC 
(<5M) compared to a low or normal TMSC (i.e. ≥5M). We adjusted for all a priori 
selected confounders (age, ethnicity, education, family history of cardiovascular 
disease, BMI, physical activity, alcohol, smoking, and duration of infertility) in 
both the multivariable linear and logistic regression analyses.  
 
4.2.9 Additional analyses 
In addition to presenting our main results as difference in mean metabolite in SD 
units per SD of concentration or motility, I also present the full tabulated results 
(confounder adjusted) in the metabolite, concentration and motility original units 
in an online repository (https://bit.ly/35aUmDz). I repeated our main analyses on 
those men with a known male factor cause of infertility (N=66 (20% of the cohort)) 
and compared these associations to those men with an unknown or known female 
partner cause of infertility (N=258 (79%))(Figures 4.13 to 4.18). I wished to 
compare the point estimates in this group to the results of the whole cohort to 
provide some indication as to whether our results might be driven by the cause of 
infertility or potentially generalisable to men of reproductive age without 
infertility. I compared the magnitudes of the results in men who were going to 
undergo assisted conception because of the couple having unexplained or a known 
female cause of infertility with those of the whole cohort using a scatterplot. As 
99% of the men recruited had full data on semen parameters and at least one 
metabolite, with <1% of these having missing covariable data (see Table 1) I did 
not need to undertake any additional analyses to explore potential biases due to 
missing data.  
 
4.2.10 Accounting for multiple testing 
Due to the correlated nature of the metabolic biomarkers, over 95% of the 
variation in the 155 metabolic biomarkers was explained by 15 principal 
components. Therefore, multiple testing correction, accounting for 15 
independent tests using the Bonferroni method, resulted in PBonferroni < 0.0033 






Three hundred and twenty-five men (98% of the 331 recruited) with available 
semen analysis and metabolomics evaluation were included in the study. 
Characteristics of the participants are shown in Table 1. Mean (SD) age of the men 
was 37.2 (5.7) years with a mean (SD) BMI of 25.2 (3) Kg/m2. The majority (92%) 
were white European, with over 50% having a university degree, 30% being ever 
smokers, 69% reporting exercising equal to or more than 3-4 times per week, 47% 
having a family history of cardiovascular disease and median alcohol consumption 
being 4 units per week. For 54% of the men the cause of them and their partner 
requiring referral for assisted conception was unexplained and for 26% the cause 
was related to their female partner; the source of requiring assisted conception 
was deemed due to sperm / male causes in 20% of the men included in this study. 
Sample production was by masturbation for 98%, with 6 men requiring surgical 
sperm retrieval. The median sperm concentration was 35 Million per ml (IQR 15, 
69 Million per ml) and median progressive motility was 53% (IQR 42, 67 %) in the 
whole sample. These differed by cause of infertility, with the median sperm 
concentration in those with a male cause being 12 Million per ml (IQR 1.4, 23 
Million per ml) and the median progressive motility being 32.5% (IQR 15,58) and 
equivalent values in men where the cause of infertility was unknown or a known 

















Ever smoked: N(%) 97 (30%) 
Alcohol (units per week)  : Median, IQR, Range 4 (2,9) 0-40 
BMI: Mean, SD, Range 25.2 (3.0) 19.4-35.1 
Highest Education N(%) 
  High School  
  Undergraduate 

















Family history of cardiometabolic disease: N(%) 153 (47%) 
















Total motile sperm count 
< 5 Million 
5- 15 Million 





% Motile : Median, IQR, Range 53 (42,67) 0-91 
Sperm concentration (M per ml):  Median, IQR, 
Range 
35 (15,69) 0-230 
Table 4.1 Baseline characteristics of the study population (N=325). 
 
 
The unadjusted associations of sperm concentration, motility and TMSC with 
confounders are shown in Tables 4.2, 4.3, and 4.4 respectively. With the exception 
of established male factor infertility having a negative association with sperm 
concentration, motility and TMSC there was no clear evidence for associations of 
baseline demographic or lifestyle characteristics, including BMI, with semen 






Difference in mean 
concentration per 
unit or category of 
confounder  
(SD) (95% CI) 
P-value 
Age (years) 0.004 (-0.02, 0.02) 0.71 
BMI (kg/m2) 0.02 (-0.01, 0.06) 0.21 
Highest Education:  
  High School 
  Undergraduate 
  Postgraduate 
 
- 
0.05 (-0.19, 0.28) 





Physical activity (per category 
increase) 
 
-0.02 (-0.14, 0.10) 
 
0.78 
Ever smoked -0.13 (-0.37, 0.11) 0.29 
Alcohol (units per week) -0.0003 (-0.02, 0.02) 0.97 
Family History (Cardiometabolic) 0.12 (-0.10, 0.34) 0.30 
Ethnicity (Non-white vs White 
European)  
-0.25 (-0.65, 0.16) 0.23 







-1.32 (-1.88, -0.77) 
-1.25 (-1.56, -0.95) 












Difference in mean 
motility per unit or 
category of 
confounder  
(SD) (95% CI) 
P-value 
Age (years) -0.002 (-0.02, 0.02) 0.88 
BMI (kg/m2) 0.001 (-0.03, 0.04) 0.94 
Highest Education  
  High School 
  Undergraduate 
  Postgraduate 
 
- 
0.05 (-0.19, 0.28) 





Physical activity (per category 
increase) 
 
-0.11 (-0.23, 0.002) 
 
0.06 
Ever smoked -0.09 (-0.32, 0.15) 0.48 
Alcohol (units per week) -0.004 (-0.02, 0.01) 0.63 
Family History (Cardiometabolic) 0.13 (-0.08, 0.35) 0.23 
Ethnicity (Non-white vs White 
European)  
-0.22 (-0.62, 0.18) 0.28 








-1.36 (-1.94, -0.78) 
-0.99 (-1.31, -0.67) 
















Age (years): Mean, SD 37.2 
(5.8) 














Ever smoked: N(%) 70 (28%) 27 (35%) 0.29 





4 (2,9)  
 
BMI: Mean, SD 25.4 
(3.0) 
24.7 (3.0) 0.06 















































Family history of 

































Table 4.4 Association of demographics/lifestyle factors with TMSC (N=325). 
 
The adjusted associations between sperm concentration and progressive motility 
and the respective metabolomics measures are presented in Figures 4.1, 4.2 and 
4.3. With the unadjusted analyses for sperm concentration and progressive 





Figure 4.1 Associations of lipoprotein classes with sperm concentration and 
progressive motility in men undertaking assisted conception.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration (red) and progressive motility (black).  
Adjusted for age, education, family history of CVD, BMI, physical activity, alcohol 





Figure 4.2 Associations of lipoprotein classes and fatty acids with sperm 
concentration and progressive motility in men undertaking assisted 
conception.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration (red) and progressive motility (black).  
Adjusted for age, education, family history of CVD, BMI, physical activity, alcohol 





Figure 4.3 Associations of metabolic traits with sperm concentration and 
progressive motility in men undertaking assisted conception.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration (red) and progressive motility 
(black).  Adjusted for age, education, family history of CVD, BMI, physical 






Figure 4.4 Associations of lipoprotein classes with sperm concentration and 
motility (unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 






Figure 4.5  Associations of lipoprotein classes and fatty acids with sperm 
concentration and motility (unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 






Figure 4.6 Associations of metabolic traits with sperm concentration and 
motility (unadjusted).  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm motility (red) and concentration (black). 
Histidine was the only metabolite with Bonferroni corrected statistical evidence 
of an association with motility in the unadjusted analyses and there was no 
statistical evidence of any metabolites associating with sperm concentration. 




confidence intervals), most of the point estimates for the lipids were very close 
to the null, except for very large, large and medium HDL particle concentrations 
and apolipoprotein A-1 which had inverse associations with point estimates  
of ~ -0.1SD with sperm motility per 1SD higher lipid. Creatinine also has a point 
estimate of 0.1SD, showing a positive association with sperm motility, though 
again with wide confidence intervals and not reaching the Bonferroni corrected 
statistical significance. In results adjusted for confounders (Figure 4.1, 4.2 and 
4.3) the associations showed very little difference to the unadjusted results. The 
adjusted association for histidine with motility was 0.12 SD per 1 SD higher 
histidine concentration (95%CI: 0.02, 0.22), though the p-value was slightly higher 
than the Bonferroni corrected value at 0.02. In contrast, lactate showed a 
negative association with motility (-0.11 SD in sperm motility (95%CI -0.23, 0.01) 
per 1 SD increase in lactate concentration) but no association with concentration. 
 
Analyses of the associations of metabolites with odds of a low TMSC compared 
with a healthy count (Figure 4.7, 4.8 and 4.9) and of odds of a very low TMSC 
compared to either a low or healthy count (Figure 4.10, 4.11 and 4.12) did not 
have statistical (Bonferroni corrected) support for any associations, though these 
analyses have less power than with the continuously measured outcomes and wide 
confidence intervals. Point estimates for adjusted associations were close to the 
null for all lipids, lipoproteins and fatty acids. For glucose, lactate, pyruvate, both 
ketone bodies and glycoprotein acetyls point estimates suggested positive 
associations with reduced compared to a normal TMSC with odds ratios of ~1.2 
and for glycerol a positive association with an odds ratio of ~1.3. There was also 
a point estimate of 0.8 for creatinine with low versus normal TMSC.  When 
comparing TMSC of <5 million to ≥ 5 million the adjusted associations for most 
very small VLDL, IDL and large, medium and small LDL concentrations, and some 
of the cholesterols and triglycerides and phospholipids had point estimates of ~0.8 
suggesting potentially important reduced odds of a very low sperm count with 
higher levels of these lipids but for which we had limited power to obtain precise 
estimates that excluded the null (Figure 4.10, 4.11 and 4.12). Degree of fatty acid 
unsaturation had a point estimate OR of ~0.6 in these analyses and some other 
metabolites were associated with very low TMSC with OR suggestive of a relative 





Figure 4.7 Associations of lipoprotein classes with odds of having a TMSC less 
than 15 Million compared with greater or equal to 15 million.  
Odds ratio for having a total motile sperm count less than 15 Million and respective 
95% confidence intervals for each metabolic trait.  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 4.8 Associations of lipoprotein classes and fatty acids with odds of 
having a TMSC less than 15 Million compared with greater or equal to 15 
million.  
Odds ratio for having a total motile sperm count less than 15 Million and respective 
95% confidence intervals for each metabolic trait.  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 4.9 Associations of metabolic traits with odds of having a TMSC less than 
15 Million compared with greater or equal to 15 million.  
Odds ratio for having a total motile sperm count less than 15 Million and respective 
95% confidence intervals for each metabolic trait.  Adjusted for age, education, 
family history of CVD, BMI, physical activity, alcohol (units per week), ever 





Figure 4.10 Associations of lipoprotein classes with odds of having a TMSC less 
than 5 Million compared with 5 million or more.  
Odds ratio for having a total motile sperm count less than 5 Million compared with 
5 million or more and respective 95% confidence intervals for each metabolic trait.  
Adjusted for age, education, family history of CVD, BMI, physical activity, alcohol 





Figure 4.11 Associations of lipoprotein classes and fatty acids with odds of 
having a TMSC less than 5 Million compared with 5 million or more.  
Odds ratio for having a total motile sperm count less than 5 Million compared with 
5 million or more and respective 95% confidence intervals for each metabolic trait.  
Adjusted for age, education, family history of CVD, BMI, physical activity, alcohol 





Figure 4.12 Associations of metabolic traits with odds of having a TMSC less 
than 5 Million compared with 5 million or more.  
Odds ratio for having a total motile sperm count less than 5 Million compared with 
5 million or more and respective 95% confidence intervals for each metabolic trait.  
Adjusted for age, education, family history of CVD, BMI, physical activity, alcohol 





When analyses were repeated only in those undergoing assisted conception for 
male factor (n=66) as opposed to unexplained or female cause of infertility 
(n=258), most of the 155 associations were broadly consistent, with a tendency 
for those with male factor associations to be stronger for both concentration and 
motility (Figures 4.13 to 4.18). In those with male factor infertility there was 
evidence of higher phenylalanine associating with higher sperm concentration and 
motility (0.44 SD (95%CI 0.09, 0.80) per 1 SD for both outcomes). Comparing all 
point estimates across all 155 metabolites between those with male factor 
infertility and those with female or unknown causes showed poor consistency 
between the two groups (Figure 4.19; goodness of fit statistic R2 = 0.1 for sperm 
concentration and 0.03 for motility). Indeed, most of the associations with sperm 
concentration were in the opposite directions between the two groups  
(slope = -0.92 (95% CI –0.48, 1.36)), including for associations of phenylalanine and 
creatinine which associated positively with concentration in those with male cause 
infertility and weakly inversely in those without. For sperm motility many 
associations were also directionally inconsistent (weak positive  
slope 0.35 (95% CI 0.004, 0.70)); associations of both phenylalanine and creatinine 
were positively associated with motility, with a stronger association in those with 






Figure 4.13 Association of lipoprotein classes with sperm concentration by 
cause of infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration for male factor infertility (red) and 
female / unexplained infertility (black).  Adjusted for age, education, family 
history of CVD, BMI, physical activity, alcohol (units per week), ever smoking, 





Figure 4.14 Association of lipoprotein classes and fatty acids with sperm 
concentration by cause of infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration for male factor infertility (red) and 
female / unexplained infertility (black).  Adjusted for age, education, family 
history of CVD, BMI, physical activity, alcohol (units per week), ever smoking, 





Figure 4.15 Association of metabolic traits with sperm concentration by cause 
of infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm concentration for male factor infertility (red) and 
female / unexplained infertility (black).  Adjusted for age, education, family 
history of CVD, BMI, physical activity, alcohol (units per week), ever smoking, 






Figure 4.16 Association of lipoprotein classes with sperm motility by cause of 
infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm motility for male factor infertility (red) and female 
/ unexplained infertility (black).  Adjusted for age, education, family history of 
CVD, BMI, physical activity, alcohol (units per week), ever smoking, ethnicity, 





Figure 4.17 Association of lipoprotein classes and fatty acids with sperm 
motility by cause of infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm motility for male factor infertility (red) and female 
/ unexplained infertility (black).  Adjusted for age, education, family history of 
CVD, BMI, physical activity, alcohol (units per week), ever smoking, ethnicity, 





Figure 4.18 Association of metabolic traits with sperm motility by cause of 
infertility 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for sperm motility for male factor infertility (red) and female 
/ unexplained infertility (black).  Adjusted for age, education, family history of 
CVD, BMI, physical activity, alcohol (units per week), ever smoking, ethnicity, 










Figure 4.19 Scatterplot of associations between sperm concentration and 
motility and metabolites in those males with female or unknown cause of 
infertility (N = 398) and restricted to males with a reported male partner cause 
of infertility (N = 87). 
Figure 4.19a shows associations with concentration by cause of infertility, Figure 
4.19b shows associations with motility by cause of infertility. The green dots 
highlight the individual metabolites, with phenylalanine and creatinine 
highlighted. The grey dashed line reflects the reference line (slope 1, intercept 0) 






In this cross-sectional exploratory study of men attending a fertility clinic for 
evaluation I did not identify any associations between circulating metabolites and 
sperm concentration, sperm progressive motility or the risk of a low or very low 
TMSC on the basis of reaching conventional 5% levels of statistical significance 
after Bonferroni correction for multiple testing. However, point estimates 
suggested some potentially clinically important associations. Higher levels of 
glycolysis metabolites and ketone bodies were associated with increased odds of 
TMSC <15M compared with ≥15M (odds ratios of ~1.2 to 1.3), and several 
lipids/lipoprotein concentrations appeared to protect against very low TMSC (<5M 
compared with ≥5M) with odds ratios of ~0.8 or greater. That this study is unique 
in exploring these associations highlights the importance of funding to undertake 
larger studies that could precisely estimate associations and provide more robust 
evidence of how large any associations are likely to be. Based on a post-hoc power 
calculation we estimate that a sample size of 3,188 would be required at the 
Bonferroni corrected p-value used in this study to detect a 20% relative difference 
in odds (i.e. OR of 0.8 or 1.2) or larger with 80% power. 
 
A potential role for lipids and semen parameters is plausible as cholesterol is the 
precursor of steroid hormones, including testosterone which is produced in the 
Leydig cells (Payne and Youngblood, 1995), testicular cholesterol has been shown 
contribute to normal spermatogenesis (de Neergaard, et al., 2018) and 
cholesterol-fed rats and rabbits showed reduced spermatid cell numbers, reduced 
seminiferous tubules’ diameters, and smaller Leydig cell nuclear dimensions 
(Gupta and Dixit, 1988). However, the association of serum lipids and semen 
parameters has been inconsistent, with some (Ergün, et al., 2007) but not all 
studies (de Neergaard, et al., 2018, Hagiuda, et al., 2014) finding an inverse 
association with lipids and sperm concentration and / or motility. The LIFE study 
(n=501) which quantified 35 different semen parameters, found that total and 
free cholesterol and phospholipid concentrations were negatively associated with 
several sperm head morphology defects but not with concentration or motility 
(Schisterman, et al., 2014). In the largest study to date of healthy individuals (n= 
7,920) total cholesterol level was positively correlated with total sperm motility 
and progressive motility, but there was no association observed for HDL, LDL, 




large study, with a comprehensive evaluation of the lipoprotein spectrum as per 
the current study combined with the extensive assessment of semen parameters 
as per the LIFE study would be useful. Further clarification of whether lipoproteins 
levels in the male reproductive tract are regulated locally as per the rat (Cooper, 
1980), and not through passive diffusion from serum would also be useful.  
 
I observed a weak negative association of increasing lactate concentrations with 
reduced motility. Human sperm have been shown to be capable of metabolising 
13C labelled glucose and pyruvate to lactate via lactate dehydrogenase (Hereng 
et al., 2011), and that lactate oxidation by lactate dehydrogenase isoenzymes has 
a significant role in energy metabolism during the middle and later stages of 
spermatogenesis (Goldberg et al., 2010). Lactate has been shown to have an 
inhibitory effect on sperm motility, in part by acidification of the cytosol 
(Matsuzaki et al., 2015; Carr et al., 1985), but also it has been suggested that 
lactate may inhibit the binding site of lactate dehydrogenase (Matsuzaki et al., 
2015). It is possible that export of lactate from sperm leads to acidification of the 
extracellular medium and contributes to a reduction in sperm motility. 
Confirmation that circulating lactate concentrations may also have a negative 
association on sperm motility warrants replication given that lactate 
concentrations increase during acute illness, and other systemic insults but also 
during strenuous exercise (Andersen et al., 2013). 
 
The impact of supplementation with omega-3 fatty acids on semen parameters 
has been assessed in two small (n=74 and 138) randomised controlled trials 
(Akbaraly, et al., 2018). Supplementation with docosahexaenoic (DHA) and 
eicosapentaenoic acids (EPA) (990 mg/d and 135 mg/d, respectively) for 10 weeks 
demonstrated no effect on sperm parameters but improved sperm DNA 
fragmentation (Martínez-Soto, et al., 2016). Although supplementation with 
higher amounts of DHA + EPA (0.72 g/d and 1.12 g/d, respectively) led to 
significant improvements in total sperm count and concentration, sperm motility, 
and morphology (Safarinejad, 2011). However, I was unable to detect any robust 
association with either omega-3 or omega-6 fatty acids and sperm parameters; for 
these exposures all point estimates were close to the null (thought the degree of 
saturation of fatty acids did have a point estimate odds ratio of ~0.8 for TMSC< 




arginine and cysteine are frequently incorporated into anti-oxidant preparations 
and, have been suggested as a means of improving semen parameters and 
potentially live-birth rates (Smits, et al., 2019), neither branched chain or 
aromatic amino acids were associated with semen parameters. Replication the 
association of histidine with motility would be useful, as it has been suggested 
that at ejaculation sperm chromatin is critically stabilized by salt bridges in which 
zinc interchelates between thiols and possibly the imidazole groups of histidine 
(Björndahl and Kvist, 2009). Low phenylalanine concentrations in seminal plasma 
have previously been reported for oligospermic males (Gupta, et al., 2011), 
however whether supplementation is beneficial is unknown.  
 
I did not observe any association with baseline demographics, including adiposity 
or alcohol intake and semen parameters. Previous larger population studies and 
meta-analyses have differed in their findings with respect to whether there is or 
is not an inverse association between adiposity and sperm concentration and 
motility (Bieniek, et al., 2016, Macdonald, et al., 2013, Pacey, et al., 2014, Povey, 
et al., 2012, Sermondade, et al., 2013). Whether this reflects that BMI is a 
relatively crude marker for adiposity, although it is strongly related to other 
health outcomes including mortality (Global, et al., 2016), or whether metabolic 
health rather than adiposity per se underlies associations with semen parameter 
as recently suggested (McPherson and Tremellen, 2020), is unclear. However, the 
NMR platform used in the current study has previously detected differences for a 
range of metabolic disorders including adiposity (Wurtz, et al., 2014), suggesting 
that adiposity or mild deviation of metabolic health may have a limited impact on 
crude semen parameters such as concentration and motility. My findings are 
broadly in line with a recent systematic review and meta-analyses, which did not 
find any consistent associations of adiposity with sperm concentration or motility 
(Salas-Huetos et al 2020). Although the authors reported an isolated negative 
association of class III obesity (≥40kg/m2) with sperm motility, my cohort had few 
such participants to be able to replicate this association. Similarly, I did not 
observe a detrimental effect of alcohol on semen parameters, consistent with 
previous meta-analyses which have suggested that a detrimental effect of alcohol 
seemed to be limited to daily drinkers, whereas occasional drinkers or low intake 





While my findings are of interest, I acknowledge some important limitations, the 
relatively small sample size, and lack of a replication cohort which is why I present 
the novel analyses I have undertaken as exploratory. As noted above I am unable 
to exclude some potentially clinically important associations and have estimated 
that a sample size of at least 3,188 would be required to obtain more precise and 
statistically robust results. The cohort comprised of men presenting to a tertiary 
infertility service, including some men with extremely low sperm counts, those 
with azoospermia and those with known female factor infertility and although we 
assessed whether the observed associations differed depending on the cause of 
infertility, my findings may not be generalisable to healthy individuals. As TMSC 
reflects the product of sperm concentration and motility, it may reflect a 
heterogeneous clinic population, particularly as a similar TMSC may be derived 
from low sperm concentration with high motility or high sperm concentration with 
low motility. Future studies of men with similarly derived TMSC or clinical 
phenotypes such as non-obstructive azoospermia would be useful. Furthermore, 
that men were confirmed (through cotinine breath test) as non-smokers, were of 
a relatively restricted BMI range and largely white European and educated to 
degree level may have introduced a selection bias which have attenuated our 
results towards the null. A single semen sample was assessed by a single trained 
operator, consistent with recent guidance that the intraclass coefficient of the 
parameters assessed is adequate to enable a single sample to be used for infertility 
referral and treatment (Barratt, et al., 2017). I used the TMSC thresholds derived 
by Tiegs and colleagues (Tiegs et al., 2019), as that study assessed 119,972 semen 
samples, rather than the 20 million threshold described by others in much smaller 
studies (Borges et al., 2016; Hajder at al., 2016) I did not assess other aspects of 
sperm function including sperm DNA fragmentation, however, at present there is 
no consensus on the optimal assay methodology and its contribution to prognosis. 
I acknowledge that at present it is unknown whether ejaculation (whether during 
sex or masturbation) alters blood metabolites levels, and future studies of paired 
pre and post ejaculation blood samples would be useful to clarify this. I also 
acknowledge that the metabolic composition of seminal fluid may have influenced 
sperm function, with several studies of seminal fluid suggesting associations of 
metabolites with semen parameters (Neto et al., 2020; Murgia et al., 2020; 
Mehrparvar et al., 2020; Mumcu et al., 2020). Similarly repeat metabolite 




role of specific metabolites. Lastly, serum metabolites were measured on the day 
of the semen sample and therefore may not reflect the entire spermatogenic 
cycle, however, previous analyses of short- and long-term repeat 1H NMR measures 
(<6 months and >3 years) have shown good intra-class coefficients supporting that 




This study provides preliminary data on a range of metabolic pathways and their 
association with semen parameters. While I found most point estimates to be close 
to the null and few associations that met conventional statistical thresholds after 
adjustment for multiple testing, I identified several metabolites that associated 
with odds of TMSC with potentially of important clinical effect sizes (differences 
in relative odds of 20%) which warrant further exploration and replication in a 










Chapter 5 Spousal concordance of serum metabolomic 
profiles by nuclear magnetic resonance spectroscopy: A 
cross sectional study of 326 couples. 
5.1 Introduction 
Phenotype-based assortative mating is well established in humans for several 
traits including age (Dribe and Lundh 2009, Sánchez-Andrés and Mesa 1994), 
height (Silventoinen et al. 2003, Stulp et al. 2017) and other physical 
characteristics such as skin pigmentation(Baldwin and Damon 1973), eye and hair 
colour (Sebro et al. 2017). In addition, there are other behavioural and social 
factors that are correlated between spouse-pairs and are thought to affect mate 
selection such as educational level (Hur 2003, Sánchez-Andrés and Mesa 1994), 
occupation (Sánchez-Andrés and Mesa 1994), socio-economic status (Dribe and 
Lundh 2009), smoking (Di Castelnuovo et al. 2009), alcohol consumption(Grant et 
al. 2007), language and culture (Nagoshi et al. 1990). For other physical and 
physiological characteristics such as weight (Hur 2003), body mass index 
(Silventoinen et al. 2003) and blood pressure (Di Castelnuovo et al. 2009), weak 
to modest positive correlations are also observed, potentially reflecting both 
initial assortative mating, and subsequent spousal interaction and convergence 
through a shared environment and behaviours (Luo 2017).    
 
Over the last decade epidemiological studies have increasingly measured 
circulating multiple metabolic traits, which collectively provide information on 
genomic, environmental and lifestyle traits. As physical, social and behavioural 
assortative mating traits may be associated with these metabolic profiles, 
correlations between spouses for a range of metabolites may be anticipated.  
However, despite the long established positive correlations of physical, social, 
and behavioural characteristics between couples, the assessment of metabolic 
measures in couples has been limited and primarily focused on conventional 
cardiovascular risk factors (Di Castelnuovo et al. 2009). For example, for total 
cholesterol, LDL cholesterol, and triglycerides, the within-spouse correlation 
coefficients are generally weak with coefficients ranging from 0.05 to 0.10 (Di 
Castelnuovo et al. 2009), with limited evidence of correlation for glucose and 





Serum nuclear magnetic resonance (NMR) metabolomics enables reproducible 
quantification of circulating lipids and abundant metabolites (Wurtz et al. 2017) 
and has been used to assess the differences in metabolites with adiposity (Wurtz 
et al. 2014), height (Jelenkovic et al. 2013), glycemia (Wurtz et al. 2012) and a 
range of physiological and pathogenic disease states (Wang et al. 2018, White et 
al. 2017, Wurtz et al. 2015). Furthermore, detailed metabolic profiling has been 
applied to assess the heritability and genetic architecture of blood metabolites 
(Draisma et al. 2013, Hagenbeek et al. 2020, Sirota et al. 2015, Tremblay et al. 
2019), that may underlie established physical, social and behavioural assortative 
mating traits. We could only identify three studies assessing four cohorts for 
within-spouse metabolite correlations. These included sample sizes of 281, 327, 
64 and 6 spousal pairs, respectively, used different metabolite platforms to each 
other and the one we use here, which covered 120, 110, 51 and 147 metabolic 
trait measures and were undertaken in extended families of twin studies 
(Draisma et al. 2013, Sirota et al. 2015, Tremblay et al. 2019). In general, they 
found weak metabolic trait spousal correlations (mean = 0.08, 0.18, 0.24), with 
these being weaker than twin correlations.    
 
The aim of the current study was to assess the correlation within couples 
undergoing fertility treatment of physical, social and behaviour characteristics, 
and 155 circulating metabolic measures. These measures were profiled by a high 
throughput cost efficient NMR platform, covering a range of metabolic pathways, 
predominantly a lipidome, including lipoprotein lipids, fatty acids, as well as 
some amino acids, ketone bodies, and glycaemic traits. Whilst other studies 
have explored spousal similarity of the physical, social and behavioural 
characteristics that we also explore here, it is important that we explore these 
in this group of couples to help interpretation of metabolite correlations.  
Specifically, if we see similar correlations in these infertile couples to those 
seen in general populations it provides some rationale for assuming the results 






5.2.1 Study Design and Participants 
Cross-sectional study of women aged 18 to 45 and their male partners who 
presented at Glasgow Royal Infirmary, UK for assessment prior to assisted 
conception between 1 April 2017 and 31 March 2019. Referral for state-funded 
assisted conception is limited to those where the female body mass index (BMI) 
≤30kg/m2 and both partners are non-smokers smokers and in a stable relationship 
defined as cohabiting for ≥2 years, while for self-funding patients female BMI 
should be <35kg/m2. Exclusion criteria for study participation were a documented 
positive pregnancy test at time of presentation and /or requiring gamete or 
embryo donation. A total of 400 women were recruited, 331 of whom had a male 
partner who agreed to participate and of those 326 couples (100%) had a blood 
sample suitable for NMR analyses (further details can be found in chapter 2).  
 
The study was conducted according to ICH Guideline for good clinical practice, 
the Declaration of Helsinki and the Convention of the Council of Europe. All 
women provided written informed consent. The study protocol was approved prior 
to study initiation by the relevant institutional review boards (see Appendix).  
 
5.2.2 Study procedures 
Physical, social, behavioural, fertility and medical history was obtained by self-
reported questionnaire at the baseline visit or from the medical notes at initial 
recruitment. Weight and height [used to calculate the body mass index (BMI)] 
were measured in light clothing and unshod. Weight was measured to the nearest 
0.1 kg using Tanita scales; height was measured to the nearest 0.1 cm using a 
Harpenden stadiometer. Smoking status was categorised as ever versus never (to 
be considered for state funded assisted conception both women and men had to 
have not smoked for at least 3 months and this was confirmed by a negative 
cotinine breath test) (further details can be found in chapter 2 section 2.5). 
 
Non-fasted blood samples were collected during the same baseline visit for NMR 
analyses and immediately spun and frozen at −80 °C and all NMR assays completed 
for this study were undertaken within 1 year of storage and with no previous 





5.2.3 NMR protocol  
Profiling of 155 lipid and metabolite measures was performed by a high-
throughput targeted NMR platform [Nightingale Health© (Helsinki, Finland)] at the 
University of Bristol. The platform applies a single experimental setup, which 
allows for the simultaneous quantification of routine lipids, 14 lipoprotein 
subclasses and individual lipids transported by these particles, multiple fatty 
acids, glucose, the glycolysis precursors lactate and pyruvate, ketone bodies, and 
amino acids in absolute concentration units (mostly mmol/l).  The NMR-based 
metabolite quantification is achieved through measurements of three molecular 
windows from each sample. Two of the spectra (LIPO and LMWM windows) are 
acquired from native serum and one spectrum from serum lipid extracts (LIPID 
window). The NMR spectra were measured using Bruker AVANCE III spectrometer 
operating at 600 MHz. Measurements of native serum samples and serum lipid 
extracts are conducted at 37OC and 22OC, respectively. Details of this platform 
have been published previously (Wurtz et al., 2017; Soininen et al., 2009) and it 
has been widely applied in genetic and observational epidemiological studies 
(Wurtz et al., 2014,2015; Wang et al., 2014,2018; White et al., 2018; Fischer et 
al., 2014; Mills et al., 2019; Deelen et al,. 2019; Akbaraly et al.,2018). Further 
details of the platform are provided in Materials and Methods Chapter 2. 
 
5.2.4 Metabolite quantification and quality control 
The NMR spectra were analysed for absolute metabolite quantification (molar 
concentration) in an automated fashion. For each metabolite a ridge regression 
model was applied for quantification in order to overcome the problems of heavily 
overlapping spectral data. In the case of the lipoprotein lipid data, quantification 
models were calibrated using high performance liquid chromatography methods, 
and individually cross-validated against NMR-independent lipid data. Low-
molecular-weight metabolites, as well as lipid extract measures, were quantified 
as mmol/l based on regression modelling calibrated against a set of manually 
fitted metabolite measures. The calibration data are quantified based on iterative 
line-shape fitting analysis using PERCH NMR software (PERCH Solutions Ltd., 
Kuopio, Finland). Absolute quantification cannot be directly established for the 
lipid extract measures due to experimental variation in the lipid extraction 
protocol. Therefore, serum extract metabolites are scaled via the total 





5.2.5 Statistical analysis  
All analyses were performed in Stata (version 15.1, StataCorp. 2017 College 
Station, TX), with figures created in R 4.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria). Characteristics were summarized as n, total range, 
mean, standard deviation, median, and 25th and 75th quantiles (IQR) as 
appropriate. Associations between physical, social and behavioural characteristics 
within couples were investigated using both Pearson and Spearman’s rank 
correlation (continuous variables) and phi for dichotomized categorical 
variables(Cohen 2013). In females and males separately, the metabolic measures 
were scaled to standard deviation (SD) units (by subtracting the mean and dividing 
by the standard deviation of all women or men respectively included in the 
analyses). This scaling allows easy comparison of multiple metabolic measures 
with different units or with large differences in their concentration distributions. 
The primary analysis was the correlation of the unadjusted metabolite measures. 
In secondary analyses I assessed whether these were influenced by potentially 
similar physical, social and behavioural characteristics. This was done by using 
linear regression, with robust standard errors as some metabolite concentrations 
had skewed distributions, the sex-specific standard deviation (SD) scores of 
metabolites on a priori selected characteristics that might result in spousal 
correlations (age, educational attainment, ever smoking, physical activity, family 
history of cardiometabolic disease, alcohol consumption, BMI, ethnicity) and 
obtaining the residuals from these regression models (i.e. the sex specific 
metabolic concentrations having removed variation due to the observed 
characteristics listed above). The correlations between the residuals from these 
regressions within couples were then calculated using both Pearson and 
Spearman’s rank correlation. Confidence intervals for these correlations were 
calculated using bootstrapping. To test whether the skewness of the metabolite 
data was having any impact on correlations, regressions were repeated using 
quantile regression and results compared. Lastly to assess whether observed 
physical, social and behavioural characteristics that have been shown to correlate 
in couples explained any metabolite correlations I compared the covariates 
adjusted and unadjusted correlation using a scatter plot of these and exploring 
the linear fit. As women are excluded from infertility treatment if their BMI is 




partners) may influence spousal correlations, I reassessed the correlation of 
spousal BMI after exclusion of the 17 male partners with a BMI > 30 kg/m2. 
 
5.3 Results 
Three hundred and twenty-six couples with complete physical, social and 
behavioural characteristics and NMR data were included in the study. 
Characteristics of the participants are shown in Table 5.1. Couples exhibited 
correlations of varying strength for most physical, social and behavioural 
characteristics including age, height, alcohol consumption, education, smoking 
status, family history and ethnicity, with correlation coefficients ranging from 
0.22 to 0.73 (Table 5.1). There was no evidence of within couple correlation for 
BMI and weight, where the correlation coefficients were -0.03 (95%CI -0.14, 0.08) 
and 0.01 (95%CI -0.10, 0.12) respectively (Table 5.1). When we repeated the 
analyses after excluding couples (n=17) where the male BMI was >30kg/m2, the 
results were unchanged with a correlation for BMI of -0.02 (95%CI -0.13, 0.09), 
p=0.75.   
 
The correlation estimates for the unadjusted metabolite measures are shown in 
Figures 5.1, 5.2 and 5.3, with overall similar results for the Spearman correlation 
coefficients (Figures 5.4, 5.5 and 5.6). Across the metabolites correlation point 
estimates were all positive and ranged from very weak to modest, with the 
median coefficient across all 155 measures being 0.12 (full range 0.01 to 0.37 
and interquartile range 0.10 to 0.18). For lipoproteins, the correlation 
coefficients ranged from 0.11 for very large VLDL and 0.13 for medium VLDL, to 
0.12 to 0.21 for very large HDL, large HDL, medium HDL and small HDL. For fatty 
acids the overall degree of unsaturation was correlated within couples (0.26, 
95% CI 0.13, 0.38). Of the individual fatty acids docosahexaenoic acid (0.37, 
95%CI 0.22, 0.52) and omega-3-fatty acids (0.32, 95%CI 0.20, 0.43) exhibited 
modest correlations within couples, with the correlation of docosahexaenoic 
acid the strongest correlation across all of the NMR measures. The contributions 
of individual fatty acid classes to total fatty acid concentrations was broadly 
similar within couples with coefficients ranging from 0.20 to 0.27.  For all the 
glycolysis related metabolites, there was modest evidence of positive 
correlations within couples with the strongest effects observed for pyruvate 




95%CI 0.15, 0.38), with the correlation for glucose 0.25 (95%CI 0.08, 0.41). Of 
the amino acids only, histidine had evidence of modest correlation (0.32 95%CI 
0.23, 0.41), with alanine, isoleucine, leucine, valine, phenylalanine, glycine and 














Age (years) 35.6 (4.4) 37.2 (5.7) 0.61 (0.53, 0.69) <0.001 
Height (cm) 164.2 (6.3) 176.5 (5.1) 0.22 (0.12, 0.32) <0.001 
Weight (kg) 66.7 (9.7) 78.6 (10.2) 
0.01 (-0.10, 
0.12) 0.86 










































































































Table 5.1 Demographic/lifestyle characteristics of couples undergoing IVF 
treatment (N=326) 






Figure 5.1 Correlations of lipoprotein classes in couples awaiting IVF 







Figure 5.2 Correlations of lipoprotein classes and fatty acids in couples 
awaiting IVF  






Figure 5.3 Correlations of metabolic traits in couples awaiting IVF 






Figure 5.4 Spearman correlations of lipoprotein classes in couples awaiting IVF. 






Figure 5.5 Spearman correlations of fatty acids in couples awaiting IVF. 






Figure 5.6 Spearman correlations of metabolic traits in couples awaiting IVF. 






Correlation estimates within couples were similar in adjusted versus unadjusted 
analyses (Figure 5.7) for most metabolites (R2 = 0.96 across all metabolites 
coefficients)  
 
Figure 5.7 Scatterplot of adjusted versus unadjusted within couple correlation 
estimates across all metabolites.  
In adjusted analyses in males and females separately, metabolites (in SD units) 
were regressed on covariates (age, educational attainment, ever smoking, 
physical activity, family history of cardiometabolic disease, alcohol consumption, 
BMI, and ethnicity) and the residuals of those models use to estimate the adjusted 
Pearson correlation coefficients within couples. Unadjusted analyses were the 
Pearson correlation coefficients of the metabolites in SD units. 
 
 
For adjusted analyses the results were similar when covariates were adjusted by  






Figure 5.8 Adjusted correlations of lipoprotein classes in couples awaiting IVF.  
Pearson correlation coefficients and 95%CI of male and female linear regression 
residuals after sex-specific adjustment for age, educational attainment, ever 
smoking, physical activity, family history of cardiometabolic disease, alcohol 





Figure 5.9 Adjusted correlations of lipoprotein classes and fatty acids in 
couples awaiting IVF. 
Pearson correlation coefficients and 95%CI of male and female linear regression 
residuals after sex-specific adjustment for age, educational attainment, ever 
smoking, physical activity, family history of cardiometabolic disease, alcohol 






Figure 5.10 Adjusted correlations of metabolic traits in couples awaiting IVF. 
Pearson correlation coefficients and 95%CI of male and female linear regression 
residuals after sex-specific adjustment for age, educational attainment, ever 
smoking, physical activity, family history of cardiometabolic disease, alcohol 





Figure 5.11 Correlations of lipoprotein classes in couples awaiting IVF using 
quantile regression.  
Pearson correlation coefficients and 95%CI of male and female quantile regression 
residuals after sex-specific adjustment for age, educational attainment, ever 
smoking, physical activity, family history of cardiometabolic disease, alcohol 





Figure 5.12 Correlations of lipoprotein classes and fatty acids in couples 
awaiting IVF using quantile regression.  
Pearson correlation coefficients and 95%CI of male and female quantile regression 
residuals after sex-specific adjustment for age, educational attainment, ever 
smoking, physical activity, family history of cardiometabolic disease, alcohol 





Figure 5.13 Correlations of metabolic traits in couples awaiting IVF using 
quantile regression.  
Pearson correlation coefficients and 95%CI of male and female quantile 
regression residuals after sex-specific adjustment for age, educational 
attainment, ever smoking, physical activity, family history of cardiometabolic 





Figure 5.14 shows the scatter plots of the unadjusted metabolite concentrations 
(in SD units) for each woman versus her male partner for the four metabolites 
with a Pearson’s correlation of greater than 0.3; Docosahexanoic acid, pyruvate, 
histidine and omega-3-fatty acids. For all four metabolites the concentrations 
were mostly concentrated around central values in both women and men but 
with a spread showing the weak to moderate correlations.  
 
Figure 5.14 Multi-panel scatterplot of individual measures of metabolites in 
326 women and their male partners for four selected metabolites with a 






When comparing Pearson with Spearman’s correlations I noticed that beta-
hydroxybutyrate exhibited different correlation coefficients (Pearson = 0.01 
(95%CI -0.10, 0.13) versus Spearman = 0.26 (95% CI 0.16, 0.36))(Figure 5.3 versus 
Figure 5.6). On further investigation there was an obvious outlier for beta-
hydroxybutyrate, with the difference attenuated by removal of the outlier: 
Spearman (adjusted) = 0.18, Pearson (adjusted) = 0.08. When males with a BMI > 
30 kg/m2 were excluded, there was still no evidence of a correlation of BMI 
within couples (n = 309, rho=-0.02(-0.13,0.09), p=0.75).  
 
5.4 Discussion 
In this cross-sectional study I demonstrate that couples attending for infertility 
treatment exhibit strong correlations for a range of physical, social and behaviour 
characteristics and modest to weak correlations for a range of lipids and some 
other metabolic measures. The similarity in correlations for height, education and 
ethnicity, with those found in other publications not restricted to couples seeing 
fertility treatment (Hur 2003, Nagoshi et al. 1990, Sánchez-Andrés and Mesa 1994, 
Silventoinen et al. 2003, Stulp et al. 2017), suggest that conventional assortative 
mating is similar in infertile couples as in the general population’ couples. That 
diet is the principal source for several of the metabolites; docosahexaenoic acid, 
histidine, phenylalanine and omega-3-fatty acids, would suggest that convergence 
due to a shared environment and active co-participation in daily activities 
including food consumption facilitates convergence of some metabolites. 
However, I acknowledge that for the vast majority of the metabolic measures 
assessed here correlations were weak and in this study I have no information for 
how long the couples have co-habited, beyond the minimum of two years.  
 
In line with previous research, the present analyses provide strong evidence of 
concordance and assortative mating for age (Feng and Baker 1994, George et al. 
2015, Schwartz and Graf 2009), modest concordance for height (Stulp et al. 2017) 
and strong concordance for educational levels (Hur 2003, Sánchez-Andrés and 
Mesa 1994), with strong evidence of endogamy with respect to self-declared 
ethnicity (Luo 2017). Age is well established as showing the greatest level of 
couple similarity among all personal characteristics, with spousal age correlations 




2017, Schwartz and Graf 2009). The reasons for our slightly lower estimate (0.61 
95% CI 0.53, 0.69) are unclear but may reflect recruitment of participants with 
known fertility issues, as both maternal and paternal age are known to be 
independently inversely associated with fecundity, however, the median age gap 
was similar to that observed in the general population(Ford et al. 2000). The 
observed modest estimate for height is similar to previous meta-analyses, which 
have suggested moderate assortative pairing for height across human populations 
(r  = 0.23, 95%CI 0.21, 0.23), and that the strength of this assortment appears to 
be relatively constant over time (Stulp et al. 2017). For ethnicity although 
endogamy remains the norm in Scotland, it has declined over recent years with 
similar declines observed in other Western countries (Frimmel et al. 2013, Luo 
2017). In contrast to this decline in ethnic endogamy, most studies in line with our 
own study, have indicated a sustained increase in educational homogamy (George 
et al. 2015), with moderate partner similarities for potential drivers for education 
including socioeconomic status, abilities and intelligence all documented (Luo 
2017). Despite previous meta-analyses suggesting weak associations (r = 0.10 to 
0.15) for BMI, weight and related indices including waist circumference and waist 
to hip ratios (Di Castelnuovo et al. 2009), we did not observe any correlation, thus, 
no concordance for BMI between couples. This is likely to reflect our unique 
population, as even when we restricted the analyses to couples where the male 
BMI was also ≤30kg/m2 to account for the female BMI treatment eligibility criteria 
we still did not observe a correlation.  
 
The observed convergence of additional lifestyle factors like alcohol consumption 
(r  =  0.62, 95%CI 0.50, 0.74) emphasizes a strong concordance between couples, 
with a dominance of consumption of a low number of units compliant with national 
guidelines (≤14 units per week), may in part reflect that the population were 
drawn from an infertility clinic where healthy preconceptual lifestyle behaviours 
may be anticipated. Meta-analyses have previously suggested an overall moderate 
similarity for alcohol use (r = 0.36)(Reynolds et al. 2006), though levels of 
similarity observed in different studies have ranged from negligible to high. For 
exercise, studies have generally reported correlations between 0.15 and 0.30 
(Aarnio et al. 1997, PÉRUSSE et al. 1989, Price and Vandenberg 1980) albeit some 
higher than 0.40 (Jurj et al. 2006, Willemsen et al. 2003).  That our observed 




concordance, is marginally higher than previous estimates reported in a meta-
analyses of smoking habits (r = 0.23, 95% CI: 0.12, 0.36) (Di Castelnuovo et al. 
2009) may reflect our eligibility criteria, as in Scotland placement on the waiting 
list for public funding of fertility treatment is dependent on confirmation of non-
smoking by cotinine breath testing for both partners.  
 
Limited evidence from twin and family studies of multiple metabolites suggest 
that the heritability (h2; proportion of phenotypic variance due to genetic factors) 
of lipids and lipid-like molecules have a mean h2 levels of 47% (range from h2 = 
0.11 to h2 0.66), while for organic acids and derivatives the mean is 0.41 (0.14-
0.72), essential amino acids 0.42 (0.23-06.4) and non-essential amino acids 0.39 
(0.22-0.69)(Draisma et al. 2013, Hagenbeek et al. 2020, Kettunen et al. 2012, 
Sirota et al. 2015, Tremblay et al. 2019). As direct genetic variation in metabolites 
profiles would not produce a correlation between couples due to the invisible 
nature of both genes and metabolites, my observed correlations are likely to be 
due to through indirect pathways including assortative mating for social and 
behavioural characteristics. In a systematic review for coronary risk factors, 
significant but low (upper limit of 95% confidence interval, maximal 0.10) spousal 
correlations were identified for total and LDL cholesterol and total triglycerides 
(Di Castelnuovo et al. 2009). These meta-analysis estimates are very similar to 
those reported here; total cholesterol 0.07 vs 0.11, LDL cholesterol 0.06 vs 0.10 
and triglycerides 0.08 vs 0.12, with the detailed NMR breakdown of the lipid 
subclasses and lipoproteins providing further similar estimates of spousal 
correlation for lipid metabolism, that illustrates very weak concordance. To date 
given limited prospective longitudinal studies, inference on whether assortative 
mating and/or cohabitation and thereby a shared environment underlie these 
associations has been achieved by using marriage duration as a surrogate for a 
common environment and potential convergence (Di Castelnuovo et al. 2009). 
These support initial indirect assortative mating (i.e. on social or behaviour 
factors that influence metabolism), and that a shared environment may further 
influence lipid metabolism but to a lesser degree (Di Castelnuovo et al. 2009).  
 
I observed weak to moderate spousal correlations for a range of essential amino 
acids and omega-3-fatty acids including the subtype docosahexaenoic acid all of 




and Yeo 1999). The sharing of a common household larder and most main meals 
has been proposed as a mechanism by which couples have similarities in types of 
food, and nutrient intakes(Bove et al. 2003). Although gender asymmetry in the 
spousal adoption of health-related dietary changes has been reported, with 
female partners more likely to adopt male partners changes than vice versa 
(Savoca and Miller 2001), this may not apply to preconceptual diets where females 
may have a dominant role in preparation for pregnancy. Consistent with the 
suggestion that shared diet may have a critical influence, heritability variance 
estimates for circulating serum levels of histidine, docosohexaenoic acid, 
phenylalanine have been all lower than those observed for lipids, with 
environmental factors such as diet having a much greater contribution (Kettunen 
et al. 2012).  
 
Glucose, the downstream glycolysis product of pyruvate and then the citric acid 
cycle carbon flux product of citrate, plus lactate and the glyceroneogenesis 
pathways were all weakly correlated, which elucidates modest concordance in my 
results. A meta-analyses of six studies, estimated that history of spousal diabetes 
was a risk factor for diabetes in their partner (effect estimate 1.26 (95% CI 1.08, 
to 1.45)(Leong et al. 2014). A data mining study of 5,643 couples and 5643 non-
couple pairs similarly found strong associations of having diabetes within couples 
(5.2% both of the couple had diabetes) than non-couples (0.1%)(Wang et al. 2017). 
Heritability and shared environmental factors are proposed to account for at least 
half of the variability in normalised fasting glucose (Boehnke et al. 1987), 
however, my study is unable to delineate their respective contributions to the 
weak association observed here.  
 
This study adds to the small number (3) of studies we could identify that have 
previously explored spousal metabolite correlations (Draisma et al. 2013, Sirota 
et al. 2015, Tremblay et al. 2019). It has a similar sample size to one of those 
previous studies (Draisma et al. 2013) and examines a similar number of metabolic 
traits to two of them (Draisma et al. 2013, Tremblay et al. 2019). It adds to those 
previous studies which were examining correlations in twin studies, where one or 
both of a spousal pair had been recruited based on being a twin. I do however 
acknowledge several limitations. Participants were couples awaiting IVF and this 




bias and may mean that our results do not generalise to a general population of 
couples of reproductive age or same-sex populations. Previous population studies 
have suggested that regardless of sex composition of the partnership, all couples 
demonstrate substantial within couple similarity in demographics including for 
age, education, race/ethnicity, work hours, and earnings (Andersson et al. 2006). 
Determination of metabolite concentrations were undertaken on non-fasting 
samples, however, collaborations of several studies using this same NMR analysis 
platform results have not differed notably between studies in which the analyses 
were undertaken in fasted and non-fasted participants (Wurtz et al. 2015). The 
analyses are cross-sectional and included couples within a narrow age range. With 
repeat assessments of couple correlations over time, or with cross-sectional data 
including couples with a wide age range and number of years of being together, it 
would be possible to explore the relative contributions of assortative mating and 
convergence on the weak metabolite correlations we have observed. Previous 
studies that have tried to explore this using marriage / cohabitation duration as a 
surrogate have found little evidence of any convergence for physical measures 
such as BMI or blood pressure, while behaviours such as smoking and alcohol 
converged during the initial period of a relationship prior to marriage / 
cohabitation, whereas convergence in physical activity was sustained throughout 
life (Ask et al. 2012) (Tambs and Moum 1992). The NMR platform used misses a 
proportion of the currently quantifiable metabolites in human serum/plasma, 
including markers of microbiota metabolism, vitamins, co-factors, and 
xenobiotics, that may be influenced by diet and preconceptual supplements. I did 
not undertake detailed dietary questionnaires, which would allow me to confirm 
the suggestion that a shared environment and common food would contribute to 
the observed correlations of metabolites.  
 
The study exhibits a strong to modest concordance between couples in most 
baseline characteristics, such as age, height, level of education attained, alcohol 
consumption and smoking status. In addition, there were weak to modest positive 
correlations for most metabolites, including very weak concordance in 







I have explored within couple correlations of multiple metabolomic traits and find 
weak to modest positive correlations for the vast majority that are not influenced 
by adjustment for traits know to be influenced by assortative mating or shared 
couple behaviours. This suggests assortative mating, for example via genes linked 
to assortative characteristics such as height and education, might have some 
potential weak to modest impact on couples having similar metabolic traits. Whilst 
we acknowledge replication in a general population would be valuable the broadly 
similar within couple correlations of physical, social, and behavioural traits in 
these couples provides some evidence that our findings might be generalisable. 
Longitudinal studies would be valuable to fully explore the relative roles of 




Chapter 6 Preconceptual male and female 
metabolite profiles are associated with ongoing 
pregnancy after IVF. 
 
6.1 Introduction 
The study of metabolites has become a fast-growing area of interest for research 
into the causes, prognosis, screening, diagnosis, and treatment of many 
conditions, including pregnancy (Wang, et al., 2018, White, et al., 2020, White, 
et al., 2017, Wurtz, et al., 2015, Wurtz, et al., 2017).  For infertility, mass 
spectrometry-based metabolomics have primarily focused on elucidating sperm 
and oocyte physiology and embryo selection (Gardner, et al., 2015, Nel-Themaat 
and Nagy, 2011, Sakkas, et al., 2015).  Characterisation of preconceptual/pre-
treatment circulating metabolites with IVF outcomes has however been limited, 
but initial small studies suggest that circulating metabolites including lipids and 
lipoproteins may be associated with embryo quality and clinical pregnancy rates 
(Jamro, et al., 2019, Onyiaodike, et al., 2018).  
 
There is considerable experimental literature supporting a role for lipids in males 
and female fertility (Maqdasy, et al., 2013, Miettinen, et al., 2001), as higher 
high-density lipoproteins (HDL) concentrations have been associated with better 
oocyte and embryo outcomes as well as improved spermatogenesis (Fujimoto, et 
al., 2010). However, the concentration of the individual lipoprotein particles may 
be critical as abnormal serum lipid profiles have been associated with poorer 
oocyte quality and embryo development (Grummer and Carroll, 1988). 
Furthermore, elevated free cholesterol has been associated with reduced 
fecundity in women independent of BMI (Schisterman, et al., 2014), particularly 
if cholesterol was abnormally elevated (Pugh, et al., 2017). A potential paternal 
contribution may also exist as male free cholesterol concentrations have been 
suggested as an independent risk factor for reduced fecundability, irrespective of 
female lipid levels (Schisterman, et al., 2014).    
 
Improvements in standard analytical procedures including those of high-
throughput 1H-nuclear magnetic resonance (NMR) techniques have enabled 




chemistry measures, while also providing quantitation of fatty acids, amino acids, 
glycolysis metabolites, ketone bodies and an inflammatory marker (Al Rashid, et 
al., 2020, Rankin, et al., 2014, Wang, et al., 2018, White, et al., 2020, White, et 
al., 2017, Wurtz, et al., 2017).  I am not aware of any study which has assessed 
female and male preconceptual metabolite levels, and the role of female and 
male preconceptual/pre-treatment metabolic profiles with IVF pregnancy 
outcomes is unknown. The aim of this study was to assess the association between 
155 metabolites in females and males undergoing their first cycle of IVF treatment 
and ongoing pregnancy rates.  
 
6.2 Methodology 
6.2.1 Study Design and Participants 
Prospective cohort study of women aged 18 to 45 and their male partners who 
presented at Glasgow Royal Infirmary, UK for assessment prior to assisted 
conception between 1 April 2017 and 31 March 2019. Exclusion criteria were a 
documented positive pregnancy test at time of presentation, body mass index 
(BMI) ≥35kg/m2, and/or requiring gamete or embryo donation. A total of 398 




The study was conducted according to ICH Guideline for good clinical practice, 
the Declaration of Helsinki and the Convention of the Council of Europe. All 
participants provided written informed consent. The study protocol was approved 
prior to study initiation by the relevant institutional review boards (see 
Appendices). 
 
6.2.2 Study procedures 
Individual demographic, lifestyle, fertility and medical history data was obtained 
through self-completed questionnaires and from clinical data by linkage to 
electronic medical records. Weight and height [used to calculate the body mass 
index (BMI)] were measured in light clothing and unshod. Weight was measured to 
the nearest 0.1 kg using Tanita scales; height was measured to the nearest 0.1 cm 
using a Harpenden stadiometer. Smoking status was categorised as ever versus 




not smoked for at least 3 months and this was confirmed by a negative cotinine 
breath test). Additional blood samples were taken for NMR analyses, immediately 
spun and frozen at −80 °C. All NMR assays completed for this study were 
undertaken within 1 year of sample storage and with no previous freeze/thaw 
cycles (further details can be found in chapter 2 section 2.7).  
 
Ovarian stimulation was performed in accordance with local treatment protocols 
according to baseline AMH and AFC measurements. In brief GnRH antagonist or 
agonist-controlled cycles were used according to the patient phenotype with a 
variable dose of gonadotrophins administered based on ovarian reserve markers 
and bodyweight. Ultrasound and biochemical monitoring were performed 
throughout stimulation with cycles cancelled if there was no evidence of follicular 
development. Final oocyte maturation was triggered with 6,500IU recombinant 
hCG when 3 or more follciles were ≥17mm in size. In cases where there was a 
clinical concern regarding potential OHSS, GnRH agonist triggering (0.5mg 
Buserelin) with subsequent elective vitrification of blastocysts was undertaken.  
Oocyte retrieval was performed under sedation 36 hours after the final trigger. 
All oocytes were fertilised by ICSI, with incubation in a time lapse incubator and 
selected embryos transferred on day 5, with vitrification of surplus embryos. 
Progesterone supplementation was commenced on the day after oocyte retrieval. 
For those having a frozen embryo transfer, a GnRH controlled medicated cycle 
was used with oestradiol valerate 6mg from day 2 of the cycle and confirmation 
of adequate endometrial thickness on day 10 prior to commencing vaginal 
progesterone. The number of embryos transferred was in accordance with the 
multiple birth minimisation strategy of the Human Fertilisation and Embryology 
Authority.   
 
Ongoing pregnancy was defined as presence of a fetal heart at 20 weeks gestation. 
Ongoing pregnancy from the first embryo transfer irrespective of whether it was 
fresh or frozen was used as the primary outcome.  
 
6.2.3 NMR protocol  
Profiling of 155 lipid and metabolite measures was performed by a high-
throughput targeted NMR platform which applies a single experimental setup, 




platform allows for the simultaneous quantification of routine lipids, 14 
lipoprotein subclasses and individual lipids transported by these particles, 
multiple fatty acids, glucose, various glycolysis precursors, ketone bodies, and 
amino acids in absolute concentration units.   
 
The NMR-based metabolite quantification was achieved by measuring through 
three molecular windows from each sample. Two of the spectra (LIPO and LMWM 
windows) were acquired from native serum and one spectrum from serum lipid 
extracts (LIPID window). The NMR spectra were measured using Bruker AVANCE III 
spectrometer operating at 600 MHz. Measurements of native serum samples and 
serum lipid extracts were conducted at 37OC and 22OC, respectively. Details of 
this platform have been published previously (Soininen, et al., 2009, Wurtz, et 
al., 2017) and it has been widely applied in genetic and observational 
epidemiological studies (Fischer, et al., 2014, Mills, et al., 2019, Wang, et al., 
2018, Wang, et al., 2016, White, et al., 2017, Wurtz, et al., 2015). Further details 
of the platform are provided in Chapter 2 Materials and Methods. 
 
6.2.4 Metabolite quantification and quality control 
For each sample, the NMR spectra were analysed for absolute metabolite 
quantification (molar concentration) in automated fashion. A ridge regression 
model was applied for quantification of each metabolite in order to overcome the 
problems of heavily overlapping spectral data. Quantification of lipoprotein lipid 
data was performed by calibrating against high performance liquid 
chromatography methods, and then individually cross-validated against NMR-
independent lipid data. Low-molecular-weight metabolites, as well as lipid 
extract measures, were quantified as mmol/l based on regression modelling 
calibrated against a set of manually fitted metabolite measures. The calibration 
data was quantified based on iterative line-shape fitting analysis using PERCH NMR 
software (PERCH Solutions Ltd., Kuopio, Finland). Absolute quantification could 
not be directly established for the lipid extract measures due to experimental 
variation in the lipid extraction protocol. Therefore, serum extract metabolites 
have been scaled via the total cholesterol as quantified from the native serum 





6.2.5 Assessment of potential confounders 
For women and men the principal confounders of age, BMI, educational 
attainment, ethnicity, family history of cardiometabolic disease (defined as first 
degree relative affected), physical activity, alcohol intake, smoking status, 
duration and cause of infertility were considered because they plausibly 
influenced both NMR metabolites and the chance of ongoing pregnancy (Lintsen, 
et al., 2005, Matthews, et al., 2009, Mushtaq, et al., 2018, Sermondade, et al., 
2019). For women whether this was primary or secondary infertility, with the 
latter defined as following a previous naturally conceived pregnancy, was also 
adjusted for as a confounder.  
 
6.2.6 Statistical analysis  
Statistical analyses were conducted using R version 3.4.2 (R Foundation for 
Statistical Computing, Vienna, Austria). Characteristics of the participants were 
summarized as n, total range, mean, standard deviation, median, and 25th and 
75th quantiles (IQR) as appropriate. Multivariable logistic regression was used to 
examine the associations of serum metabolic profiles with ongoing pregnancy 
separately for males and females. Robust standard errors were estimated for all 
associations, as some metabolite concentrations had skewed distributions. The 
metabolic measures were scaled to sex-specific standard deviation (SD) units (by 
subtracting the mean and dividing by the standard deviation of either all men or 
women included in the analyses). This scaling allows easy comparison of multiple 
metabolic measures with different units or with large differences in their 
concentration distributions.  As an additional sensitivity analyses to account for 
any potential sex-specific differences in metabolite distributions we also assessed 
the associations in the original metabolite units for both sexes (for example per 
1mmol/l increase).  
 
In the main analysis, adjustments were made for all a priori selected confounders 
(age, education, alcohol use, physical activity, smoking, BMI, ethnicity, family 
history of cardiometabolic disease, cause of female infertility, duration of 
infertility and whether the woman had primary or secondary infertility).  I 
assessed the consistency of the magnitude and direction of the covariate adjusted 
odds ratios for women and men with ongoing pregnancy using a scatterplot and 




concordance for metabolite profiles (Chapter 5, Al Rashid, et al., 2020), I 
performed additional analyses to assess the association of metabolite 
concentrations with ongoing pregnancy after restriction to women (n=322) with a 
male partner in the study.    
 
6.3 Results 
Four hundred women and 326 male partners were initially recruited, with 392 
women (98%) and 322 men proceeding to treatment. Baseline characteristics of 
the female and male participants are shown in Table 6.1. The mean (SD) age of 
the women was 35.5 (4.4) years, with the majority (92%) White European, with a 
mean (SD) BMI of 24.7 (3.2) and 68% with primary infertility. Median AMH was 16.1 
pmol/l (IQR 8.9, 28.0) and median AFC of 12 (IQR 7, 16). The male partners were 
of a slightly older mean age 37.2 (5.7) years, and 20% exhibited a known male 




 Females (N=398) Males (N=325) 
Age (years): Mean, SD, Range 35.5 (4.43) 22-45 37.2 (5.7) 25-55 
BMI (kg/m2) : Mean, SD, Range 24.7 (3.2) 18.2-32.5 25.2 (3.0) 19.4-
35.1 
Alcohol (units per week):  
Median, IQR, Range 4 (1,8) 0-27 4 (2,9) 0-40 
Highest Education N(%) 
  School 
  Undergraduate 









Ever smoked: N(%) 104 (26%) 97 (30%) 
Physical activity (times per 
week)  
  Never/once 
  Twice 
  3-4 times 











Family history of 
cardiometabolic disease: N(%) 
208 (52%) 153 (47%) 
Ethnicity: N(%) 
  White European 
  Asian 









Cause of infertility  
  Tubal disorder 
  Endometriosis 
  Ovulatory disorder 
  Azoospermia 
  Oligozoospermia 
  Male factor/No male partner 
  Female factor 
  Other/Unexplained 



















Duration infertility (years): 
Median, IQR, Range  
3 (2,4) 1-13 
Primary infertility: N(%) 271 (68%) - 
Gravidity: Median, IQR, Range 0 (0,1) 0-12 - 
Parity: Median, IQR, Range 0 (0,0) 0-4 - 




Total AFC:    12 (7,16) 0-40 - 
Table 6.1 Baseline characteristics of the study population. 
 
 
The clinical outcomes of the index ovarian stimulation cycle are shown in Table 
6.2. An equal weighting of GnRH agonist and antagonist cycles were undertaken 
with a median duration of 11 (IQR 9, 12) days of stimulation. A small proportion 




embryos available on day 5 for transfer.  The majority (83%) of women had a single 
blastocyst transferred, with an overall ongoing pregnancy rate of 47.2% per cycle 
started and a multiple pregnancy rate of 1.1%.  
 
 Clinical outcomes 
(N=392) 
Stimulation protocol: N (%) 
  GnRH agonist 




Total FSH units (IU): Median, IQR 2588 (1800, 3150) 
Duration of stimulation (days): Median, IQR 11 days (9,12)  
Number of oocytes retrieved: Median, IQR, Range 8 (6, 11) 0 - 33 
Number of MII oocytes: Median, IQR, Range 7 (4, 9) 0 - 28  
Number of 2PN embryos: Median, IQR, Range 5 (3, 7) 0 - 23 
Number of embryos frozen: Median, IQR, Range 1 (0, 3) 0 - 23 
Number of embryos transferred: N (%) 
  Single embryo 




Clinical outcomes per cycle started: N (%) 
  Cycle cancelled for anticipated poor response 
  No oocytes retrieved 
  No Embryo available for transfer 
 
  Not Pregnant 
  Biochemical Pregnancy  
  Miscarriage 
  Ongoing Pregnancy* 











Multiple ongoing pregnancy: N (%) 
  Singleton  
  Twins  
183 (98.9%) 
2 (1.1%) 
Table 6.2 Clinical outcomes of the study population. 
*An ongoing pregnancy was defined as each pregnancy showing a positive 
heartbeat at ultrasound after 20 weeks of gestation. 
**pregnancy terminated for medical reasons 
 
 
The adjusted associations of the metabolites for females and males and ongoing 
pregnancy are presented in Figure 6.1, 6.2 and 6.3 with the unadjusted analyses 
of male and female metabolites and ongoing pregnancy presented in Figure 6.4, 





Figure 6.1 Associations of lipoprotein classes with ongoing pregnancy in 
males and females.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility, 






Figure 6.2 Associations of lipoprotein classes and fatty acids with ongoing 
pregnancy in males and females.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility, 






Figure 6.3 Associations of metabolic traits with ongoing pregnancy in males 
and females.  
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility, 





Figure 6.4 Unadjusted associations of lipoprotein classes in male and female 








Figure 6.5 Unadjusted associations of lipoprotein classes and fatty acids in 










There was evidence of an association between Histidine and ongoing pregnancy in 
females (OR = 1.28 (95% CI 1.03, 1.60) per one SD increase) and also in males, 
with similar magnitudes in both (OR = 1.26 (95% CI 0.99, 1.60) per one SD 
increase). In females, alanine (OR=1.31 (1.05, 1.64)), Isoleucine (OR=1.28 
(1.02,1.61)) and Leucine (OR=1.24 (0.99,1.55)) were positively associated with 
ongoing pregnancy. Pyruvate has a positive association in males and ongoing 
pregnancy (OR=1.30 (1.02,1.66)). Other metabolic measurements, including 
lipids, lipoprotein sub-participles and fatty acids were closer to the null in both 
parents. 
 
Across all metabolite measurements there was very little evidence of consistency 
(of magnitude and direction) in associations between women and men (R2 = 0.29; 
Figure 6.7).  When I repeated analyses only including women (n=322) with a male 
partner in the study, results were consistent with the main analysis results (Figures 





Figure 6.7 Scatterplot of associations of male and female metabolite profiles 
with ongoing pregnancy rates.  
In adjusted analyses in males and females separately, standard deviation (SD) 
scores of metabolites were regressed on covariates (age, educational attainment, 
ever smoking, physical activity, family history of cardiometabolic disease, alcohol 
consumption, BMI, and ethnicity) with ongoing pregnancy rates. The green dots 
highlight the individual metabolites. The grey dashed line reflects the reference 







Figure 6.8 Associations of lipoprotein classes with ongoing pregnancy in 
males and females for the 322 women with male partners in the study. 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility, 







Figure 6.9 Associations of lipoprotein classes and fatty acids with ongoing 
pregnancy in males and females for the 322 women with male partners in the 
study. 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility,  





Figure 6.10 Associations of metabolic traits with ongoing pregnancy in males 
and females for the 322 women with male partners in the study 
Effect sizes per 1 SD in metabolite concentrations and respective 95% confidence 
intervals are shown for males (red) and females (black).  Analyses in females 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of female infertility, 
duration of infertility, type of infertility (primary vs secondary). Analyses in males 
adjusted for age, education, alcohol use, physical activity, smoking, BMI, 
ethnicity, family history of cardiometabolic disease, cause of male infertility, 





In this prospective cohort of women and men undergoing their first cycle of IVF 
treatment, I demonstrate that women and men with higher preconception serum 
histidine levels were more likely to experience an ongoing pregnancy from IVF 
than those with lower levels. In addition, I identify positive associations of 
isoleucine, leucine and alanine in women, and of pyruvate in men which 
associated with successful IVF. I did not find clear associations with lipids, 
lipoproteins, fatty acids or other metabolic measurements in either parent and 
across all metabolites, there was little evidence of consistency between women 
and men. These results were robust to adjustment for demographic and clinical 
confounders. To my knowledge, this is the first study assessing detailed metabolic 
profiling in both men and women with clinical pregnancy outcomes. However, 
estimates were imprecisely estimated and I lacked statistical power to determine 
specific differences between women and men (as can be seen in Figure 6.1, 6.2 
and 6.3 the confidence intervals overlap between the parents for all associations). 
 
The identification of histidine, an essential alpha amino acid with a functional 
imidazole group as being associated with ongoing pregnancy is novel. Histidine is 
a positively charged α-amino acid and contains an α-amino group (which is in the 
protonated –NH3+ form under biological conditions), a carboxylic acid group (which 
is in the deprotonated –COO− form under biological conditions), and an imidazole 
side chain (which is partially protonated). The acid-base properties of the 
imidazole side chain are relevant both to formation of complexes with many metal 
ions as the it commonly serves as a ligand in metalloproteins and it can also 
improve the catalytic efficiency of many enzymes due to the rapid proton 
shuffling. 
 
Histidine is a precursor for several biologically active amines including histamine 
and carnosine and it can also be converted to ammonia and urocanic acid via the 
enzyme histidine ammonia lyase, or 3-methylhistidine which serves as a biomarker 
for skeletal muscle damage via certain methyltransferase enzymes. The imidazole 
ring is also capable of scavenging reactive oxygen species. It has been reported 
that low plasma concentrations of histidine are associated with protein-energy 
wasting, and markers of inflammation, oxidative stress and insulin sensitivity 




supplementation in a placebo-controlled randomised controlled trial associated 
with improved adiposity, insulin resistance, inflammatory oxidative stress markers 
(Feng, et al., 2013). In both women and men, increasing adiposity is inversely 
associated with IVF success rates (Mushtaq, et al., 2018, Sermondade, et al., 
2019), however, the observed associations persisted after adjustment for BMI 
suggesting alternative pathways may also contribute.  These may include its anti-
oxidant properties, as anti-oxidant therapy has been associated with improved 
clinical outcomes in some but not all trials (Showell, et al., 2017, Smits, et al., 
2019).  
 
Alternatively, the observed association  may be through the composition of other 
proteins such as histidine-rich glycoprotein (HRG) which has been extensively 
documented throughout the female reproductive tract, including in blastocysts 
(Nordqvist, et al., 2010)Human HRG is a 507-amino acid multidomain protein 
consisting of 2 N-terminal regions with homology to cystatin-like domains (termed 
N1 and N2), a central histidine-rich region (HRR) flanked by 2 proline-rich regions 
(PRR1 and PRR2), and a C-terminal domain. On the basis of the modular 
architecture of HRG, it has been proposed that HRG may act as an adaptor 
molecule that interacts with multiple ligands simultaneously through several 
independent binding sites and that collectively, HRG can potentially regulate 
numerous biologic processes. Previous small studies have also suggested that 
single nucleotide polymorphism (SNPs) in HRG that increase HRG circulating 
levels, may be associated with the chance of successful IVF treatment in both 
sexes (Lindgren, et al., 2016, Nordqvist, et al., 2011). The biological mechanism 
underlying this is less clear, as HRG can function as an adaptor molecule and 
regulate numerous important biologic processes, such as immune 
complex/necrotic cell/pathogen clearance, cell adhesion, angiogenesis, 
coagulation, and fibrinolysis (Poon et al., 2011). With respect to its immune 
function HRG can modulate the formation of immune complexes, FcγR function, 
exhibits antimicrobial and endotoxin-neutralizing properties, and also facilitate 
the removal of later ie plasma membrane permeabilised apoptotic and necrotic 
cells (Poon et al., 2011). Studies utilising HRG-/- mice have shown that HRG is an 
important factor for efficient clearance of fungal and bacterial infections and may 





With respect to angiogenesis, HRG and peptides derived from the histidine-rich 
region of HRG have been shown to exhibit both pro- and/or anti-angiogenic 
properties, depending on the experimental systems (Poon et al., 2001). Further 
assessment of the potential contribution of HRG peptides to endometrial and 
embryo development demonstrated that HRG enhanced migration and tube 
formation of human endometrial endothelial cells but inhibited proliferation 
(Lindgren et al., 2016). vascular endothelial growth factor (VEGF)-induced 
migration was also inhibited by the HRG proline peptide and both peptides 
reduced VEGF-induced proliferation. Except for a prolonged time from first 
cleavage after thawing to development of the morula, no difference in embryo 
morphokinetics or embryo quality was noted in human embryos cultured in the 
presence of the HRG proline peptide. Taken together, these results suggest that 
treatment with a specific HRG peptide might prime the endometrium for 
implantation and be beneficial for adequate placentation. However, addition of a 
specific HRG proline peptide to human embryos has no beneficial effects in terms 
of embryo development (Lindgren et al., 2016). Whether HRG simply functions as 
a regulator or is a key molecule in either a nonredundant or redundant pathway 
remains to be determined. Whilst the consistent association in both women and 
men makes chance less likely, I acknowledge this association needs independent 
replication and studies that can determine causality.  
 
In previous analyses detailed in Chapter 3, I demonstrated cross-sectional 
associations of AMH with isoleucine, leucine and tyrosine (Al Rashid et al., 2020), 
suggesting that these are influenced by or reflect ovarian reserve and the 
possibility that associations of isoleucine and leucine with successful pregnancy in 
women in this study may reflect the influence of variation in ovarian reserve 
(underlying fertility) on IVF pregnancy success. Alanine, which was also associated 
with pregnancy in this study, and leucine have both previously been demonstrated 
within follicular fluid (Marianna, et al., 2017), with reduced levels in the sera and 
follicular fluid of endometriosis patients associated with lower pregnancy rates 
than controls (Jana, et al., 2013). In a porcine in vitro maturation model alanine 
and leucine supplementation have also been associated with improved pronuclear 
development and blastocyst formation, suggesting a female-specific contribution 
(Hong and Lee, 2007). Concentrations of these and other amino acids have also 




nuclear transfer (SCNT) as compared to standard IVF pregnancies (Groebner, et 
al., 2011), and through this disrupted embryo-maternal interaction in the 
preimplantation period have been suggested to contribute to the observed 
developmental abnormalities and lower pregnancy rates observed for SCNT cycles 
(Zhou, et al., 2014). 
 
Few previous observational studies have examined the association between 
circulating lipoproteins and clinical IVF outcomes in detail. A previous smaller 
(N=167) analysis was limited to conventional serum lipid measurements (HDL, LDL 
and Triglycerides) and suggested that Triglycerides were negatively associated 
with the chances of a live-birth, however, this association was attenuated to the 
null when analyses were restricted to non-Asian participants (Jamro, et al., 2019). 
In contrast, analyses of natural cycle frozen embryo transfers (N=143) suggested 
that higher triglyceride and the erythrocyte ratio of saturated to unsaturated fatty 
acids concentrations were both positively associated with the chance of ongoing 
pregnancy (Onyiaodike, et al., 2018). In the current study with a predominantly 
non-Asian population, there was also evidence of a weak association of 
Triglycerides in women and ongoing pregnancy. Endogenous triglycerides are a key 
energy source during oocyte maturation and preimplantation embryo development 
(Ferguson and Leese, 2006), with mammalian blastocysts dependent on their own 
energy stores to drive cell division (Gardner, 1998). However, human embryos that 
successfully develop to blastocysts have lower triglyceride content, although it is 
difficult to determine if this is due to less initial storage or greater oxidation rates 
providing more energy while the blastocyst was being formed (Leary, et al., 2014). 
A well-stocked oocyte in terms of lipid available for oxidation (i.e. saturated fat) 
may have an advantage over one that lacks such lipid (Onyiaodike, et al., 2018). 
 
This study has several strengths including the detailed phenotyping and that I 
assessed both women and men, enabling the consideration of maternal and 
paternal metabolic profiles on the chances of ongoing pregnancy. That I previously 
showed in Chapter 5 limited spousal correlation for the serum metabolite 
measured, further supports their evaluation in both partners. I do however 
acknowledge several limitations including that I cannot assume that the small 
number of associations are causal.  Whilst this is the largest study to explore these 




intervals and I am not aware of any independent study that has measures of 
multiple metabolites and ongoing pregnancy (or even the amino acids that we 
observed associations with) in which to attempt to replicate our findings. Though 
I acknowledge the necessity to replicate and hope that my findings will stimulate 
others to obtain these measures in couples undergoing IVF. The small sample size 
also limits our ability to robustly test sex differences and the suggestive sex-
specific results should be treated with caution until they can be replicated in 
larger studies. Participants were confirmed (through cotinine breath test) non-
smokers and the women were of a relatively restricted BMI range. The participants 
were also largely white European and educated to degree level. This homogeneous 
relatively healthy population may have resulted in some selection bias and may 
mean that the results do not generalise to other infertile populations or other IVF 
centres with different treatment protocols. I limited analyses to the clinical 
outcome of the first embryo transfer, to provide a time-limited evaluation of the 
primary outcome with all participants able to contribute equally. Given the 
predicted number of pregnancies after completion of all embryo transfers and 
current point estimates I anticipate their inclusion for those who were initially 
unsuccessful would have limited impact on the overall conclusions.  Live-birth 
data was not available due to the regional provision of assisted conception 
services. Analyses were undertaken on non-fasting samples, however, several 
studies using this same NMR analysis platform results have not differed notably 
between studies in which the analyses were undertaken in participants who had 
been advised to fast and those who had not (Maqdasy et al.,2013). Lastly, while 
NMR platform used in these analyses covers considerably more of the lipidome 
than conventional clinical chemistry measures we acknowledge it misses a high 
proportion of the currently quantifiable metabolites in human serum/plasma, 
including markers of energy balance, microbiota metabolism, vitamins, co-factors 
and xenobiotics, that may influence the chance of pregnancy. High throughput 
analyses of a wider range of metabolites measured by mass spectrometry are 
possible but considerably more expensive than the NMR platform used here, 
resulting in their use being frequently restricted to subsamples of cohorts (Sovio, 








My findings are the first to report a higher likelihood of ongoing pregnancy after 
IVF among both women and men with higher preconceptual histidine 
concentrations, as part of a wider profile that encompasses lipoproteins, a range 
of amino acids and other metabolites related to overall health. The association of 
isoleucine and leucine with pregnancy in women may reflect an influence of 
variation in ovarian reserve influencing pregnancy success in IVF. Although the 
mechanisms underlying these associations are unclear our results if confirmed 
have the potential for clinical intervention. Serum metabolites are readily 
ascertained, and modification of concentrations including that of histidine may be 
achieved through supplementation. Confirmation of these findings is warranted 





Chapter 7 General discussion 
In this thesis, I have outlined the development of a novel cohort of 731 participants 
(400 women and 331 men) undertaking assisted conception with extensive pre-
treatment phenotyping, meticulous clinical and laboratory data and prolonged 
follow-up allowing ongoing pregnancies from both fresh and frozen embryo 
outcomes to be considered as clinical outcomes. Each participant has also 
contributed to the creation of a unique comprehensive biobank encompassing pre-
treatment serum, plasma, DNA and vaginal swab samples. I have used this cohort 
to address a range of novel and clinically important questions, with a particular 
focus on circulating metabolic measures and the ovarian reserve, semen 
parameters, the correlation between couples and the clinical outcome of 
treatment as defined by an ongoing pregnancy. In the creation of this exceptional 
resource as summarised in Figure 7.1, I anticipate that this cohort through 
collaboration will continue to make a major contribution to a considerable number 
of areas of active research and further understanding of how the pre-treatment 
phenotype may impact on immediate and longer-term outcomes. It is with this 
aspiration that this final chapter concludes my thesis and suggests potential areas 
of future research.  
 
7.1 General findings 
The study discussed in chapter 3 observed a positive association between AMH and 
branch chain amino acids, such as isoleucine, leucine and tyrosine, medium HDL 
and small HDL, omega-6 fatty acids and polyunsaturated fatty acids, and negative 
association with acetate. AFC showed directionally consistent association but with 
overall weaker in magnitude. These associations strengthened when I restricted 
the analysis to a subgroup of women with male factor infertility. In addition, I 
observed a positive association of AMH and AFC with a range of lipids. Some of the 
associated metabolites, particularly branched-chain amino acids, have been 
linked to several cardiometabolic risk factors, including adiposity, fasting glucose, 




disease (Tobias et al., 2018). My work would support a potential mechanism linking 
ovarian reserve to cardiometabolic health.  
The exploratory study conducted in chapter 4 shows no identification of any 
associations between the measured metabolites and sperm parameters, such as 
concentration, progressive motility, or the risk of low or very low total motile 
sperm count. However, the point estimates indicate some potentially important 
associations. For instance, higher glycolysis metabolites and ketone bodies were 
associated with higher odds of total motile sperm count <15M; also, various 
lipids/lipoprotein concentrations seem to prevent extremely low TMSC. There was 
also a weak negative association between acetate and sperm motility. Replication 
of these findings in both larger studies and in smaller less heterogenous sub-
populations would be useful.    
In chapter 5 I demonstrated that couples show a strong correlation for the range 
of physical, social, and behavioural characteristics with modest to weak 
correlations for lipids and a few other metabolic measures which are solely diet 
derived. This suggests that assortative mating is similar in infertile couples as in 
the general population, with further convergence through active sharing in the 
shared environment and diet.  
In the prospective cohort study presented in chapter 6, I demonstrate a novel 
finding that a higher level of preconception serum histidine in both women and 
men is associated with higher chances of achieving ongoing pregnancy after 
undergoing IVF than those with lower levels of histidine. I also identify positive 
associations of leucine, isoleucine and alanine in women and pyruvate in men, 
associated with IVF success rate. However, I did not observe associations with 
lipids, lipoproteins, fatty acids or other metabolic measurements in either 
partner, and there was little evidence of consistency between women and men. 
To my knowledge, this is the first study to evaluate the detailed metabolic 
characteristics of men and women with clinical pregnancy outcomes. 
An a priori power calculation defined the sample size for the cohort, however, I 
acknowledge that for several of the outcomes, potentially clinically relevant but 
modest effect sizes were observed. Replication in larger studies would be useful 




lack of power in IVF cohorts and trials is a well-recognised issue, with small studies 
of seemingly well-defined clinical phenotypes often not replicating in larger 
studies. That I chose to include a more heterogeneous population improves the 
generalisability of my findings, but I appreciate that potential effects in specific 
sub-populations may be attenuated. 
 
 
7.2 Ovarian ageing  
Ovarian ageing involves the natural decline in both quantity and quality of oocytes 
in the primordial follicle pool with increasing age. The endpoint of this process is 
menopause when too few follicles remain to sustain a normal menstrual cycle. 
The median age of menopause is 51 years, with accelerated ovarian ageing and 
early menopause (<45 years) occurring in 10% of women, with 1-5% experiencing 
premature ovarian insufficiency before the age of 40 years (Coulam et al 1985, 
Shuster et al. 2010). The concept of the ovarian reserve as a biomarker for health 
has been supported by several studies identifying that the age of natural 
menopause and especially a young age of natural menopause to be associated with 
an increased risk of disease or events normally considered to be age-related such 
as cardiovascular disease (CVD), coronary heart disease, cancer-related mortality 
and all-cause mortality (Jacobsen et al., 2003; Ossewaarde et al., 2005; Otsuki et 
al., 2018; Zhu et al., 2019). Similarly, women with a poor response to ovarian 





Figure 7.1 Summary of IVF cohort, outcomes and associated Biobank samples. 
The number of females and males recruited, and the associated biological samples 
NMR metabolomics has been undertaken, timelapse variables of the embryos, 
clinical pregnancy outcomes, vaginal swabs processed for microbiome analysis, 
pretreatment characterisation (full details of forms in Appendix IV), stimulation 
and laboratory details, maternal and paternal DNA samples (stored as buffy coats 
for preparation) and plasma and serum aliquots.  
 
 
oocyte yield had a significantly higher hazard of age-related events including CVD, 
osteoporosis and early receipt of retirement benefit and an overall higher Charlson 
comorbidity index (Christensen et al., 2020). Thus, premature depletion of the 
ovarian reserve, and the onset of either POI or early menopause, may be a marker 
of accelerated somatic ageing. The concept of the ovarian reserve as a biomarker 
for health is further supported by data showing that women with late menopause 




disease and a decreased risk of all-cause mortality than women with an average 
age of menopause (Ossewaarde et al., 2005)  
 
The underlying mechanisms of the increased CVD risk and morbidity associated 
with premature depletion of the ovarian reserve remain to be clarified, although 
the timing of the increased disease risk in relation to the menopause has led some 
to suggest that oestrogen deficiency may be a contributing cause (Rocca et al., 
2018). However, consistent with my findings premenopausal women with 
unexplained very low ovarian reserve (AMH, AFC) have previously been shown to 
have a more unfavourable CVD risk profile, with bone mass mineral density also 
reduced, as compared to women of a similar age but with normal ovarian reserve 
(Pal et al., 2008; Bleil et al., 2013; Cedars, 2013; Verit et al., 2014; de Kat et al., 
2016). This would suggest that oestrogen independent processes are also 
contributing. That I observed in young women associations between ovarian 
reserve markers and non-lipid metabolites which have previously been robustly 
been associated with cardiovascular disease mortality (Deelen et al., 2019), would 
further support that a range of mechanisms that are not purely atherosclerotic 
may be responsible for the link between ovarian ageing and somatic ageing. This 
may include shared genetic, metabolic and environmental factors, and 
clarification of their relative contribution may be feasible through future cohorts 
incorporating mother-offspring pairs and sibling studies where their respective 
contribution of genetic and a shared environment can be delineated.  
 
Telomere length has been proposed to act as a biomarker for ageing (Sanders and 
Newman 2013) and the possible relationship between female fertility and 
telomere length continues to be debated (Kosebent et al., 2018). DNA methylation 
(DNAm) patterns have previously also been used to predict chronological age with 
high accuracy (Horvath S. 2013), with the predicted DNAm age considered a 
biological measure of ageing. When the estimated DNAm age is greater than the 
chronological age, the term “age acceleration” is used to describe faster rates of 
ageing (Horvath, 2013). To date, several studies have found such deviations 
between the DNAm age and the chronological age in various tissue types and 
individuals (Horvath et al., 2015a; Horvath, et al., 2015b; Sehl et al., 2017), with 
accelerated DNAm age in blood associated with all-cause risk of mortality (Marioni 




predictor, several more specialized epigenetic clocks have been developed to 
measure different aspects of the ageing process (Weidner et al., 2014; Giuliani et 
al., 2016; Levine et al., 2018). Of these DNAm age acceleration in leukocytes has 
been associated with reproductive life events such as menarche, puberty, and 
early menopause (Levine et al., 2016; Simpkin et al., 2017; Binder et al., 2018). 
Given these links, establishing the relationship of DNAm with the ovarian reserve 
biomarkers (AMH and AFC) would be of interest, with preliminary data from 39 
women suggesting that accelerated ageing was associated with a lower AMH 
(Monseur et al., 2020). In young women (n =175), a poor ovarian response has also 
been associated with epigenetic age acceleration within WBC samples (Hanson et 
al., 2020). In contrast, age-related changes were not observed in CC (Hanson et 
al., 2020), potentially reflecting that epigenetic clocks failed to accurately 
predict the age of cumulus cells, (Morin et al., 2018). Whether DNAm clocks are 
associated with oocyte quality or the probability of pregnancy would be worth 
exploring further and could be evaluated using the leucocyte samples (n= 400 
women) stored for DNA preparation within my cohort.  
 
Clarification of whether a low ovarian reserve and/or ART treatment outcomes 
such as low oocyte yield enables simple and early identification of women at risk 
for accelerated somatic ageing is urgently required, as this may allow the early 
onset of preventative initiatives such as lifestyle changes and/or pharmacological 
interventions. Although suggested interventions may appear relatively generic and 
include counselling on adopting a healthier lifestyle (e.g. regular physical 
exercise, avoidance of smoking and importance of maintaining a healthy body 
weight), that the individual would have been identified through a different 
mechanism to classical risk factor screening may lead them to consider this 
“teachable” moment more seriously, thereby allowing potentially greater 
mitigation of some of the adverse risks associated with premature ageing.  
 
7.3 Male Factor  
Male factor infertility is a very common problem, affecting 1 in 10 men of 
reproductive age (Datta et al., 2016). The majority of cases are idiopathic, with 
no relevant past medical history or abnormal findings on physical examination, 
endocrine, genetic and biochemical laboratory testing. There is currently no 




improve sperm function (Martins da Silva et al., 2017). This large unmet need for 
a universally available direct treatment for the sub-fertile man (i.e. men with 
poor sperm) to increase the chance of natural conception and live birth is of 
critical global importance and prompted the analysis of metabolite profiles and 
their association with semen parameters. Although I identified several novel 
associations, the effect sizes were modest and substantially larger study sizes of 
>3,000 participants would be required to robustly confirm our findings. Future 
work incorporating alternative and more comprehensive metabolome profiling 
may identify alternative therapeutic targets, that may be amenable to either 
dietary or pharmaceutical modification.  
 
Alternative targets that may not be highlighted by metabolite profiling include 
the potential contribution of reactive oxygen species (ROS) which are normal by-
products of cellular metabolism. Small amounts of ROS are required for normal 
sperm function, but when ROS are in excess or uncontrolled, they become toxic 
(Aitken et al., 2011), with excessive ROS causing direct damage to DNA 
(Gharagozloo et al., 2016), as well as to the sperm cell membrane, which impacts 
on motility and the ability to fertilise an oocyte (Aitken and Curry, 2011). The 
current thinking is that free radical generation, oxidative DNA damage, DNA 
fragmentation and cell death lie on a continuum (Aitken et al., 2011). 
Spermatozoa are particularly sensitive to ROS because they possess limited 
endogenous antioxidant protection while presenting abundant substrates for free 
radical attack (Koppers et al., 2010). Whilst there is universal agreement that OS 
is an underlying cause and affects a significant proportion (30-70%) of sub-fertile 
men (Aitken et al., 2017) and there is a rationale for using antioxidant 
supplements, accurate identification of who would benefit from treatment has 
been difficult to determine. To date, assays have primarily focused on indirect 
oxidative stress determination for example sperm DNA damage. Whether 
alternative blood oxidative stress assays may be useful is at present unknown, but 
there are several advantages including easy collection and assay execution, 
relatively low cost and the facility to test many samples in laboratory routine or 
large studies. An example of this would be Diacron reactive oxygen metabolites 
test (d-ROM) (Vassalle et al 2008), a simple commercial colourimetric assay, 
designed to quantify early peroxidation species (reactive oxygen species) rather 




can catalyze peroxides in the sample under acidic conditions (pH 4.8), forming 
alkoxy and peroxy radicals, which subsequently react with an amine, leading to 
the formation of coloured products that can be measured spectrophotometrically.  
 
Reactions require iron ions; thus, samples must be collected as serum and 
heparinized plasma, which I have collected. The stability of the reactive oxygen 
species in stored serum samples results in reliability; with differences between 
samples that were immediately dosed and aliquots stored for 24 h at 4°C 
nonsignificant, with serum samples showed a very good degree of stability for up 
to 1 year of storage at -20 and -80°C (Jansen et al., 2015). Further work could 
include the measurement of d-ROM within the stored samples and correlation with 
semen parameters and clinical outcomes to evaluate its potential in the 
stratification of males who would benefit from anti-oxidant therapy. This may also 
inform the design of future randomised controlled trials of anti-oxidants, as at 
present the WHO Expert Synthesis Group (ESG) recently concluded that there was 
insufficient evidence to support the use of supplemental antioxidant therapies to 
treat men with abnormal semen parameters and/or male infertility (Barratt et al., 
2017). Rather than simply randomising all men with abnormal semen parameters 
or all men receiving fertility treatment irrespective of their sperm count, 
identification of a sub-group with elevated ROS may be feasible. This would have 
the beneficial effect of increasing power and reducing trial size, by avoiding any 
therapeutic effect being diluted by a wider population where it would be unlikely 
to be beneficial as their ROS status was normal.  
 
Alternatively, by measuring ROS or metabolites with semen itself rather than 
blood may be a means as to which identify men which may have relative 
deficiencies of anti-oxidants or excessive or deficient metabolites that may be 
amenable to correction. However, although several studies have undertaken 
metabolomics in seminal fluid (Murgia et al., 2020; Mumcu et al., 2020; 
Mehrparvar et al., 2020), they have been of limited size, have primarily used 
select groups and have used single samples, albeit some performing technical 
repeats, rather than replicating the results on a separate ejaculate sample (Gilany 
et al., 2017). This approach may also be potentially limited to those with evidence 
of sperm in the ejaculate rather than non-obstructive azoospermia where there 




could collect seminal fluid, including repeat samples and used automated semen 
analyses to help further reduce variability than my single operator approach. 
However, validation of collection and processing of the semen samples would be 
critical, to ensure that stored samples are representative of fresh ejaculates with 
respect to ROS concentrations and metabolomics.  
 
The sperm epigenome is uniquely complex (Immler et al., 2018) and susceptible 
to environmentally associated modification (Schagdarsurengin & Steger, 2016) in 
part because there are various points in the development that the epigenome is 
susceptible to modification, that is, paternal embryonic development, 
spermatogenesis, and offspring early embryonic development (Gold et al., 2018). 
At each time point, the internal and external environments appear to have a major 
influence on how the epigenome is modified (Soubry et al., 2014). For example, 
sperm DNA methylation patterns have recently been shown to predict paternal 
age with a high degree of accuracy (Jenkins et al., 2018). There is also evidence 
to suggest that idiopathic male subfertility and abnormal semen parameters, in 
particular oligozoospermia, are associated with abnormal spermatozoal DNA 
methylation of imprinted regions (Åsenius et al., 2020). However, no specific DNA 
methylation signature of either subfertility or abnormal semen parameters has 
been convincingly replicated in genome-scale, unbiased analyses and the clinical 
benefits of findings to date is therefore limited. Preliminary data also suggest that 
environmental factors, such as smoking, may also alter DNA methylation patterns 
to an age beyond actual chronologic age (Åsenius et al., 2020). While two small 
cohorts (n = 67 and n= 294) have assessed the association with adiposity on sperm 
methylation of imprinted loci in targeted analyses, the results are non-consistent 
with the larger study finding no associations (Soubry et al., 2016; Potabattula et 
al., 2019). Overall, despite several studies independently demonstrating 
associations between spermatozoal DNA methylation and fertility, smoking status, 
exercise interventions and exposure to some environmental pollutants, none of 
these studies has consistently identified DNA methylation changes at the same 
genomic regions (Åsenius et al., 2020). Therefore, although this data is of interest, 
the drawbacks of analysis of human spermatozoal DNA methylation is similar to 
other epigenetic studies of human phenotypes and tissues, and include study 
design, experimental processes and statistical analyses, while some challenges are 




robust, reproducible findings, sample sizes need to be sufficiently large to meet the 
power needs of the study design. As sperm is not routinely collected outside of 
reproductive medicine settings, multicentre collaborations will likely be required to 
meet the need for increased sample sizes. Such collaborations should harmonize 
protocols for phenotyping of participants, processing samples and data analyses to 
limit batch effects. In that regard, blood is routinely taken from all patients, and 
clarification of the extent to which peripheral blood DNA methylation reflects semen 
parameters and clinical outcomes would be useful to determine and could be done 
using my stored samples, whether as an initial pilot or part of a larger collaboration.  
 
My work with metabolites and sperm highlighted the critical issue; of study size, 
as the effect sizes that I observed, would be biologically plausible estimates (odds 
ratios of 1.2 to 1.3), and if confirmed in independent cohorts would be potentially 
clinically meaningful. It is highly unlikely that interventions that could be applied 
to the general population are associated with substantially greater effect sizes. In 
contrast, male reproductive research is unfortunately frequently undertaken in 
substantially smaller studies with limited evidence or attempts at replication. 
Similarly randomised controlled trials of interventions have been small, for 
example in the assessment of supplementary oral antioxidants, 61 different 
randomised controlled trials assessing 18 different antioxidants have been 
undertaken (26 RCTs were placebo-controlled), but the overall population 
contained within all these trials was only 6,264 subfertile men (Smits et al., 2019). 
Of these only 11 studies (with 15 treatment arms) reported clinical pregnancy 
rates per couple (Peto OR 2.97, 95% CI 1.91 to 4.63, 786 men), and 7 RCTs 
reporting live birth rates (Peto odds ratio (OR) 1.79, 95% confidence interval (CI) 
1.20 to 2.67, 750 men) (Smits et al., 2019). For the male reproductive field to 
move forward substantially, greater effort in understanding basic biology, 
validation and replication of possible therapeutic targets and then large scale 
RCTs with biologically relevant endpoints such as clinical pregnancy or live-birth 
are required. Fortunately, global opinion leaders are beginning to campaign for 
male reproductive health to be placed centre stage in the political and research 
agenda (De Jonge et al., 2019). Whether a paradigm shift can occur with 
increasing recognition of the links between reproductive health and somatic 
health is at present unclear (Capogrosso et al., 2018; Choy et al., 2018; Latif et 
al., 2018, Jensen et al., 2009), but I hope that my Biobank of male serum, plasma 




7.4 Couple-based Interventions  
Infertility clinics are relatively unique in medicine, as they accommodate the 
needs of couples rather than individuals. Partners support each other during 
treatment and the emotional upheavals engendered by it. My analyses 
demonstrating that the couples within my cohort exhibit strong correlations for a 
range of physical, social and behaviour characteristics is consistent with 
conventional assortative mating, with infertile couples similar to couples within 
the general population. A critical difference was the lack of correlation for BMI or 
weight, as previous meta-analyses have suggested weak correlations between 
partners with regards to BMI (r = 0.15 across 34,582 couples in 19 studies) and 
weight (r = 0.11 across 6,765 couples in 9 studies) (Di Castelnuovo et al., 2009). 
Although this meta-analysis included all age-groups, a study examining 3356 
expectant couples attending antenatal clinics found a positive partner correlation 
for BMI (r = 0.21) (Edvardsson et al., 2013). In that study, a woman's odds of being 
obese were more than six times higher if their partner was also obese, in 
comparison with women whose partner was of normal weight (OR 6.2, 95% CI 4.2–
9.3). More than one-third (37.8%, P < 0.001) of the couples in the Pregnancy in 
PCOS II trial (PPCOS II) were concordant for obesity (Polotsky et al., 2015). A 
Danish population cohort study reported that couples presenting for IVF resembled 
each other in BMI, though they did not supply supportive data (Petersen et al., 
2013). Despite these observations in similar populations to my own, that I did not 
observe an association may lead to some to question the proposal for couple-based 
weight-loss interventions in infertile couples (Best et al., 2017). However, as I 
observed concordance in diet-derived metabolites and physical activity and that 
the main barriers to exercise reported by women (Banting et al., 2014) is lack of 
time and fatigue, and that their main physical activity supports are their partners 
(Banting et al., 2014), this compels me to consider whether couple-based 
interventions might be more useful than individual interventions.  
 
For weight loss, the few available trials including partners have used a variety of 
intervention approaches. These have included partner training for social support 
to increase positive reinforcement (e.g. praise), role modelling healthier eating, 
setting goals and focusing on problem-solving; also reduction of negative social 
control including criticism, punishment and nagging (McLean et al., 2003). To 




it will be necessary to study support but also processes that have received less 
attention such as social control, companionship, person-to-person contact, and 
access to resources and material goods (Berkman et al., 2000). Given the inherent 
strains of infertility and the irritability that accompanies behaviour change, 
interventions should also promote relationship-strengthening behaviours such as 
companionship and emotional and physical intimacy. Several RCTs have been 
recently been developed using a couple-based approach to different aspects of 
infertility management including optimisation of preconceptual lifestyle advice 
(PreLiFe-RCT) (Boedt et al., 2019), and the assessment of a web-based 
educational programme for the treatment of unexplained subfertility 
(Pleasure&Pregnancy RCT)(Dancet et al., 2019) with their results eagerly awaited.  
 
That I observed weak to moderate spousal correlations for a range of metabolites 
including some that are purely dietary derived is also consistent with previous 
reports (Draisma et al. 2013; Sirota et al. 2015; Tremblay et al. 2019). If these 
and the lipids associated with cardiometabolic disease were amenable to 
modification and shown to exhibit sustained changes after intervention through 
maintained behaviour change this could have beneficial effects across the lifespan 
for both partners and potentially for their offspring. Future intervention studies 
will, however, need to account for the strong cultural differences in eating, 
physical activity, and close relationships and require adequately powered studies 
to also be undertaken in other countries to establish the generalizability of their 
findings.  
 
7.5 Implantation  
Embryo implantation is the highly coordinated process whereby a blastocyst-stage 
embryo attaches and invades the maternal endometrium before placentation and 
pregnancy (Dey et al., 2004; Achache and Revel, 2006). This complex multistep 
process classically comprising three phases: apposition, adhesion and invasion. 
During apposition, the human blastocyst is usually guided to a specific endometrial 
location to implant by bidirectional crosstalk mediated by soluble molecules (Cha 
et al., 2012; Thouas et al., 2015), enabling orientation of the embryonic pole with 
the inner cell mass (ICM) towards the epithelium (Dey et al., 2004; Cha et al., 
2012). It then directly contacts the endometrium during the adhesion phase by 




cells (EECs). In this phase, communication between blastocyst and endometrium 
is mainly based on ligand-receptor reactions, but soluble factors are also involved 
in the dialogue. Finally, in the invasion phase, TE cells undergo differentiation 
and the embryonic trophoblast becomes invasive and penetrates the epithelium, 
breaking through the basement membrane into the stroma to reach the maternal 
vasculature (Schlafke and Enders, 1975; Bentin-Ley et al., 2000). Despite 
substantial advances in clinical and laboratory techniques, such as new strategies 
for oocyte stimulation, oocyte/embryo vitrification, selection of euploid embryos, 
have all contributed to enhanced pregnancy rates, at present, there is limited 
ability to predict or control the embryo’s ability to attach to the maternal 
endometrium. Greater clarification of the physiological and molecular factors 
involved in this process is essential for designing effective strategies to correct 
implantation failure.  
 
To date different omic based approaches have largely focused on unravelling the 
complexity of the implantation process, with the assessment of endometrial 
receptivity through analysis of endometrial biopsies or endometrial secretions, 
while embryo potential has been evaluated by assessment of follicular fluid, 
cumulus cells, embryo culture media or embryo biopsy derived material. With 
each sample type having their respective transcriptomic, epigenomic, proteomic 
and metabolomic signatures evaluated as appropriate. However, despite a large 
amount of biomarker related data from this wide range of techniques there is still 
insufficient evidence to highlight the differential regulation of a specific molecule 
with the clinical outcome of ongoing pregnancy. In my thesis I did not focus on 
any of these specific tissues, but rather applied metabolomics to peripheral blood 
samples from the couple to assess whether a common signature that would 
embrace both maternal and paternal components and therefore also potentially 
the embryo could be identified, with possibly additional specific molecules from 
either source.  
 
The identification of histidine as a metabolite which was common to both partners 
was unexpected, and the mechanism underlying this remains unclear. This has not 
been identified in any of the omic studies done to date on endometrial, oocyte, 
or embryo related samples and requires urgent replication. Putative mechanisms 




clinical low-grade inflammation (as determined by C-reactive protein (CRP) 
concentrations) before implantation has been associated with poorer reproductive 
outcomes (Brouillet et al., 2020). Determination of CRP levels and other potential 
systemic markers of inflammation within the cohort as part of further work would 
be useful, as to date studies evaluating CRP concentrations before IVF have been 
small (N = 16 to 135). However, there does appear to be a consistent association 
between increased CRP levels and impaired folliculogenesis (Lorenz et al., 2015), 
poor embryo development (Haikin Herzberger et al., 2019) and a reduced window 
of implantation (Macklon et al., 2014) all contributing to reduced pregnancy rates 
(Levine et al., 2019).   
 
I also identified several amino acids with the maternal circulation that exhibited 
novel positive associations with ongoing pregnancy, isoleucine, leucine and 
alanine. Previous studies assessing the metabolome of embryos have similarly 
identified; alanine, and leucine concentrations within embryo culture media and 
embryo viability, with a systematic review identifying that these findings had been 
replicated in at least two studies concerning embryo viability, or clinical 
pregnancies (Hernández-Vargas eta l., 2020). Determination of whether maternal 
circulating amino acid concentrations reflect those of the embryo would be useful 
in future studies as although embryonic culture concentrations were thought to 
reflect DNA damage and correction (Houghton et al 2004), evidence of correlations 
between the circulating levels and culture media would suggest alternative 
mechanisms may also contribute. Equally evaluation as to whether the wider 
embryo secretome (Seli et al., 2008, Sanchez-Ribas et al., 2012, Nadal-Desbarats 
et al., 2013, Pudakalakatti et al., 2013) or follicular fluid (Pinero-Sagredo et al., 
2010) as determined by NMR, are correlated with maternal circulating metabolite 
profile similarly determined by NMR would be of interest.  
 
7.6 Alternative Analytical Platforms  
At present, the primary analytical technologies used in metabolomics include 
liquid chromatography coupled with single-stage mass spectrometry (LC-MS) ( or 
tandem mass spectrometry (LC-MS/MS), gas chromatography coupled to mass 
spectrometry (GC-MS), high or ultrahigh performance liquid chromatography 
coupled to UV or fluorescent detection (HPLC/UPLC), and nuclear magnetic 




has its advantages and disadvantages, with the choice of platform primarily 
depending on the focus of the study as well as on the nature of the samples. While 
LC-MS and GC-MS methods are increasingly popular, accounting for more than 80% 
of the published metabolomics studies to date), there is still considerable and 
growing interest in the use of NMR for metabolomics reflecting its unique 
advantages. In particular, NMR is non-destructive, nonbiased, easily quantifiable, 
requires little or no chromatographic separation, sample treatment, or chemical 
derivatization, and it permits the routine identification of novel compounds. 
Furthermore, NMR is highly automatable and exceptionally reproducible, making 
high-throughput, large-scale metabolomics studies much more feasible with NMR 
spectroscopy than with LC-MS or GC-MS. NMR spectroscopy can be used to assess 
unique classes of metabolites (especially protein-bound metabolites such as 
lipoprotein particles), that cannot be done via LC-MS and GC-MS (Dona et al., 
2016). 
 
However, NMR also has several disadvantages, with the most significant challenge 
for NMR being its lack of sensitivity. Compared to LC-MS and GC-MS, NMR 
spectroscopy is often 10 to 100 times less sensitive. This means that a typical NMR-
based metabolomic study usually only returns information on 50–200 identified 
metabolites with concentrations >1 µM, while a typical LC-MS study can return 
information on 1000+ identified metabolites with concentrations of >10 to 100 nM 
(Emwas et al., 2019). It is widely appreciated that there are several thousand 
measurable or detectable metabolites in human blood, yet only a few of these 
(the most abundant), can be reliably be detected by NMR. While high-abundance 
metabolites are almost always physiologically important, low-concentration 
metabolites are often more important as diagnostic biomarkers. This means that 
NMR-based metabolomics are often unable to detect these important molecules 
or cannot be used in diagnostic clinical applications. 
 
In general, NMR spectrometers are also quite expensive compared to mass 
spectrometers or many other common analytical tools. Moreover, NMR 
instruments require highly skilled operators as well as substantial laboratory space 
with nonvibrational floors and isolation from magnetic and radio frequency 
interference. These factors, in addition to the overriding issue of low sensitivity, 




terms of translational clinical applications, the same issues regarding space, cost, 
and personnel also make it difficult for NMR to replace existing clinical analysers 
for routine measurements in hospitals or clinics. As a general rule, mass 
spectrometry has had more success than NMR in the clinical chemistry lab because 
of its lower costs, its smaller instrumental footprint, and its ability to measure 
low-concentration metabolite species that are more frequently used in diagnostic 
assays. 
 
Despite these limitations the advent of near-total automation in the NMR workflow 
(including sample preparation, sample loading, spectral acquisition, and spectral 
deconvolution), the ability to quantify absolute levels, comprehensive blood 
metabolite coverage (155 metabolites), the high-throughput, the robust quality 
control, the cost-effectiveness and the already extensive use in genetic and 
epidemiological studies, the 1H-NMR platform was an obvious choice for use in my 
thesis. Future studies will be able to use my stored samples on alternative 
metabolomics platforms, potentially in a more targeted sub-group and matched 
controls, for example, men with severe oligospermia (<5 million sperm per ml), or 
couples with failed fertilisation, thereby overcoming the potential cost issues 
while facilitating a discovery-based approach for new biological insights and 
potential interventions given their wider and untargeted coverage. This approach 
has been successfully done in other cohorts with detailed phenotyping, for 
identification of novel biomarkers for prediction of pre-eclampsia (Sovio et al., 
2020) and fetal growth restriction (Sovio et al., 2020b).  
 
Several analytical platforms can be used in metabolic profiling. However, the 
choice of this specific NMR platform reflected that this platform is able to quantify 
a wide range of measures, with equivalent results to standard clinical chemistry 
analysers, has been shown to be scalable with widespread use in large 
epidemiological cohorts including the UK Biobank, the analytes have been shown 
to relevant cardio-metabolic health outcomes and that is a cost-efficient platform 
which has been used widely by our long-standing collaborators at the Bristol 
University where an NMR platform is established as part of a global network. 
7.7 The Microbiome  
While not addressed in my thesis, there are strong indications that the vaginal and 




et al., 2020). The invasive techniques required for endometrial samples limited 
my ability to attain samples on a large scale, with the collection of vaginal samples 
enabling widespread acceptance by patients, standardisation relative to the 
menstrual cycle and a large number of self-obtained samples to be collected. That 
the vaginal microbiome is recognised as playing an important role in protecting 
the vagina, the first barrier from the external environment to the upper 
reproductive tract, was also a critical factor in my decision to collect vaginal 
samples.  
 
In non-pregnant, healthy women the vaginal microbiome is dominated by four 
Lactobacillus species: L. crispatus, L. iners, L. jensenii or L. gasseri (Ravel et al., 
2011).  There appears to be five vaginal microbial community state types (CST); 
four of them (I, II, III and V) are Lactobacillus-dominant and are more commonly 
found in European and Asian women. CST-IV, more frequent in Hispanic and 
African-American women, differs due to the increased abundance of strictly 
anaerobic bacteria (Gardnerella, Ureaplasma) and reduced presence of 
Lactobacillaceae (Ravel et al., 2011). Lactobacillus spp. produce lactic acid that 
helps to keep the vaginal pH below 4.5 and creates inhospitable conditions for 
pathogens to grow (Graver and Wade, 2011). In addition to the vaginal microbiota 
composition exhibiting large ethnic differences it also appears to vary across the 
life-course depending on physiological events, like menstrual cycle and 
pregnancy, and external factors, such as sexual activity, hygiene habits and 
medical treatments (Gajer et al., 2012; Ravel et al., 2011; Zhou et al., 2007). 
 
Several studies suggest that altered vaginal microbiota may be associated with 
poor IVF and pregnancy outcomes. Specifically, vaginal microbiota which is rich in 
Lactobacillus spp. without bacterial vaginosis, either clinical or subclinical leads 
to more positive outcomes with ART (Babu et al., 2017; Eckert et al., 2003; 
Mangot-Bertrand et al., 2013; Moore et al., 2000). The extent to which an 
unfavourable microbiota is associated with an unfavourable outcome after IVF 
appears to be strong as Haahr et al. (2016) studied the microbiota of 84 women 
undergoing IVF, and of the 22 women who had an altered composition, only two 
women (9%) achieved a clinical pregnancy as compared to 29 women (47%) with a 
normal microbiota composition. Similarly, in a prospective study of 192 women 




Lactobacillus spp. in their vaginal microbiota (5.9% if unfavourable profile) 
(Koedooder et al., 2019). The dominance of L. crispatus was also identified as an 
important factor in predicting pregnancy, as women who had a favourable profile 
based on <60% L. crispatus had a high chance of pregnancy: more than half of 
these women (50 out of 95) achieving pregnancy.  Using this data and with 
confirmation by external validation the authors proposed an algorithm with high 
specificity [97%], but low sensitivity [26%] for not becoming pregnant after IVF 
(Koedooder et al., 2019). Others have also confirmed the positive association of 
L. crispatus dominant microbiomes with higher live birth rates (Haahr et al 2019, 
Vergaro et al., 2019). However, as can be seen from these essentially pilot studies, 
it is at present hard to draw definitive conclusions given the different molecular 
approaches used, the small sample sizes and the non-standardised collection 
techniques. The samples collected within my cohort combined with detailed 
knowledge of potential exogenous factors including smoking, stress, drug exposure 
and antibiotic exposure, which have all been shown to alter the gut microbiome 
(Falony et al., 2016), could make a potentially further useful addition to the 
literature once sequencing techniques and bioinformatic pipelines have been 
standardised (Koedooder et al 2016).  
 
7.8 Conclusion  
In this thesis, I have shown that it is feasible to establish a novel cohort of couples 
undertaking IVF with extensive and detailed pre-treatment phenotyping with 
linkage to laboratory and clinical outcomes to address a series of novel interlinked 
research questions. That my work will also have the legacy of an extensive Biobank 
encompassing maternal and paternal plasma, serum and DNA and vaginal samples 
already prepared and suitable for future microbiome analysis, further enhances 
the utility of the cohort, thereby ensuring that my work will continue to have 
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